Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma
- Odronextamab monotherapy led to complete responses in all patients with previously untreated follicular lymphoma evaluable for efficacy, per initial results from the safety lead-in portion of the confirmatory Phase 3 OLYMPIA-1 trial
- 12/09/2024
|
Regeneron Pharmaceuticals, Inc. Being Investigated on Behalf of Regeneron Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details.
- NEW YORK, NY / ACCESSWIRE / December 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ:REGN) concerning possible violations of federal securities laws. On October 31, 2024, Regeneron released its third quarter 2024 financial results, reporting "U.S. net sales for EYLEA HD® and EYLEA® increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from EYLEA HD.
- 12/09/2024
|
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
- Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease control, as measured by lactate dehydrogenase (LDH) levels, compared to standard-of-care ravulizumab
- 12/07/2024
|
Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
- NEW YORK, NY / ACCESSWIRE / December 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ:REGN) concerning possible violations of federal securities laws. On October 31, 2024, Regeneron released its third quarter 2024 financial results, reporting "U.S. net sales for EYLEA HD® and EYLEA® increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from EYLEA HD.
- 12/06/2024
|
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
- BENSALEM, Pa. , Dec. 6, 2024 /PRNewswire/ -- Law Offices of Howard G.
- 12/06/2024
|
Levi & Korsinsky Reminds Shareholders of an Investigation into Regeneron Pharmaceuticals, Inc. (REGN) Regarding Potential Securities Fraud Allegations
- NEW YORK, NY / ACCESSWIRE / December 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ:REGN) concerning possible violations of federal securities laws. On October 31, 2024, Regeneron released its third quarter 2024 financial results, reporting "U.S. net sales for EYLEA HD® and EYLEA® increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from EYLEA HD.
- 12/06/2024
|
Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 36th Annual Healthcare Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Piper Sandler 36th Annual Healthcare Conference Call December 5, 2024 9:30 AM ET Company Participants Ryan Crowe - Senior Vice President, Investor Relations & Strategic Analysis Chris Fenimore - Senior Vice President, Finance & Chief Financial Officer Conference Call Participants Chris Raymond - Piper Sandler Chris Raymond Okay, let's go ahead and get started. Thanks everybody for being here.
- 12/05/2024
|
REGN ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Regeneron Pharmaceuticals, Inc. Shareholders Who Lost Money
- NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ:REGN) concerning possible violations of federal securities laws. On October 31, 2024, Regeneron released its third quarter 2024 financial results, reporting "U.S. net sales for EYLEA HD® and EYLEA® increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from EYLEA HD.
- 12/04/2024
|
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
- LOS ANGELES, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) investors concerning the Company's possible violations of the federal securities laws.
- 12/04/2024
|
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
- BENSALEM, Pa., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) investors concerning the Company's possible violations of federal securities laws.
- 12/03/2024
|
Medigene Receives Milestone Payment from Regeneron Pharmaceuticals, Inc.
- Planegg/Martinsried, December 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today announced a USD $1 million milestone payment from Regeneron Pharmaceuticals, Inc. was triggered. Regeneron purchased the MAGE-A4-TCR program as part of its acquisition of 2seventy bio Inc.'s pre-clinical and clinical oncology and autoimmune cell therapy pipeline, which closed in April 2024. The payment was triggered by a development milestone for a trial in China led by JW Therapeutics (also a prior collaborator of 2seventy bio, Inc.) of Regeneron's MAGE-A4 cell therapy, which contains a Medigene generated T cell receptor (TCR) targeting MAGE-A4.
- 12/03/2024
|
The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
- LOS ANGELES , Dec. 2, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz continues its investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) on behalf of investors concerning the Company's possible violations of federal securities laws.
- 12/02/2024
|
Shareholder Rights Advocates at Levi & Korsinsky Investigate Regeneron Pharmaceuticals, Inc. (REGN) Regarding Possible Securities Fraud Violations
- NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ:REGN) concerning possible violations of federal securities laws. On October 31, 2024, Regeneron released its third quarter 2024 financial results, reporting "U.S. net sales for EYLEA HD® and EYLEA® increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from EYLEA HD.
- 11/29/2024
|
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Regeneron investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you ca.
- 11/27/2024
|
ATTENTION Regeneron Pharmaceuticals, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
- NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ:REGN) concerning possible violations of federal securities laws. On October 31, 2024, Regeneron released its third quarter 2024 financial results, reporting "U.S. net sales for EYLEA HD® and EYLEA® increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from EYLEA HD.
- 11/26/2024
|
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
- BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) investors concerning the Company's possible violations of federal securities laws. On April 10, 2024, the US Department of Justice (“DOJ”) announced the United States had filed a complaint against Regeneron under the False Claims Act. That announcement stated the complaint “alleges that Regeneron fraudulently inflat.
- 11/26/2024
|
The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
- LOS ANGELES, Nov. 25, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) on behalf of investors concerning the Company's possible violations of federal securities laws.
- 11/25/2024
|
Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) 2024 Jefferies London Healthcare Conference November 19, 2024 6:00 AM ET Company Participants Ryan Crowe - SVP, IR and Strategic Analysis Marion McCourt - EVP, Commercial Conference Call Participants Akash Tewari - Jefferies Akash Tewari Good morning, everyone. Thanks so much for joining us.
- 11/19/2024
|
Regeneron: The Biotech Stock To Buy Now
- Biotech stocks, including Regeneron, have seen significant declines due to regulatory and political uncertainty, presenting a potential buying opportunity as seller exhaustion nears. Regeneron's 40% drop is driven by multiple factors, including Eylea's market share concerns, DOJ lawsuits, and general sector uneasiness. Despite the drop, Regeneron remains a highly profitable company with a robust pipeline, trading at a dirt-cheap valuation and offering long-term growth potential.
- 11/19/2024
|
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
- The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.
- 11/18/2024
|
Final Trades: Berkshire Hathaway, Regeneron, DocuSign and Leidos Holdings
- The Investment Committee give you their top stocks to watch for the second half.
- 11/15/2024
|
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
- Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistamines FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade Paris and Tarrytown, NY, November 15, 2024. The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment.
- 11/15/2024
|
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
- Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade TARRYTOWN, N.Y. and PARIS, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) to treat adults and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment.
- 11/15/2024
|
2 Top Growth Stocks to Buy on the Dip
- Their recent issues are nothing to fret over for investors focused on the long game.
- 11/14/2024
|
Regeneron initiated with a Neutral at Citi
- Citi initiated coverage of Regeneron with a Neutral rating and $895 price target. Multiple clinical data readouts should "keep investors engaged" over the next 12-24 months and while Eylea-HD, or high dose, is "off to a good start," standard Eylea headwinds could lead to declining franchise growth, the analyst tells investors.
- 11/13/2024
|
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
- Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria
- 11/13/2024
|
Regeneron Announces Investor Conference Presentations
- TARRYTOWN, N.Y., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
- 11/11/2024
|
3 Recession-Resistant Stocks: Low Beta, High Margins, Low Debt
- When thinking about stocks with recession-resistant characteristics, a few key metrics come to mind. First are low-beta stocks.
- 11/06/2024
|
Is It Time to Buy October's Worst-Performing Nasdaq Stocks?
- Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today.
- 11/06/2024
|
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
- Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one year
- 11/06/2024
|
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
- Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Approval based on phase 3 data showing significantly more children aged one to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one year Dupixent is the first-ever medicine in the EU indicated to treat these young patients, who persistently struggle to eat at a critical stage in life where growth is crucial Paris and Tarrytown, NY, November 6, 2024. The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year of age.
- 11/06/2024
|
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Regeneron investments or would like to inquire about potentially pursuing claims to recover your loss under the fede.
- 11/04/2024
|
Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)
- Regeneron shares fell 9.2% after the Q3 2024 report, making the company's valuation more attractive. The strong report was the 15th of 16 in the last four years to beat expectations. Investors were spooked by slowing sales growth for EYLEA and lack of revenue expectations in 2024 Guidance.
- 11/04/2024
|
The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On April 10, 2024, the US Department of Justice (“DOJ”) announced the United States had filed a complaint against Regeneron under the False Claims Act. That a.
- 11/01/2024
|
Regeneron: Investors In Panic Mode On Increased Eylea Fears
- Shares of Regeneron are in free fall after recent litigation setbacks on Eylea and with Amgen launching a biosimilar low-dose version of Eylea. Investors may be overestimating the negative impact of this development. Dupixent remains in high growth mode with an expanding collaboration profit margin, and Libtayo is also delivering healthy revenue growth.
- 11/01/2024
|
HRMY vs. REGN: Which Stock Is the Better Value Option?
- Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two stocks is more attractive to value investors?
- 10/31/2024
|
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2024 Earnings Call Transcript
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Ryan Crowe - SVP, IR and Strategic Analysis Leonard Schleifer - Board Co-Chair, Co-Founder, President and CEO George Yancopoulos - Board Co-Chair, Co-Founder, President and Chief Scientific Officer Marion McCourt - EVP, Commercial Chris Fenimore - SVP, Finance and CFO Conference Call Participants Taylor Hanley - JPMorgan Tyler Van Buren - TD Cowen Brian Abrahams - RBC Capital Markets Carter Gould - Barclays Terence Flynn - Morgan Stanley Christopher Raymond - Piper Sandler Salveen Richter - Goldman Sachs Mohit Bansal - Wells Fargo Evan Seigerman - BMO Capital Markets David Risinger - Leerink Partners William Pickering - Bernstein Cory Kasimov - Evercore ISI Operator Good morning and welcome to the Regeneron Pharmaceuticals' Third Quarter 2024 Earnings Conference Call. My name is Shannon and I will be your operator for today's call.
- 10/31/2024
|
Regeneron (REGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
- The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 10/31/2024
|
REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales
- Regeneron reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Eylea HD, Dupixent and Libtayo sales.
- 10/31/2024
|
Regeneron (REGN) Tops Q3 Earnings and Revenue Estimates
- Regeneron (REGN) came out with quarterly earnings of $12.46 per share, beating the Zacks Consensus Estimate of $11.75 per share. This compares to earnings of $11.59 per share a year ago.
- 10/31/2024
|
Regeneron beats results estimates on demand for eczema treatment, eye drug
- U.S. drugmaker Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven by strong demand for its eczema treatment Dupixent and blockbuster eye disease drug Eylea.
- 10/31/2024
|
Regeneron Reports Third Quarter 2024 Financial and Operating Results
- TARRYTOWN, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2024 and provided a business update.
- 10/31/2024
|
Regeneron to Report Q3 Earnings: What's in the Offing?
- Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports third-quarter 2024 results.
- 10/28/2024
|
Top Stocks To Buy Now? 2 Biotech Stocks To Watch
- Biotech stocks to keep an eye on in the stock market right now.
- 10/28/2024
|
Unlocking Q3 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics
- Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
- 10/28/2024
|
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
- One of these players has split its stock in the past. The other one hasn't.
- 10/28/2024
|
Regeneron (REGN) Earnings Expected to Grow: Should You Buy?
- Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/24/2024
|
Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
- Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status Confirmatory data to support U.S. regulatory resubmission by year-end; if approved, Dupixent would be the first new targeted treatment for people living with chronic spontaneous urticaria in more than 10 years More than 300,000 people in the U.S. suffer from chronic spontaneous urticaria that is inadequately controlled by antihistamines TARRYTOWN, N.Y. and PARIS, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi will present positive data from the Phase 3 LIBERTY-CUPID Study C evaluating the investigational use of Dupixent® (dupilumab) in biologic-naïve patients with uncontrolled chronic spontaneous urticaria (CSU) who receive background therapy with antihistamines.
- 10/24/2024
|
Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
- Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status Confirmatory data to support US regulatory resubmission by year-end; if approved, Dupixent would be the first new targeted treatment for people living with chronic spontaneous urticaria in more than 10 years More than 300,000 people in the US suffer from chronic spontaneous urticaria that is inadequately controlled by antihistamines Paris and Tarrytown, NY, October 24, 2024. Positive data from the phase 3 LIBERTY-CUPID Study C evaluating the investigational use of Dupixent (dupilumab) in biologic-naive patients with uncontrolled chronic spontaneous urticaria (CSU) who receive background therapy with antihistamines will be presented in a late-breaking oral presentation at the American College of Allergy, Asthma and Immunology (ACAAI) 2024 Annual Scientific Meeting in Boston, Massachusetts.
- 10/24/2024
|
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
- Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
- 10/23/2024
|
Amgen to launch US Eylea biosimilar after ruling in Regeneron patent case
- Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said.
- 10/22/2024
|
5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates
- Let us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings.
- 10/22/2024
|
Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema
- 88% of EYLEA HD patients had a last assigned dosing interval of ≥12 weeks at week 156, while sustaining visual and anatomic improvements achieved in the first 96 weeks, in this extension study of the Phase 3 PHOTON trial presented at AAO
- 10/18/2024
|
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
- The stock market's impressive and resilient performance in 2024, with the SPDR S&P 500 ETF up over 21% YTD and trading at all-time highs, has led many investors to chase high-flying stocks at all-time highs. However, this approach can be risky as stocks stretched to the upside might face corrections.
- 10/11/2024
|
Regeneron (REGN) Loses -11.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- The heavy selling pressure might have exhausted for Regeneron (REGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 10/10/2024
|
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
- The stock market's impressive and resilient performance in 2024, with the SPDR S&P 500 ETF NYSE: SPY up over 21% YTD and trading at all-time highs, has led many investors to chase high-flying stocks at all-time highs. However, this approach can be risky as stocks stretched to the upside might face corrections.
- 10/10/2024
|
Regeneron Gains 13.5% Year to date: How to Play the Stock?
- REGN maintains momentum as Eylea HD gains traction and Dupixent maintains momentum, even as lead drug Eylea faces challenges.
- 10/08/2024
|
Should You Buy the Dip on This Top Growth Stock?
- The biotech needs to overcome an issue most drugmakers face at some point.
- 10/05/2024
|
Stock Picks From Seeking Alpha's September 2024 New Analysts
- In September, thirty new analysts joined Seeking Alpha, offering diverse stock picks and insights, from Strong Buy to Strong Sell ratings. Highlighted picks include InMode Ltd., Intel Corporation, and iShares 20+ Year Treasury Bond ETF, each with unique investment theses and strong buy ratings. Analysts' backgrounds range from software engineering to finance, enhancing their stock research with diverse perspectives and methodologies.
- 10/04/2024
|
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
- Sanofi and Regeneron's Dupixent becomes the first biologic treatment approved for COPD in the United States.
- 09/30/2024
|
Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
- These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
- 09/29/2024
|
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
- Shares of Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) edged higher Friday after their chronic obstructive pulmonary disease (COPD) treatment received approval from the Food and Drug Administration (FDA).
- 09/27/2024
|
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease
- On Friday, the FDA approved Regeneron Pharmaceuticals, Inc. REGN and Sanofi SA's SNY Dupixent (dupilumab) as an add-on maintenance treatment of inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype, generally known as “smoker's lung.”
- 09/27/2024
|
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
- The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease commonly known as "smoker's lung", the companies said on Friday.
- 09/27/2024
|
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
- Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype
- 09/27/2024
|
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
- Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype Following recent approvals in the EU and China, the US approval is based on two landmark phase 3 studies that showed Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung function and health-related quality of life compared to placebo Dupixent is the leading biologic medicine for all of its FDA-approved indications in new-to-brand prescriptions, and the most prescribed biologic by pulmonologists in the US Paris and Tarrytown, NY, September 27, 2024. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.
- 09/27/2024
|
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
- Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life
- 09/27/2024
|
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
- Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark phase 3 studies showing Dupixent significantly reduced exacerbations, improved lung function, and also improved health-related quality of life COPD is the most prevalent chronic respiratory disease in China, and is a priority within the government's Healthy China 2030 public health plan Dupixent is now approved in four indications across respiratory and dermatological diseases in China Paris and Tarrytown, New York, Sept. 27, 2024. The National Medical Products Administration (NMPA) in China has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils.
- 09/27/2024
|
Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
- TARRYTOWN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2024 financial and operating results on Thursday, October 31, 2024, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
- 09/26/2024
|
Final Trades: Trane Tech, American Tower, Regeneron and Taiwan Semi
- The Investment Committee give you their top stocks to watch for the second half.
- 09/25/2024
|
Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors
- Regeneron Pharmaceuticals is a leading biotech firm with a strong portfolio, including Eylea, Dupixent, and Libtayo, and a robust investigational pipeline. Despite legal setbacks from Amgen's Eylea biosimilar, the legal battle continues, and REGN's patents protect EYLEA HD until at least 2037. Moreover, Dupixent and Libtayo remain strong growth drivers, contributing significantly to Regeneron's revenue with expanding approvals and indications.
- 09/25/2024
|
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
- Chief District Judge Thomas Kleeh denied Regeneron Pharmaceuticals, Inc.‘s REGN effort to prevent the sale of Amgen Inc‘s AMGN Eylea biosimilar.
- 09/24/2024
|
Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea
- A federal judge rejected Regeneron's request for a preliminary injunction against Amgen in its lawsuit for Eylea's biosimilar.
- 09/24/2024
|
Winners & Losers: Las Vegas Sands, FMC Corp, Regeneron and Palantir
- The Investment Committee highlight some of today's winners and losers.
- 09/24/2024
|
HRMY vs. REGN: Which Stock Should Value Investors Buy Now?
- Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or Regeneron (REGN). But which of these two stocks presents investors with the better value opportunity right now?
- 09/24/2024
|
Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion
- REGN and SNY get positive CHMP opinion on the label expansion of Dupixent in the EU for eosinophilic esophagitis in children down to 1 year of age.
- 09/23/2024
|
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
- Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission compared to placebo, consistent with improvements seen in adults and adolescents
- 09/20/2024
|
Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
- Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater proportion of children on Dupixent achieved histological remission, compared to placebo, consistent with improvements seen in adults and adolescents If approved, Dupixent would be the first and only medicine in the EU indicated for EoE in this age group Paris and Tarrytown, NY, September 20, 2024. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the expanded approval of Dupixent (dupilumab) in the European Union (EU) for eosinophilic esophagitis (EoE) in children down to 1 year of age.
- 09/20/2024
|
Biotech stock plays outside of GLP-1 weight-loss market
- BMO Capital Markets managing director of biopharma equity research Evan Seigerman joins Market Domination to discuss the best biotech plays outside of the GLP-1 weight-loss space. The sky-high demand for GLP-1 weight-loss drugs has led the biotech sector to reach new heights over the last year, and Seigerman believes the trend is as "hot as ever.
- 09/19/2024
|
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
- REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.
- 09/16/2024
|
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
- Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP Current treatment options leave many patients with uncontrolled disease and often result in the recurrence of nasal polyps Dupixent is the leading biologic medicine for all five FDA-approved indications in new-to-brand prescriptions TARRYTOWN, N.Y. and PARIS, Sept.
- 09/13/2024
|
Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals
- This is the second pivotal late-stage study on SNY/REGN's Dupixent in chronic spontaneous urticaria indication to meet primary and key secondary endpoints.
- 09/11/2024
|
EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile
- Three new post-hoc analyses highlight EYLEA HD rapid and sustained fluid control and consistent safety profile over two years in patients with wet age-related macular degeneration (wAMD)
- 09/11/2024
|
Prediction: These 2 Companies Will Split Their Stocks by 2027
- These two drugmakers have been delivering significantly above-average returns for years. Both still have excellent prospects and could decide to split their stocks as their share prices get higher.
- 09/11/2024
|
Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
- Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second pivotal study in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in itch and urticaria activity scores compared to placebo More than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistamines Data will support regulatory resubmission in the US by year-end; if approved, Dupixent would be the first targeted therapy for CSU in a decade Paris and Tarrytown, NY, September 11, 2024. A Dupixent (dupilumab) confirmatory phase 3 study (LIBERTY-CUPID Study C) met the primary and key secondary endpoints for the investigational treatment of patients with uncontrolled, biologic-naïve CSU receiving background therapy with antihistamines.
- 09/11/2024
|
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)
- Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in itch and urticaria activity scores compared to placebo
- 09/11/2024
|
Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study
- Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Study met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is the first medicine to show significant steroid-sparing effect in this debilitating and life-threatening disease If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S. and European Union Paris and Tarrytown, NY, September 11, 2024. A Dupixent (dupilumab) pivotal study (ADEPT) in bullous pemphigoid (BP) met the primary and all key secondary endpoints evaluating its investigational use in adults with moderate-to-severe disease.
- 09/11/2024
|
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
- Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo
- 09/11/2024
|
2 Biotech Stocks To Watch In September 2024
- Here are biotech stocks to check out this month.
- 09/10/2024
|
Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer
- Late-breaking data at WCLC show Libtayo monotherapy nearly doubled median overall survival and reduced the risks of death and disease progression by 41% and 50%, respectively, compared to chemotherapy
- 09/09/2024
|
Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
- At WCLC, five-year survival data to be presented on Libtayo (PD-1 inhibitor) first-line monotherapy in advanced non-small cell lung cancer
- 09/09/2024
|
Regeneron Pharmaceuticals, Inc. (REGN) Wells Fargo 2024 Healthcare Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Wells Fargo 2024 Healthcare Conference September 5, 2024 12:45 PM ET Company Participants Marion McCourt - EVP, Commercial Ryan Crowe - SVP, IR and Strategic Analysis Conference Call Participants Mohit Bansal - Wells Fargo Mohit Bansal Great. So my name is Mohit Bansal, and thank you for the post lunch session.
- 09/05/2024
|
Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030
- Regeneron is an innovative drugmaker that continues to perform well. Shopify's changed and improved business should lead to stronger returns.
- 09/05/2024
|
Regeneron Pharmaceuticals, Inc. (REGN) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 11:30 AM ET Company Participants Ryan Crowe - Senior Vice President, Investor Relations and Strategic Analysis Chris Fenimore - Senior Vice President, Finance and Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Great. Thanks for joining us, everybody.
- 09/04/2024
|
Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma
- REGN's oncology portfolio gets a boost with the approval of odronextamab for treating follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).
- 08/27/2024
|
Regeneron Stock: Valuation Now Demands More Growth
- Regeneron Pharmaceuticals stock reached new all-time highs this month, driven by the Eylea franchise returning to growth in the second quarter, and despite minor regulatory setbacks for the oncology pipeline. Dupixent and Libtayo delivered strong growth in the second quarter. European Commission approvals of Dupixent for COPD and odronextamab for two hematologic malignancies offer some consolation after FDA delays and rejections for the same applications.
- 08/26/2024
|
HRMY or REGN: Which Is the Better Value Stock Right Now?
- Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two stocks offers value investors a better bang for their buck right now?
- 08/26/2024
|
Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
- Approval of Ordspono is based on data demonstrating robust and durable responses in both relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma, including in the post-CAR-T setting
- 08/26/2024
|
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
- 20 abstracts, including 4 oral presentations, offer new treatment insights for chronic obstructive pulmonary disease (COPD), asthma and chronic rhinosinusitis with nasal polyps (CRSwNP)
- 08/26/2024
|
Regeneron (REGN) Gets CRL From FDA for Multiple Myeloma Drug
- Regeneron (REGN) suffers a delay in obtaining FDA approval of linvoseltamab for the treatment of relapsed/refractory multiple myeloma.
- 08/21/2024
|
US FDA declines to approve Regeneron's blood cancer therapy
- The U.S. Food and Drug Administration declined to approve Regeneron's therapy for a common form of blood cancer, the company said on Tuesday.
- 08/20/2024
|
Regeneron Provides Update on Biologics License Application for Linvoseltamab
- TARRYTOWN, N.Y., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for linvoseltamab in relapsed/refractory (R/R) multiple myeloma (MM) that has progressed after at least three prior therapies. This anticipated outcome was previously disclosed during Regeneron's second quarter 2024 earnings call.
- 08/20/2024
|
2 Biotech Stocks To Watch In August 2024
- Biotech stocks to keep on your radar this month.
- 08/13/2024
|
7 Stocks That Usually Benefit From a Recession
- As the dark clouds of a potential recession loom on the horizon, investors are scrambling to find safe havens for their hard-earned money. While it's true that most stocks tend to suffer during economic downturns, there are always a few outliers that manage to defy the odds and emerge stronger than ever.
- 08/13/2024
|
3 Biotech Stocks Poised for a Comeback After Last Week's Market Meltdown
- Due to their sometimes speculative nature, biotech stocks are especially sensitive to broader market corrections like the one experienced last week. This can be exceptionally stressful for investors, especially those who bought into biotech stocks at overbought points in the stocks' trading cycle.
- 08/13/2024
|
HRMY vs. REGN: Which Stock Is the Better Value Option?
- Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two stocks presents investors with the better value opportunity right now?
- 08/09/2024
|
3 Biotech Stocks With Promising Drug Pipelines: August 2024
- Investing in biotech stocks with promising pipelines has to be the most exciting area of the market. A successful drug approval can not only unveil a blockbuster treatment worth billions of dollars, but it can literally change people's lives for the better.
- 08/08/2024
|
3 Healthcare Stocks Positioned for Possible Market Outperformance
- So far in 2024, healthcare stocks have run into periodic earnings challenges compared to historical first quarters. For example, quarterly earnings for healthcare stocks across the board were down 25% compared to first-quarter 2023 earnings.
- 08/07/2024
|
Regeneron: Expanded Product Base Taking Root, More Is Certainly On The Way
- Regeneron is a powerhouse in drug discovery with a promising pipeline and innovative treatments. Revenues are stable with flagship drugs like Eylea providing a revenue cushion and Dupixent driving growth. The next-generation drugs in oncology and obesity are the next potential wave of growth, with even more exciting treatments following them.
- 08/07/2024
|
Regeneron (REGN) Q2 Earnings Gain From Eylea HD, Dupixent
- Regeneron's (REGN) decent second-quarter results can be attributed to strong uptake of Eylea HD sales and high Dupixent profits, even though lead drug Eylea is under pressure.
- 08/05/2024
|
Is Regeneron Pharmaceuticals Due for a Stock Split?
- Regeneron shares have recently crossed over the $1,000 price point. The company has achieved significant growth and there could more to come.
- 08/03/2024
|
Regeneron's Robust Pipeline And Financial Health Signal Continued Growth
- Regeneron's Q2 2024 revenue grew 12% year-over-year, reaching $3.55 billion. Dupixent's global net sales increased by 27% to $3.56 billion, driving overall revenue growth. Eylea HD mitigated market share losses by earning $304 million and stabilizing the Eylea franchise.
- 08/02/2024
|
Defensive Sectors Breakout: 3 Stocks to Buy Now for Protection
- Over the past month we have observed some very interesting activity across the market's more defensive sectors, considerable outperformance. Below we can see just how significantly the Utilities ( XLU ), Healthcare ( XLV ), Energy ( XLE ) and Real Estate ( XLRE ) sector ETF have outperformed the S&P 500 (in orange).
- 08/01/2024
|
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2024 Earnings Call Transcript
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Ryan Crowe - Senior Vice President, Investor Relations and Strategic Analysis Leonard Schleifer - Board Co-Chair, Co-Founder, President and Chief Executive Officer George Yancopoulos - Board Co-Chair, Co-Founder, President and Chief Scientific Officer Marion McCourt - Executive Vice President, Commercial Chris Fenimore - Senior Vice President, Finance and Chief Financial Officer Conference Call Participants Tyler Van Buren - TD Cowen Evan Seigerman - BMO Capital Markets Brian Abrahams - RBC Capital Markets Cory Kasimov - Evercore ISI Christopher Raymond - Piper Sandler Katherine Wang - Jefferies Chris Schott - JPMorgan Tim Anderson - Wolfe Research David Risinger - Leerink Partners Salveen Richter - Goldman Sachs Carter Gould - Barclays Mohit Bansal - Wells Fargo Operator Welcome to the Regeneron Pharmaceuticals Second Quarter 2024 Earnings Conference Call. My name is Shannon and I will be your operator for today's call.
- 08/01/2024
|
Compared to Estimates, Regeneron (REGN) Q2 Earnings: A Look at Key Metrics
- The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 08/01/2024
|
Regeneron (REGN) Tops on Q2 Earnings, Eylea HD, Dupixent Fuel Sales
- Regeneron (REGN) reports strong Q2 results, wherein both the top and bottom lines beat estimates due to higher Eylea HD and Libtayo sales and profits from Dupixent sales.
- 08/01/2024
|
Regeneron beats quarterly results on strong demand for eczema, eye treatments
- Drugmaker Regeneron Pharmaceuticals exceeded estimates for second-quarter revenue and profit on Thursday, driven by strong demand for its top-selling eczema and eye drugs.
- 08/01/2024
|
Regeneron (REGN) Surpasses Q2 Earnings and Revenue Estimates
- Regeneron (REGN) came out with quarterly earnings of $11.56 per share, beating the Zacks Consensus Estimate of $10.57 per share. This compares to earnings of $10.24 per share a year ago.
- 08/01/2024
|
Regeneron Stock Climbs After Strong Second-Quarter Performance
- A strong second-quarter performance lifted the already extended shares of the New York-based drugmaker Regeneron.
- 08/01/2024
|
Regeneron Reports Second Quarter 2024 Financial and Operating Results
- TARRYTOWN, N.Y., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2024 and provided a business update.
- 08/01/2024
|
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
- Let's focus on biotech stocks like GSK, VRTX, BIIB, MRNA and REGN, which are scheduled to report this week.
- 07/30/2024
|
Regeneron Pharmaceuticals Inc Investors With Losses Are Urged To Contact The Schall Law Firm As It Initiates An Investigation Into Allegations
- LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/30/2024
|
Regeneron Pharmaceuticals Inc Investors With Losses Are Urged To Contact The Schall Law Firm As It Initiates An Investigation Into Allegations
- LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/29/2024
|
Countdown to Regeneron (REGN) Q2 Earnings: Wall Street Forecasts for Key Metrics
- Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
- 07/29/2024
|
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
- Eli Lilly and Regeneron are among the world's leading drugmakers. Both stocks have performed exceptionally well in recent years.
- 07/27/2024
|
Regeneron Pharmaceuticals Inc Investors With Losses Are Encouraged To Contact The Schall Law Firm As They Initiate An Investigation Into Allegations
- LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/26/2024
|
Regeneron Pharmaceuticals Inc Investors With Losses Are Encouraged To Contact The Schall Law Firm As They Initiate An Investigation Into Allegations
- LOS ANGELES, CA / ACCESSWIRE / July 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/25/2024
|
Regeneron (REGN) Earnings Expected to Grow: Should You Buy?
- Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/25/2024
|
Regeneron Pharmaceuticals Inc Investors With Losses Are Encouraged To Contact The Schall Law Firm As They Initiate An Investigation Into Allegations
- LOS ANGELES, CA / ACCESSWIRE / July 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/24/2024
|
Regeneron Pharmaceuticals Inc Investors With Losses Are Encouraged To Contact The Schall Law Firm As They Initiate An Investigation Into Allegations
- LOS ANGELES, CA / ACCESSWIRE / July 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/23/2024
|
Regeneron Pharmaceuticals Inc Investors With Losses Are Encouraged To Contact The Schall Law Firm As They Initiate An Investigation Into Allegations
- LOS ANGELES, CA / ACCESSWIRE / July 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/22/2024
|
HRMY or REGN: Which Is the Better Value Stock Right Now?
- Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two stocks presents investors with the better value opportunity right now?
- 07/22/2024
|
Regeneron Pharmaceuticals Incorporated Investors With Losses Are Encouraged By The Schall Law Firm To Reach Out Amidst Initiation Of An Allegations Investigation
- LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/19/2024
|
Investors Of Regeneron Pharmaceuticals Incorporated With Losses Are Urged To Connect As The Schall Law Firm Begins An Investigation Into Allegations
- LOS ANGELES, CA / ACCESSWIRE / July 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/18/2024
|
3 Standout Stocks to Buy for the Next Bull Market
- Wall Street investors are constantly looking for stocks to buy for a bull market. The S&P 500 index has recently reached a new record high, solidifying the bull market that began in October 2022.
- 07/18/2024
|
Regeneron Pharmaceuticals Inc Investors With Losses Are Invited To Reach Out As The Schall Law Firm Begins An Investigation Into Allegations
- LOS ANGELES, CA / ACCESSWIRE / July 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/17/2024
|
Stocks to Buy: 7 Founder-Led Companies Set to Outperform
- What would you say if there was a reliable, evergreen indicator that a company will consistently out-innovate its competitors and, by extension, have a greater chance of long-term survival and market outperformance? While it may seem a pipe dream, research indicates that founder-led companies do just that, creating a unique set of parameters when looking for stocks to buy.
- 07/17/2024
|
Regeneron Pharmaceuticals Inc Investors With Losses Are Invited To Reach Out As The Schall Law Firm Begins An Investigation Into Allegations
- LOS ANGELES, CA / ACCESSWIRE / July 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/15/2024
|
Investors Of Regeneron Pharmaceuticals Inc With Losses Are Encouraged To Contact As The Schall Law Firm Initiates A Probe Into Claims
- LOS ANGELES, CA / ACCESSWIRE / July 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/13/2024
|
Regeneron Pharmaceuticals Inc Investors With Losses Are Urged To Reach Out As The Schall Law Firm Begins An Investigation Into Allegations
- LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/12/2024
|
Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings
- Regeneron Pharmaceuticals, Inc. stock has increased over 20% in 2024, trading at $1,071 per share at the time of writing. Regeneron's valuation is high but arguably justified by potential growth, with impressive revenue and pipeline projections. While still a promising investment, a "hold" recommendation is advised due to competition, pipeline setbacks, and operational challenges.
- 07/11/2024
|
Investors With Losses Are Encouraged To Contact As The Schall Law Firm Initiates An Investigation Into Claims Against Regeneron Pharmaceuticals Inc
- LOS ANGELES, CA / ACCESSWIRE / July 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/11/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
- NEW YORK , July 10, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 07/10/2024
|
Regeneron Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm
- Investors can contact the law firm at no cost to learn more about recovering their losses
- 07/10/2024
|
The Schall Law Firm Begins A Probe Into Allegations Against Regeneron Pharmaceuticals Inc And Urges Investors With Losses To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / July 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/10/2024
|
Calls of the Day: Visa, Regeneron, Target, Spotify, Netflix, Starbucks and McDonald's
- The Investment Committee discuss the latest calls of the day.
- 07/10/2024
|
Investigation Into Claims Against Regeneron Pharmaceuticals Inc Is Initiated By The Schall Law Firm And Investors Who Have Incurred Losses Are Encouraged To Contact
- LOS ANGELES, CA / ACCESSWIRE / July 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/09/2024
|
The Schall Law Firm Initiates Probe Into Claims Against Regeneron Pharmaceuticals Inc And Encourages Affected Investors To Make Contact
- LOS ANGELES, CA / ACCESSWIRE / July 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/08/2024
|
3 No-Brainer Stocks to Buy in July
- Eli Lilly could be headed for a market capitalization above $1 trillion. Regeneron has overcome bumps and shows no signs of slowing down.
- 07/08/2024
|
3 Pharma Stocks Already Ushering in the Next Biotech Boom
- Let's get down to it: why should investors consider pharma stocks? Primarily, it comes down to the permanence of the underlying narrative.
- 07/08/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
- NEW YORK, July 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 07/07/2024
|
The Schall Law Firm Launches Examination Of Allegations Against Regeneron Pharmaceuticals Inc And Invites Suffering Investors To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / July 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/07/2024
|
The Schall Law Firm Starts Inquiry Into Accusations Against Regeneron Pharmaceuticals Inc And Urges Impacted Investors To Communicate
- LOS ANGELES, CA / ACCESSWIRE / July 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/06/2024
|
Swing Trading Regeneron Stock Shows How To Bob And Weave
- What do boxers and swing traders have in common? Avoiding big hits and striking at opportunities when they come.
- 07/05/2024
|
The Schall Law Firm Begins Investigation Into Claims Against Regeneron Pharmaceuticals Inc And Encourages Affected Investors To Contact
- LOS ANGELES, CA / ACCESSWIRE / July 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/05/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
- NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ:REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 07/05/2024
|
7 High Priced Stocks That Would Benefit From a Stock Split
- Several high-profile stock splits have occurred recently. First, Nvidia (NASDAQ: NVDA ) decided to implement a 10-for-1 stock split which took effect June 10.
- 07/04/2024
|
Impacted Investors Are Invited By The Schall Law Firm To Reach Out As They Start A Probe Into Allegations Against Regeneron Pharmaceuticals Inc
- LOS ANGELES, CA / ACCESSWIRE / July 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/03/2024
|
Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
- Regeneron (REGN) and partner Sanofi get approval for their blockbuster drug Dupixent for the chronic obstructive pulmonary disease indication in the EU.
- 07/03/2024
|
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
- First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life
- 07/03/2024
|
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
- Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark phase 3 studies showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life Dupixent is the first new treatment approach for COPD in more than a decade and a new option for approximately 220,000 adults in the EU Approval represents the sixth approved indication for Dupixent in the EU and seventh approved indication globally Paris and Tarrytown, NY, July 3, 2024. The European Medicines Agency (EMA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils.
- 07/03/2024
|
The Schall Law Firm Initiates Probe Into Allegations Against Regeneron Pharmaceuticals Inc And Invites Impacted Investors To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/02/2024
|
Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm
- NEW YORK , July 2, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
- 07/02/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
- NEW YORK , July 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 07/02/2024
|
Regeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
- Regeneron (REGN) gets positive CHMP recommendation for odronextamab for the treatment of adults with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.
- 07/02/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN
- NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 06/30/2024
|
The Schall Law Firm Begins Investigation Into Claims Against Regeneron Pharmaceuticals Inc And Encourages Affected Investors To Make Contact
- LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/28/2024
|
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
- Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in both relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in both relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma
- 06/28/2024
|
Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
- TARRYTOWN, N.Y., June 27, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2024 financial and operating results on Thursday, August 1, 2024, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
- 06/27/2024
|
3 Biotech Stocks That Could Make Your Grandchildren Rich
- In the world of investing, biotech stocks represent a unique blend of high risk and high reward. After a period of volatility in the broader markets in 2022 and 2023, biotech stocks are now drawing attention for their potential to deliver substantial long-term returns.
- 06/27/2024
|
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
- Majority of patients in this age group with eosinophilic esophagitis (EoE) receiving Dupixent achieved histologic remission, with improvements sustained up to one year
- 06/26/2024
|
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
- Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM Majority of patients in this age group with eosinophilic esophagitis receiving Dupixent achieved histologic remission, with improvements sustained up to one year Dupixent is the first-and-only medicine indicated for eosinophilic esophagitis in the US for this age group Paris and Tarrytown, NY, June 26, 2024. The New England Journal of Medicine has published results from a positive phase 3 study of Dupixent (dupilumab) in children aged one to 11 years with eosinophilic esophagitis (EoE).
- 06/26/2024
|
The Schall Law Firm Initiates Inquiry Into Allegations Against Regeneron Pharmaceuticals Inc And Urges Investors Who Have Incurred Losses To Establish Communication
- LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/26/2024
|
The Schall Law Firm Initiates Probe Into Allegations Against Regeneron Pharmaceuticals Inc And Urges Impacted Investors To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/25/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
- NEW YORK , June 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 06/24/2024
|
Regeneron Pharmaceuticals' Approach To Improve Quality Of Weight Loss Has Merit: Goldman Sachs
- Regeneron Pharmaceuticals Inc REGN released multiple ascending dose (MAD) data from a Phase 1 study evaluating garetosmab (anti-activin A) and trevogrumab (anti-myostatin) on body composition in healthy volunteers (n=34) at the American Diabetes Association meeting.
- 06/24/2024
|
The Schall Law Firm Begins Investigation Into Claims Against Regeneron Pharmaceuticals Inc And Encourages Affected Investors To Make Contact
- LOS ANGELES, CA / ACCESSWIRE / June 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/24/2024
|
Ophthalmologists Favor Genentech's Vabysmo and Regeneron's Eylea HD for Diabetic Macular Edema Treatment Despite Payer Constraints
- New prescriptions for Vabysmo and Eylea HD outpace reported current brand share, indicating further growth of the brands, according to Spherix Global Insights. New prescriptions for Vabysmo and Eylea HD outpace reported current brand share, indicating further growth of the brands, according to Spherix Global Insights.
- 06/24/2024
|
The Schall Law Firm Commences Probe Into Allegations Against Regeneron Pharmaceuticals Inc And Urges Impacted Investors To Establish Communication
- LOS ANGELES, CA / ACCESSWIRE / June 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/23/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
- NEW YORK, June 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 06/22/2024
|
The Schall Law Firm Starts Investigation Into Claims Against Regeneron Pharmaceuticals Inc And Encourages Affected Investors To Initiate Contact
- LOS ANGELES, CA / ACCESSWIRE / June 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/22/2024
|
The Schall Law Firm Initiates Probe Into Allegations Against Regeneron Pharmaceuticals Inc And Urges Impacted Investors To Establish Communication
- LOS ANGELES, CA / ACCESSWIRE / June 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/21/2024
|
The Schall Law Firm Begins Investigation Into Claims Against Regeneron Pharmaceuticals Inc And Encourages Affected Investors To Contact Them
- LOS ANGELES, CA / ACCESSWIRE / June 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/20/2024
|
The Schall Law Firm Initiates Probe Into Allegations Against Regeneron Pharmaceuticals Inc And Urges Impacted Investors To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/19/2024
|
The Schall Law Firm Begins Investigation Into Claims Against Regeneron Pharmaceuticals Inc And Encourages Affected Investors To Connect
- LOS ANGELES, CA / ACCESSWIRE / June 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/18/2024
|
Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
- Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.
- 06/18/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
- NEW YORK, NY / ACCESSWIRE / June 17, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ:REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 06/17/2024
|
The Schall Law Firm Has Initiated A Probe Into Allegations Against Regeneron Pharmaceuticals Inc (NASDAQ:REGN) And Urges Investors Who Have Incurred Losses To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/17/2024
|
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
- At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously published in the Journal of Clinical Oncology
- 06/16/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
- NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 06/13/2024
|
Regeneron's Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market
- RBC Capital Markets analyst Brian Abrahams reiterated an Outperform rating on Regeneron Pharmaceuticals, Inc. REGN, raising the price forecast to $1,299 from $1,200.
- 06/13/2024
|
The Schall Law Firm Has Begun An Investigation Into Claims Against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) And Encourages Investors Who Have Suffered Losses To Make Contact
- LOS ANGELES, CA / ACCESSWIRE / June 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/11/2024
|
Regeneron (REGN), SNY Win FDA Nod for Kevzara Label Expansion
- The FDA approves label expansion of Regeneron (REGN) and Sanofi's Kevzara for the treatment of polyarticular juvenile idiopathic arthritis.
- 06/11/2024
|
Regeneron Pharmaceuticals, Inc. (REGN) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Goldman Sachs 45th Annual Global Healthcare Conference June 11, 2024 8:00 AM ET Company Participants Ryan Crowe - Head of IR Chris Fenimore - CFO Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Good morning, everyone. Thank you for joining us and welcome to Day 2 of the Goldman Sachs Healthcare Conference.
- 06/11/2024
|
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
- Approval in patients with pJIA weighing 63kg or greater adds to Kevzara's position in treating adult chronic inflammatory conditions of moderately to severely active rheumatoid arthritis and polymyalgia rheumatica
- 06/11/2024
|
2 Biotech Stocks For Your June 2024 Watchlist
- Biotech stocks to check out in the stock market now.
- 06/10/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
- NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ:REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 06/09/2024
|
The Schall Law Firm Has Begun An Investigation Into Claims Against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) And Encourages Investors Who Have Suffered Losses To Contact Them
- LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/09/2024
|
The Schall Law Firm Has Initiated A Probe Into Allegations Against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) And Urges Investors Who Have Experienced Losses To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/08/2024
|
The Schall Law Firm Announces An Investigation Into Claims Against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) And Encourages Investors Who Have Suffered Losses To Get In Touch
- LOS ANGELES, CA / ACCESSWIRE / June 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/07/2024
|
Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
- NEW YORK, NY / ACCESSWIRE / June 7, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN). Investors who purchased Regeneron securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/REGN.
- 06/07/2024
|
Stock Split Watch: 3 Growth Stocks That Could Be Next
- Shares of MercadoLibre, Booking Holdings, and Regeneron have reached prices in the neighborhood of $1,000 or more, making them obvious candidates for stock splits. None of these three companies has ever done a forward stock split.
- 06/07/2024
|
The Schall Law Firm Declares An Inquiry Into Allegations Against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) And Urges Investors Who Have Incurred Losses To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/06/2024
|
Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
- NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN). Investors who purchased Regeneron securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/REGN/.
- 06/06/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
- NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 06/05/2024
|
The Schall Law Firm Announces An Investigation Into Claims Against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) And Encourages Investors With Losses To Make Contact
- LOS ANGELES, CA / ACCESSWIRE / June 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/05/2024
|
Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
- NEW YORK, NY / ACCESSWIRE / June 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN). Investors who purchased Regeneron securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/REGN.
- 06/05/2024
|
Health Care Stocks Show Relative Strength as S&P 500 Stalls
- Several stocks are breaking out and trading near all-time highs.
- 06/04/2024
|
The Schall Law Firm Declares an Inquiry into Accusations Against Regeneron Pharmaceuticals, Inc. and Advocates for Investors with Losses to Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/04/2024
|
Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
- NEW YORK, NY / ACCESSWIRE / June 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN). Investors who purchased Regeneron securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/REGN.
- 06/04/2024
|
REGN CRUCIAL INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / June 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/03/2024
|
Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
- NEW YORK, NY / ACCESSWIRE / June 3, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN). Investors who purchased Regeneron securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/REGN.
- 06/03/2024
|
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/02/2024
|
Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
- NEW YORK, NY / ACCESSWIRE / June 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN). Investors who purchased Regeneron securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/REGN.
- 06/02/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
- NEW YORK, NY / ACCESSWIRE / June 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ:REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 06/01/2024
|
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/01/2024
|
ONGOING INVESTIGATION UPDATE: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/31/2024
|
Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
- NEW YORK, NY / ACCESSWIRE / May 31, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN). Investors who purchased Regeneron securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/REGN.
- 05/31/2024
|
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
- Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function
- 05/31/2024
|
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
- Dupixent recommended for EU approval by the CHMP to treat patients with COPD Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function If approved, Dupixent would be the first-ever targeted therapy for COPD in the EU and the first new treatment approach for this disease in more than a decade Paris and Tarrytown, N.Y. May 31, 2024.
- 05/31/2024
|
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
- Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation Paris and Tarrytown, NY May 31, 2024. The US Food and Drug Administration (FDA) has extended by three months the target action date of its priority review of the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD).
- 05/31/2024
|
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
- TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by three months the target action date of its priority review of the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD). The revised target action date is September 27, 2024. The FDA did not raise any concerns regarding the approvability of Dupixent for this indication.
- 05/31/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
- NEW YORK , May 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 05/30/2024
|
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/30/2024
|
3 Of My Favorite Names On Wells Fargo's Biotech Buyout List
- Wells Fargo recently tagged numerous midcap biotech/biopharma stocks as potential buyout targets. There are many names on this list that have been mentioned as acquisition candidates in the past and that could find themselves in Big Pharma's sights. I highlight three of my favorite equities on Wells Fargo's report that I currently hold in my personal accounts in the paragraphs below.
- 05/29/2024
|
Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
- -BHV-1510 is a novel trophoblast cell surface antigen-2 (Trop-2) directed antibody drug conjugate (ADC) that has demonstrated a highly differentiated preclinical monotherapy efficacy profile, the potential for broader therapeutic margin than other Trop-2 ADCs currently in development, and synergistic affects when combined with anti-PD1 therapy -Biohaven also entered into a clinical supply agreement with Regeneron to study the combination of BHV-1510 with Regeneron's anti-PD-1 Libtayo® (cemiplimab-rwlc) in the Phase 1/2 clinical trial -Malignancies of epithelial tissue account for the vast majority of all cancers and the advanced or metastatic forms of these carcinomas represent an urgent unmet medical need NEW HAVEN, Conn. , May 29, 2024 /PRNewswire/ -- Biohaven Ltd.
- 05/29/2024
|
2 Biotech Stocks to Buy in May
- Vertex is diversifying, moving beyond a therapeutic area it has thoroughly dominated. Regeneron has three important growth drivers and a pipeline that should produce more.
- 05/25/2024
|
Regeneron (REGN) Announces Positive Data on Oncology Candidate
- Regeneron's (REGN) REGN7075, in combination with its oncology drug Libtayo, generates anti-tumor responses in patients with microsatellite-stable colorectal cancer.
- 05/24/2024
|
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
- Oral presentation to highlight activity of REGN7075 in combination with Libtayo from dose-escalation portion of trial in patients with microsatellite stable colorectal cancer, which has historically proven unresponsive to immunotherapy
- 05/23/2024
|
Mary Kay Awards Grants to Five Aspiring Young Scientists at Regeneron International Science and Engineering Fair
- DALLAS--(BUSINESS WIRE)--Mary Kay Inc., a corporate cheerleader in support of STEM education and youth pursuing their dreams, recently awarded three grants to five standout high school scientists, selected from nearly 2,000 participants representing almost 70 countries, with grants at the Regeneron International Science & Engineering Fair (ISEF) in Los Angeles. The grants—totaling nearly $10,000—were awarded to students with innovative projects focused on finding cures for cancers affecting.
- 05/23/2024
|
3 Stocks That Have Turned $25,000 Into More Than $1 Million in 15 Years
- Nvidia achieved some phenomenal returns of late, and even before the emergence of generative artificial intelligence, it was a millionaire maker. Netflix transformed itself from a DVD rental company to a massive, profitable streaming leader in 15 years.
- 05/23/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
- NEW YORK , May 22, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 05/22/2024
|
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
- NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation
- 05/20/2024
|
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
- Dupixent ® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD Paris and Tarrytown, N.Y. May 20, 2024.
- 05/20/2024
|
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
- Fundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying prioritization. While the media focuses on attaining wealth, that doesn't mean much if you don't have health.
- 05/20/2024
|
International Assets Investment Management LLC Decreases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
- International Assets Investment Management LLC lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 13.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 673 shares of the biopharmaceutical company’s stock after selling 102 shares during the period. International Assets Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $591,000 as of its most recent SEC filing. A number of other institutional investors have also made changes to their positions in REGN. Drive Wealth Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 4.0% during the 4th quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock valued at $273,000 after buying an additional 12 shares during the last quarter. Sutton Wealth Advisors Inc. grew its holdings in Regeneron Pharmaceuticals by 38.2% during the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 13 shares in the last quarter. Clearview Wealth Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 1.5% in the 4th quarter. Clearview Wealth Advisors LLC now owns 855 shares of the biopharmaceutical company’s stock worth $751,000 after purchasing an additional 13 shares during the last quarter. Smithfield Trust Co lifted its position in shares of Regeneron Pharmaceuticals by 11.0% during the third quarter. Smithfield Trust Co now owns 141 shares of the biopharmaceutical company’s stock worth $117,000 after purchasing an additional 14 shares during the last quarter. Finally, Simon Quick Advisors LLC grew its stake in Regeneron Pharmaceuticals by 3.2% in the fourth quarter. Simon Quick Advisors LLC now owns 449 shares of the biopharmaceutical company’s stock worth $394,000 after purchasing an additional 14 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds. Regeneron Pharmaceuticals Stock Up 1.5 % Shares of NASDAQ:REGN opened at $982.29 on Monday. The firm has a 50 day simple moving average of $942.68 and a 200 day simple moving average of $909.82. Regeneron Pharmaceuticals, Inc. has a 52 week low of $684.80 and a 52 week high of $998.33. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. The company has a market cap of $108.24 billion, a PE ratio of 29.02, a price-to-earnings-growth ratio of 2.02 and a beta of 0.17. Insider Activity In related news, CEO Leonard S. Schleifer sold 22,830 shares of the company’s stock in a transaction on Friday, May 17th. The stock was sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the transaction, the chief executive officer now directly owns 466,877 shares of the company’s stock, valued at $457,179,964.71. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 22,830 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the transaction, the chief executive officer now owns 466,877 shares of the company’s stock, valued at approximately $457,179,964.71. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Marion Mccourt sold 358 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $967.50, for a total transaction of $346,365.00. Following the completion of the sale, the executive vice president now directly owns 13,431 shares of the company’s stock, valued at $12,994,492.50. The disclosure for this sale can be found here. Insiders sold 55,925 shares of company stock worth $54,616,836 over the last quarter. Corporate insiders own 8.83% of the company’s stock. Analyst Ratings Changes Several brokerages have issued reports on REGN. Sanford C. Bernstein assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price objective on the stock. Truist Financial restated a “buy” rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Cantor Fitzgerald reiterated a “neutral” rating and set a $925.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, May 3rd. UBS Group raised their price target on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. Finally, Bank of America boosted their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research report on Friday, April 12th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $989.36. View Our Latest Stock Analysis on REGN Regeneron Pharmaceuticals Company Profile (Free Report) Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. Read More Five stocks we like better than Regeneron Pharmaceuticals Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time MarketBeat Week in Review – 5/13 – 5/17 Where to Find Earnings Call Transcripts Take-Two Interactive Software Offers 2nd Chance for Investors Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
- 05/20/2024
|
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/19/2024
|
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/18/2024
|
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
- Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world's largest pre-college science, technology, engineering and math (STEM) competition. Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world's largest pre-college science, technology, engineering and math (STEM) competition.
- 05/17/2024
|
IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/17/2024
|
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
- NEW YORK--(BUSINESS WIRE)---- $REGN #Investigation--The law firm of Kirby McInerney LLP reminds investors that the firm is investigating potential claims against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN). The firm's ongoing investigation concerns whether Regeneron and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On April 10, 2024, the U.S. Department of Just.
- 05/16/2024
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/16/2024
|
These 2 No-Brainer Growth Stocks Are Breaking New Ground
- Eli Lilly and Regeneron are developing competing hearing-loss gene therapies. These drugmakers have solid businesses thanks to their innovative qualities.
- 05/16/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/15/2024
|
Calls of the Day: Roblox, Regeneron, Costco and Edison
- The Investment Committee discuss the latest Calls of the Day
- 05/14/2024
|
Regeneron Pharmaceuticals Inc (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN ) RBC Capital Markets Global Healthcare Conference May 14, 2024 9:00 AM ET Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Chris Fenimore - Senior VP of Finance & CFO Conference Call Participants Brian Abrahams - RBC Brian Abrahams All right. Let's get started.
- 05/14/2024
|
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
- If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled CRSwNP, a condition driven in part by underlying type 2 inflammation that obstructs the sinuses and nasal passages and can lead to a loss of sense of smell
- 05/13/2024
|
Will the Biotech Sector Shift From Lagger to Leader?
- The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the sector has enjoyed a significant rally after bouncing off its uptrend support and now consolidating near several major Simple Moving Averages (SMA).
- 05/10/2024
|
Regeneron's experimental gene therapy improves hearing in one patient
- Regeneron Pharmaceuticals said on Wednesday its investigational gene therapy improved hearing to normal levels in a child within 24 weeks in an early to mid-stage study.
- 05/08/2024
|
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
- Preliminary data detailed in an ASGCT oral presentation include results for one of the youngest children in the world to receive a gene therapy for genetic deafness
- 05/08/2024
|
Regeneron Announces Investor Conference Presentations
- TARRYTOWN, N.Y., May 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
- 05/06/2024
|
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
- Biotechnology offers breakthrough drugs and treatments that open new doors in the field of medicine. Companies are releasing more drugs and developing state-of-the-art methods to treat previously untreatable conditions.
- 05/04/2024
|
Shhh! 3 Secret Pharma Stocks Flying Below Wall Street's Radar
- Pharma stocks and massive potential go hand in hand. With devastating diseases like cancer, diabetes and heart disease still far from finding a cure, drugs that treat these conditions often command exorbitant prices.
- 05/03/2024
|
Regeneron's Q1 Results Came Up a Bit Short
- The biotech missed analysts' expectations on both EPS and revenue. Dupixent and Libtayo delivered substantial sales growth.
- 05/02/2024
|
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
- Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.
- 05/02/2024
|
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say
- Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 05/02/2024
|
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
- CRISPR Therapeutics, Regeneron, and Sanofi all deserve a close look now. These three biotechs have important growth drivers on the market.
- 05/02/2024
|
Regeneron's stock dips after earnings fall short of estimates
- Regeneron Pharmaceuticals Inc.'s stock REGN, +1.44% fell 3% early Thursday, after the company's first-quarter earnings fell short of estimates. The company had net income of $722 million, or $6.27 a share, in the quarter, down 12% from $818 million, or $7.17 a share, in the year-earlier period.
- 05/02/2024
|
Regeneron misses profit estimates on weaker Eylea and Dupixent sales
- U.S. drugmaker Regeneron Pharmaceuticals Inc missed Wall Street estimates for first-quarter profit on Thursday due to softer sales of its blockbuster eye drug Eylea and its eczema treatment, Dupixent.
- 05/02/2024
|
Regeneron Reports First Quarter 2024 Financial and Operating Results
- TARRYTOWN, N.Y., May 02, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2024 and provided a business update.
- 05/02/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 04/30/2024
|
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
- Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
- 04/30/2024
|
Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
- An increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided Regeneron (REGN) in partially offsetting the decline in Eylea sales.
- 04/30/2024
|
Down -8.24% in 4 Weeks, Here's Why Regeneron (REGN) Looks Ripe for a Turnaround
- Regeneron (REGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 04/29/2024
|
Countdown to Regeneron (REGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
- Evaluate the expected performance of Regeneron (REGN) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
- 04/29/2024
|
EXEL vs. REGN: Which Stock Is the Better Value Option?
- Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Regeneron (REGN). But which of these two stocks is more attractive to value investors?
- 04/25/2024
|
AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
- AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to-head study.
- 04/25/2024
|
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
- Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday.
- 04/25/2024
|
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
- Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
- 04/17/2024
|
Why Regeneron (REGN) Could Beat Earnings Estimates Again
- Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 04/16/2024
|
Regeneron to defend US Justice Department's complaint on drug-pricing manipulation
- Regeneron Pharmaceuticals said on Monday the U.S. Justice Department's complaint against the company misreporting the average sales price for its macular degeneration drug Eylea is "meritless" and it plans to defend this case in court.
- 04/15/2024
|
Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea
- The U.S. Department of Justice files a complaint against Regeneron (REGN), alleging fraudulent drug pricing practices related to its lead drug, Eylea.
- 04/12/2024
|
Regeneron Stock Under Microscope After DOJ Price Reporting Complaint—Key Levels to Watch
- Shares in biotech giant Regeneron Pharmaceuticals (REGN) go under the microscope Thursday after the U.S. Department of Justice (DOJ) accused the company of manipulating Medicare's drug pricing reporting by inflating the average sales price of its best-selling eye disease drug Eylea.
- 04/11/2024
|
Regeneron Pharma falls after US government alleges fraud
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN) faced a blow in pre-market trading after being hit with fraud allegations from the US Justice Department. Regeneron allegedly inflated the sales price of its macular degeneration drug Eylea to boost revenues from Medicare, according to the department.
- 04/11/2024
|
EXEL or REGN: Which Is the Better Value Stock Right Now?
- Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Regeneron (REGN). But which of these two stocks presents investors with the better value opportunity right now?
- 04/09/2024
|
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
- TARRYTOWN, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 2, 2024, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
- 04/01/2024
|
Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate
- Regeneron Pharmaceuticals, Inc.'s Eylea HD reinforces its market dominance in treating wet AMD, competing effectively against biosimilars and Roche's Vabysmo. Libtayo's revenue growth is impressive, with expectations to become a blockbuster, enhancing Regeneron's oncology presence. Regeneron benefits financially from Dupixent sales and a strong balance sheet, indicating robust financial health and investment in pipeline development.
- 03/26/2024
|
Regeneron's (REGN) Lymphoma Candidate Rejected by the FDA
- Regeneron's (REGN) efforts to expand its oncology portfolio get a hit as the FDA refuses to approve the lymphoma drug odronextamab.
- 03/26/2024
|
3 Biotech Stocks to Buy for the Next Bull Run: March 2024
- As we step into March 2024, the spotlight is turning towards the biotech sector, with investors searching for biotech stocks to buy. Biotech stocks are ready to soar after a period of under-performance relative to the broader market.
- 03/26/2024
|
US FDA declines to approve Regeneron's blood cancer therapy
- Regeneron Pharmaceuticals said on Monday the U.S. FDA has declined to approve its blood cancer therapy for two most common subtypes of non-Hodgkin lymphoma due to an issue related to enrollment of its confirmatory trials.
- 03/25/2024
|
Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs
- Prescription weight loss drugs, like GLP-1 agonists and orlistat, offer effectiveness for some individuals and have proven effects the market has taken notice of. These drugs focus on curbing appetite, which investors in weight loss drug stocks have noticed.
- 03/22/2024
|
US appeals court revives Regeneron's antitrust lawsuit against Novartis
- A U.S. appeals court on Monday revived an antitrust lawsuit by Regeneron Pharmaceuticals against Novartis related to prescription treatments to address a condition that can lead to eye disorders including permanent blindness.
- 03/18/2024
|
Calls of the Day: Regeneron, Thermo Fisher, Darden Restaurants and Nucor
- The Investment Committee debate the latest calls of the day on a number of stocks.
- 03/13/2024
|
Regeneron (REGN) Gets FDA Nod for Praluent Label Extension
- Regeneron (REGN) obtains FDA approval for Praluent as an adjunct to diet and other LDL-C, lowering therapies to include pediatric patients aged eight and older with HeFH.
- 03/12/2024
|
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)
- 03/12/2024
|
Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.
- Madrigal Pharmaceuticals could be days away from winning its first FDA approval. Regeneron Pharmaceuticals expects several key regulatory decisions this year.
- 03/09/2024
|
2 Biotech Stocks to Buy Hand Over Fist in March
- Regeneron boasts a pair of growth drivers that should still have plenty of fuel left. Exelixis is close to expanding its lineup with a promising late-stage candidate.
- 03/08/2024
|
EXEL vs. REGN: Which Stock Is the Better Value Option?
- Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Regeneron (REGN). But which of these two stocks offers value investors a better bang for their buck right now?
- 03/06/2024
|
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
- If you're looking for biotech stocks to buy, the iShares Biotechnology ETF (NASDAQ: IBB ) is an excellent place to start. It tracks the performance of the ICE Biotechnology Index, a collection of U.S. companies in the biotech industry.
- 03/04/2024
|
Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024
- Regeneron Pharmaceuticals reported strong Q4/2023 earnings, exceeding expectations and showing impressive growth from Dupixent and Libtayo. The company's next generation of blockbuster drugs are offsetting fading EYLEA sales, extending Regeneron's growth track into the next decade. Regeneron's big growth drivers are its Retinal franchise, Dupixent, and Libtayo, with potential supplementary drivers in immuno-oncology combinations and the obesity market.
- 02/10/2024
|
EXEL or REGN: Which Is the Better Value Stock Right Now?
- Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Regeneron (REGN). But which of these two stocks offers value investors a better bang for their buck right now?
- 02/08/2024
|
Regeneron Announces Investor Conference Presentations
- TARRYTOWN, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
- 02/06/2024
|
Stock-Split Watch: Could These 2 Market-Beaters Be Next?
- MercadoLibre's shares are trading at more than $1,000, while Regeneron's are getting close to that price. Neither company has ever conducted a stock split.
- 02/06/2024
|
Regeneron (REGN) Q4 Earnings & Sales Top, Eylea Sales Decline
- Regeneron (REGN) beats earnings and sales estimates in fourth-quarter 2023, fueled by Dupixent. However, sales of the lead drug, Eylea, continue to fall.
- 02/02/2024
|
Regeneron's Push Into Obesity, Q4 2023 Earnings Review
- Regeneron returned to topline growth in 2023 and this has led to the company's valuation rising to my expected EV/revenue range. The company is making significant investments in the obesity space, focusing on preserving lean mass and reducing fat mass. Q4 2023 earnings review shows further stabilization of the Eylea franchise, continued strong growth of Dupixent, and Libtayo, and we could see additional approvals this year.
- 02/02/2024
|
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2023 Earnings Call Transcript
- Regeneron Pharmaceuticals, Inc. (REGN) Q4 2023 Earnings Call Transcript
- 02/02/2024
|
Regeneron (REGN) Reports Q4 Earnings: What Key Metrics Have to Say
- Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 02/02/2024
|
Regeneron (REGN) Q4 Earnings and Revenues Top Estimates
- Regeneron (REGN) came out with quarterly earnings of $11.86 per share, beating the Zacks Consensus Estimate of $10.43 per share. This compares to earnings of $12.56 per share a year ago.
- 02/02/2024
|
3 Top Pharma Stocks to Buy Now: February 2024
- Looking for pharma stocks to buy in February 2024? The pharmaceutical industry has always drawn a big crowd of investors.
- 02/01/2024
|
Gear Up for Regeneron (REGN) Q4 Earnings: Wall Street Estimates for Key Metrics
- Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
- 01/30/2024
|
5 U.S. Corporate Giants to Buy on Solid Economic Data
- We have narrowed our search to five U.S. corporate giants that have strong potential for 2024. These are: NFLX, PGR, BK, ANET, REGN.
- 01/29/2024
|
Earnings Preview: Regeneron (REGN) Q4 Earnings Expected to Decline
- Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 01/26/2024
|
US FDA approves Dupixent to treat younger kids with esophageal condition
- The U.S. health regulator has approved the use of Regeneron and Sanofi's Dupixent to treat an allergic inflammation of the esophagus in children aged one to 11 years old and weighing at least 15 kg, the companies said on Thursday.
- 01/25/2024
|
3 Blue-Chip Healthcare Stocks to Buy and Hold Forever: January 2024
- Blue-chip healthcare stocks tend to be among the top portfolio picks for long-term investors today. Though their blue-chip status implies maturity, which they have, it also implies that the companies have limited growth prospects.
- 01/23/2024
|
S&P 500 Index Hits All-Time High: 5 Must-Buy Stocks
- We have narrowed our search to five S&P 500 stocks that have strong growth potential in 2024. These are: NVDA, REGN, ANET, IT, MLM.
- 01/22/2024
|
Regeneron (REGN), Sanofi's Dupixent Gets Label Update in US
- The FDA updates Regeneron (REGN) and Sanofi's Dupixent label in the United States to include efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement.
- 01/17/2024
|
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
- Biotech stocks, and the sector in general, saw a widespread beat down over the past two years. Venture capital dried up, post-pandemic healthcare landscapes shifted, and regulatory clampdowns tightened already-slim margins.
- 01/16/2024
|
Regeneron (REGN) Is Up 3.97% in One Week: What You Should Know
- Does Regeneron (REGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 01/12/2024
|
3 health care stocks off to strong starts in 2024
- Up 2% five trading days into the new year, global health care stocks have already matched their return for all of 2023. It's very early, but the sector has outpaced all other 10 economic groups since the ball dropped in Times Square.
- 01/10/2024
|
AI is the big thing right now, but the real tool is genetics, says Regeneron CEO Dr. Schleifer
- Regeneron CEO Dr. Leonard Schleifer joins 'Mad Money' host Jim Cramer to talk cancer treatments, quarterly earnings, weight loss medication and more.
- 01/09/2024
|
Regeneron CEO: We want to retain efficacy and eliminate bad side effects with our cancer treatments
- Regeneron CEO Dr. Leonard Schleifer joins 'Mad Money' host Jim Cramer to talk cancer treatments, quarterly earnings, weight loss medication and more.
- 01/09/2024
|
Regeneron CEO says the next big thing for biotech isn't AI, it's gene therapy
- Regeneron CEO Leonard Schleifer detailed the biotech company's newest ventures in the pharmaceutical industry.
- 01/09/2024
|
Regeneron (REGN) Down as Q4 Eylea Preliminary Sales Disappoint
- Regeneron (REGN) shares decline after it announces preliminary Q4 sales for the ophthalmology drug Eylea.
- 01/09/2024
|
Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript)
- Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript)
- 01/08/2024
|
Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade)
- Regeneron Pharmaceuticals, Inc.'s shares have risen over 25% in recent months, reaching over $910 per share - a premium explained partly by share buybacks. The company's market cap is around $100 billion, despite generating substantially lower revenues compared to larger Pharmas such as, e.g., Gilead Sciences and Bristol Myers Squibb. Regeneron has consistently delivered profitable net income, however, and management may be prepared to start paying a dividend soon.
- 01/08/2024
|
Regeneron hints at 4Q US sales of Eylea below expectations
- Regeneron Pharmaceuticals (NASDAQ:REGN) shares fell over 3% in early Monday afternoon trading after it told investors that US net product sales of its franchise of Eylea totalled about $1.46 billion in the fourth quarter of 2023, below analysts' consensus estimates. The figures for the eye drug were divulged in a presentation by the company at the 42nd Annual J.P.
- 01/08/2024
|
5 Stocks in S&P 500 ETF That Braved the Worst Start Since 2016
- The S&P 500 had the worst start to a year since 2016, reflecting a sharp reversal of the roaring rally in the final two months of 2023. Despite the losses, some stocks in the ETF stood tall.
- 01/08/2024
|
Regeneron reports preliminary Q4 U.S. sales of Eylea at $1.34 bln
- Regeneron Pharmaceuticals said on Monday its franchise of eye drug Eylea recorded preliminary sales of $1.34 billion in the United States in the fourth quarter.
- 01/08/2024
|
Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024
- TARRYTOWN, N.Y., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2023 financial and operating results on Friday, February 2, 2024, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
- 01/05/2024
|
3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024
- REGN, BGNE & SRPT are three biotech companies that are likely to outperform the sector on the back of strong fundamentals.
- 01/05/2024
|
Earnings Estimates Moving Higher for Regeneron (REGN): Time to Buy?
- Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 01/03/2024
|
Regeneron (REGN) Surges 3.0%: Is This an Indication of Further Gains?
- Regeneron (REGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
- 01/03/2024
|
Top 5 Momentum Picks for January After a Fabulous 2023
- We have narrowed our search to five large-cap stocks that have strong momentum for January. These are BGNE, SHOP, REGN, SPLK and CASY.
- 01/03/2024
|
Buy These 4 Low-Beta Stocks to Counter Market Volatility
- It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Otter Tail (OTTR), Regeneron (REGN), Kanzhun Limited (BZ) and Stride (LRN) are well-poised to gain.
- 01/03/2024
|
2 gene-editing stocks reshaping hereditary disease treatments
- Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal Drug Administration (FDA) approved a sickle-cell disease treatment, Casgevy, utilizing gene-editing technology developed by Vertex Pharmaceuticals Inc. NASDAQ: VRTX and CRISPR Therapeutics AG NASDAQ: CRSP.
- 01/02/2024
|
Where Will Regeneron Pharmaceuticals Be in 1 Year?
- The recent launch of Eylea HD should lead to stronger sales growth for Regeneron next year. The company's hematology-oncology business could get a boost with a possible drug approval.
- 12/22/2023
|
7 Undervalued Nasdaq-100 Stocks for Bargain Hunters
- Understandably, with the innovation sector printing a remarkable performance, all eyes have centered on Nasdaq-100 stocks. Indeed, on a year-to-date basis, the index shot up about 52%.
- 12/21/2023
|
5 Big Drug Stocks That May Continue to Outperform in 2024
- Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.
- 12/18/2023
|
It's Almost 2024: 3 Top Stocks to Buy Before the New Year
- Coca-Cola offers investors the security of growing dividend payments. Alphabet and Regeneron have delivered long track records of growth -- and more is on the way.
- 12/17/2023
|
Wells Fargo's top pharma picks for 2024
- Mohit Bansal, Wells Fargo Analyst, joins 'Closing Bell: Overtime' to discuss Wells Fargo's pharma picks for 2024.
- 12/15/2023
|
Regeneron Pharmaceuticals Inc. (REGN) American Society of Hematology 2023 Investor Conference - (Transcript)
- Regeneron Pharmaceuticals Inc. (NASDAQ:REGN ) American Society of Hematology 2023 Investor Conference Call December 14, 2023 8:30 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations George Yancopoulos - Board Co-Chair, Co-Founder, President and Chief Scientific Officer Andres Sirulnik - Senior Vice President, Translational & Clinical Sciences, Hematology Conference Call Participants Beth Scott - TD Cowen Nicole Germino - Truist Securities Carter Gould - Barclays Malcolm Hoffman - BMO Capital Markets David Risinger - Leerink Partners Christopher Raymond - Piper Sandler Hartaj Singh - Oppenheimer and Company Operator Welcome to the Regeneron Pharmaceuticals' ASH 2023 Investor Conference Call. My name is Shannon and I'll be your operator for today's call.
- 12/14/2023
|
Regeneron (REGN) Posts Positive Data on Blood Cancer Candidate
- Regeneron's (REGN) multiple myeloma candidate demonstrates strong rates and depth of response in pre-treated patients.
- 12/08/2023
|
3 biotech powerhouses poised to thrive amid sector rebound
- The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, has lagged the overall market during the year. However, in recent weeks, the sector has enjoyed a significant rally and turnaround off its 52-week lows.
- 12/08/2023
|
Could Regeneron Pharmaceuticals Stock Help You Become a Millionaire?
- Regeneron has a strong and diverse business with a couple of key assets in Eylea and Dupixent. The company also has dozens of trials ongoing that can further bolster its growth prospects.
- 12/08/2023
|
Calls Of The Day: Autozone Deere and Regeneron named top picks
- Autozone, Deere, Regeneron and Apollo Global getting some bullish calls today. The Investment Committee debates what it means for the stocks and how to trade them.
- 12/06/2023
|
Replimune shares plunge as skin cancer therapy fails to meet primary clinical-trial goals
- Replimune Group Inc. shares REPL, +5.21% dropped more than 40% premarket on Tuesday after the biotech company said an investigational cancer therapy had failed to meet its primary goals in a clinical trial in skin cancer. The therapy, RP1, was studied in combination with cemiplimab, a Regeneron Pharmaceuticals Inc. REGN, +1.04% monoclonal antibody branded as Libtayo.
- 12/05/2023
|
Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio
- TARRYTOWN, N.Y., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and simultaneous webcast to provide an update on the company's hematology portfolio on Thursday, December 14, 2023 at 8:30 AM ET. This investor call follows Regeneron data updates presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, from December 9-12, 2023.
- 11/30/2023
|
Regeneron (REGN), Sanofi's Dupixent Succeeds in 2nd COPD Study
- Regeneron (REGN) and partner Sanofi (SNY) post positive data from the second COPD study and plan to submit a sBLA to the FDA by the end of 2023.
- 11/27/2023
|
3 Biotech Stocks To Watch Before December 2023
- Biotech stocks to check out in the stock market today.
- 11/27/2023
|
Regeneron (REGN) Stock Rallies 10% YTD: What Lies Ahead?
- Regeneron (REGN) shares gain 10% year to date on Eylea HD's approval and Dupixent's momentum. Pipeline progress is impressive as well.
- 11/24/2023
|
HRMY vs. REGN: Which Stock Is the Better Value Option?
- Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two stocks offers value investors a better bang for their buck right now?
- 11/21/2023
|
Regeneron Announces Investor Conference Presentation
- TARRYTOWN, N.Y., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
- 11/15/2023
|
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Truist Securities BioPharma Symposium (Transcript)
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Truist Securities BioPharma Symposium November 8, 2023 3:20 PM ET Company Participants Dr. Len Schleifer - President and Chief Executive Officer Ryan Crowe - Investor Relations Conference Call Participants Robyn Shelton - Truist Securities Robyn Shelton Good morning, everyone. What a delight to have Dr. Len Schleifer here today.
- 11/11/2023
|
Regeneron Pharmaceuticals Inc. (REGN) UBS Biopharma Conference (Transcript)
- Regeneron Pharmaceuticals Inc. (NASDAQ:REGN ) UBS Biopharma Conference Call November 9, 2023 11:00 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Brook Jennings - Vice President, Immunology Marketing Conference Call Participants Colin Bristow - UBS Colin Bristow Well, good morning, and welcome to the UBS Biopharma Conference. I am Colin Bristow, one of the biotech analysts here.
- 11/11/2023
|
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
- Amid some rising questions for the economy, value-seeking investors may want to consider underappreciated biotech stocks. As a sector that, while not immune to broader pressures, generally manages to march to its own beat, the underlying innovation may offer an alternative upside pathway.
- 11/09/2023
|
HRMY vs. REGN: Which Stock Should Value Investors Buy Now?
- Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two stocks is more attractive to value investors?
- 11/03/2023
|
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2023 Earnings Call Transcript
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Ryan Crowe – Vice President-Investor Relations Leonard Schleifer – President and Chief Executive Officer George Yancopoulos – President and Chief Scientific Officer Marion McCourt – Executive Vice President and Head-Commercial Bob Landry – Executive Vice President and Chief Financial Officer Conference Call Participants Evan Seigerman – BMO Capital Markets Mohit Bansal – Wells Fargo Chris Raymond – Piper Sandler Colin Bristow – UBS Tyler Van Buren – TD Cowen Carter Gould – Barclays Robyn Karnauskas – Truist Securities Salveen Richter – Goldman Sachs Brian Abrahams – RBC Capital Markets Yatin Suneja – Guggenheim Dane Leone – Raymond James Brian Skorney – Baird Operator Welcome to the Regeneron Pharmaceuticals Third Quarter 2023 Earnings Conference Call. My name is Shannon, and I will be your operator for today's call.
- 11/02/2023
|
Regeneron Pharma's adjusted earnings beat estimates
- Regeneron Pharmaceuticals Inc.'s stock REGN, +1.46% rose fractionally on Thursday after the drug maker said its profit dropped by 23%, while its adjusted results beat analyst expectations. Regeneron said its third-quarter net income fell 23% to $1 billion, or $8.89 a share, from $1.32 billion, or $11.66 a share, in the year-ago quarter.
- 11/02/2023
|
1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years
- The healthcare sector has produced several of the best-performing stocks since World War II. The secret to their outperformance has been their laser-like focus on innovation.
- 11/02/2023
|
Regeneron beats quarterly profit estimates on eczema treatment strength
- Regeneron Pharmaceuticals on Thursday beat Wall Street estimates for third-quarter profit, driven by strong demand for its eczema treatment Dupixent.
- 11/02/2023
|
Curious about Regeneron (REGN) Q3 Performance? Explore Wall Street Estimates for Key Metrics
- Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2023.
- 11/01/2023
|
Regeneron Announces Investor Conference Presentations
- TARRYTOWN, N.Y., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
- 10/25/2023
|
2 Healthcare Stocks Near 52-Week Highs Still Worth Buying
- Healthcare stocks, on balance, haven't been great investments in 2023. Regeneron Pharmaceuticals and Vertex Pharmaceuticals have been two glaring exceptions to this trend.
- 10/16/2023
|
AI Stocks AVGO And ANET Lead 5 Resilient Names Near Buy Points
- AI stocks Broadcom and Arista lead five names near buy points all sporting a flat base, showing resilience in a tough market.
- 10/14/2023
|
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
- Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 10/06/2023
|
This Market-Beating Stock Just Gave Investors More Reasons to Invest
- Regeneron recently earned a key regulatory approval. The company also expanded its pipeline with an acquisition.
- 10/05/2023
|
Here's the Best Big Pharma Stock of the Decade so Far (and It's Not Even Close)
- There have been relatively few big winners among pharma stocks so far in the 2020s. One big pharma stock stands out as the clear leader by roughly tripling over the last nearly four years.
- 10/05/2023
|
Regeneron, Intellia Therapeutics expand research collaboration to make gene editing therapies
- Regeneron Pharmaceuticals and Intellia Therapeutics have expanded their research collaboration to develop additional CRISPR-based gene editing therapies focused on neurological and muscular diseases, the companies said on Tuesday.
- 10/03/2023
|
Stock Split Watch: Is Regeneron Pharmaceuticals Next?
- Regeneron's share price has climbed by more than 100% over five years and is trading near its record high. The company sells a variety of products across indications and has a solid pipeline that could drive future growth.
- 09/30/2023
|
Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023
- TARRYTOWN, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2023 financial and operating results on Thursday, November 2, 2023, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
- 09/28/2023
|
Are Gene Therapy Stocks The Market's Next Big Winners?
- It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASDAQ: SRPT, which are developing gene therapies. ‘
- 09/25/2023
|
This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost
- Regeneron's sales growth rate has been struggling over the past year. Revenue from its top-selling drug, Eylea, fell 7% in the most recent quarter.
- 09/20/2023
|
Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare
- Regeneron Pharmaceuticals, Inc. is a pharmaceutical company headquartered in Tarrytown that has played a key role in the fight against COVID-19. Regeneron's revenue for the second quarter of 2023 was $3.16 billion, an increase of 10.5% compared to the second quarter of 2022. At the end of the second quarter, the remaining authorization to repurchase Regeneron Pharmaceuticals shares amounted to $2.332 billion.
- 09/19/2023
|
Regeneron's pricing deal with federal government may have ‘far-reaching consequences,' analysts say
- Regeneron Pharmaceuticals Inc.'s REGN, +0.74% agreement with the federal government to limit the list price of any new COVID monoclonal antibody commercialized as a result of their public-private partnership may have “far-reaching consequences” for drug pricing, Beacon Policy Advisors analysts wrote in a note Friday. Under the deal, part of the federal government's Project NextGen initiative to accelerate development of new COVID vaccines and treatments, Regeneron agreed that the U.S. list price of any new product stemming from the partnership will be less than or equal to its price in comparable markets globally, the U.S. Department of Health and Human Services announced last week.
- 09/15/2023
|
Is Regeneron Stock Fully Valued At $820?
- Regeneron stock (NASDAQ: REGN) has seen a 6% rise in a month, compared to a 1% fall for the broader S&P500 index.
- 09/11/2023
|
Regeneron CFO Landry to retire, top accountant Fenimore to become CFO
- Regeneron Pharmaceuticals Inc. REGN, +0.66% said late Friday that Chief Financial Officer Robert E. Landry will retire in February, and Christopher Fenimore, the pharma company's current head of accounting and controller, will succeed Landry upon his retirement.
- 09/08/2023
|
2 Top Biotech Stocks to Buy in September
- Vertex and Regeneron have delivered solid financial results and stock market performance. Both biotechs have exciting pipelines that should produce key new approvals or label expansions.
- 09/08/2023
|
Regeneron (REGN) Gains 13% in 1 Month on FDA Nod For Eylea HD
- Regeneron (REGN) gains 13% in a month on the FDA's approval of a higher dose of Eylea and other positive updates.
- 08/31/2023
|
Oncology Market's Huge Potential Puts These Stocks in Focus
- The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made meaningful contributions in cancer treatment.
- 08/28/2023
|
Is Regeneron Stock a Buy Now?
- Regeneron's latest regulatory approval comes at an opportune time. The company's current lineup should continue generating growing sales.
- 08/25/2023
|
Regeneron Announces Investor Conference Presentations
- TARRYTOWN, N.Y., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
- 08/23/2023
|
Regeneron gets federal funding for next-generation COVID treatment
- Regeneron Pharmaceuticals Inc. REGN, -0.32% said Tuesday that the Biomedical Advanced Research and Development Authority has agreed to support the development, manufacturing and licensure of a next-generation COVID-19 monoclonal antibody. The agreement, part of the U.S. Department of Health and Human Services' Project NextGen initiative, provides up to $326 million of government funding, Regeneron said, noting that the federal agency will fund up to 70% of Regeneron's costs for certain clinical development activities for the therapy.
- 08/22/2023
|
Regeneron (REGN) Gets FDA Nod for Higher Dose of Eylea
- Regeneron (REGN) obtains FDA approval for a higher dose of aflibercept injection under the brand name Eylea HD for various ophthalmology indications. The regulatory body also approves Veopoz.
- 08/21/2023
|
Cramer dubs Regeneron stock a ‘favourite' after two new FDA approvals
- Regeneron Pharmaceuticals Inc (NASDAQ: REGN) secured FDA approval for Eylea HD – a higher-dose of its treatment for Macular Degeneration on Monday. Jim Cramer is bullish on Regeneron stock Shares of the biotech giant responded with an over 3.0% gain this morning.
- 08/21/2023
|
This biotech name is one of Jim Cramer's favorite stocks and he thinks it can go even higher
- "I think it's going to be worth more," Jim Cramer said Monday after Regeneron got good news from the FDA on its macular degeneration treatment.
- 08/21/2023
|
Cramer's Stop Trading: Regeneron
- CNBC's Jim Cramer explains why he is keeping an eye on shares of Regeneron
- 08/21/2023
|
Regeneron's Eylea could return to growth after nod to high-dose version- analysts
- A quicker-than-expected U.S. approval for Regeneron Pharmaceuticals' high-dose eye disease drug, Eylea, should help return the blockbuster treatment back to growth in the next few years, Wall Street analysts said.
- 08/21/2023
|
Regeneron Pharmaceuticals shares rise on FDA approval of higher dose of eye disorder drug EYLEA
- Regeneron Pharmaceuticals (NASDAQ:REGN) shares moved higher in pre-market trading after the biotechnology company reported on Friday that a higher dose of its eye disorder drug EYLEA has been approved by the Food and Drug Administration (FDA). The FDA approved EYLEA HD (aflibercept) Injection 8 mg for patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR).
- 08/21/2023
|
Regeneron shares climb after FDA approval of macular degeneration treatment
- Shares of Regeneron Pharmaceuticals Inc. REGN, +1.97% gained 1.4% premarket on Monday after the company said late Friday that the U.S. Food and Drug Administration had approved a higher-dose formulation of its macular degeneration treatment Eylea. The eight-milligram Eylea injection, jointly developed by Regeneron and Bayer AG BAYRY, -1.36%, is approved for treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, Regeneron said in a release.
- 08/21/2023
|
Is Regeneron Pharmaceuticals Still a Top Growth Stock?
- Regeneron Pharmaceuticals has delivered market-beating results for shareholders over the prior 10 years. With competition heating up, however, the biotech may be entering a period of slowing growth.
- 08/21/2023
|
Regeneron Gets Boost With FDA Approval Of High-Dose Eylea (Rating Upgrade)
- Regeneron reported strong Q2 2023 financial results, with an 11% YoY revenue surge to $3.2B, outperforming expectations. The FDA approved high-dose Eylea (8 mg), offering less frequent treatment, addressing prior third-party filler concerns and bolstering outlook. I recommend upgrading Regeneron's stock from 'Hold' to 'Buy', given the strong financials, promising drug developments, and recent FDA approval.
- 08/19/2023
|
US FDA approves Regeneron's 8-mg dose of eye disease drug Eylea
- The U.S. Food and Drug Administration approved the 8-mg dose of Regeneron Pharmaceuticals' eye disease drug Eylea, the company said in a statement on Friday.
- 08/18/2023
|
Regeneron gets FDA green light on first treatment for life-threatening immune disease
- Regeneron Pharmaceuticals Inc. REGN, +0.55% said Friday that the U.S. Food and Drug Administration has approved its treatment for CHAPLE disease, a rare and life-threatening hereditary immune disease. The treatment, Veopoz, is the first to be approved for the condition, which can cause the body to attack normal cells and damage blood and lymph vessels in the upper digestive tract.
- 08/18/2023
|
Regeneron's (REGN) Application for Blood Cancer Drug Accepted
- Regeneron's (REGN) application seeking approval of odronextamab for patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma gets accepted for review in the EU.
- 08/18/2023
|
3 Strong Biotech Performers To Watch As Sector Nears Breakout
- The biotech sector, iShares Biotechnology ETF NASDAQ: IBB, has been trading in a tight consolidation for several months. The ETF has a 50-day range of $124.38 and $131.81.
- 08/17/2023
|
The 7 Best Value Stocks to Buy in August
- While several market ideas have blossomed this year, many are overpriced, which naturally draws eyes to the best value stocks to buy. Here, we're talking about publicly traded securities that trade at a lower price relative to fundamental metrics, most commonly sales or earnings.
- 08/10/2023
|
Regeneron (REGN) to Buy Decibel, Gains on Hearing Loss Therapies
- Regeneron (REGN) further builds upon its collaboration with Decibel by acquiring the company to expand its gene therapy programs for hearing loss.
- 08/10/2023
|
Decibel Therapeutics Shares Soar on Acquisition by Regeneron Pharmaceuticals
- Shares of Decibel Therapeutics skyrocketed after Regeneron Pharmaceuticals agreed to buy the biotech firm for up to $213 million to expand its gene therapy pipeline.
- 08/09/2023
|
Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal
- Decibel Therapeutics (NASDAQ: DBTX ) stock is soaring higher on Wednesday after signing a deal with Regeneron Pharmaceuticals (NASDAQ: REGN ). This deal has Regeneron Pharmaceuticals agreeing to acquire Decibel Therapeutics for $4 per share in cash.
- 08/09/2023
|
Decibel Therapeutics shoots up 72% on Regeneron bid
- Shares of Boston's Decibel Therapeutics Inc soared 72% in the first minutes of trading after Regeneron Pharmaceuticals weighed looks calculated to be a knock-out bid for the tiny drug developer. The deal values Decibel Therapeutics, which is working on treatments aimed at enhancing and restoring hearing and balance, at $109 million.
- 08/09/2023
|
Regeneron buying small cap Decibel Therapeutics for $4 a share
- Regeneron Pharmaceuticals Inc. REGN, +0.72% said Wednesday it would pay $4 a share for Decibel Therapeutics Inc. DBTX, +1.09%, a 43% premium over its closing price of $2.79 a share in the previous session. Boston-based Decibel Therapeutics is a clinical-stage biotechnology company with a focus on discovering and developing transformative treatments to restore and improve hearing and balance.
- 08/09/2023
|
2 Top Stocks to Buy in August and Hold Forever
- Both of these companies are proven innovators in a necessary industry. Regeneron has two major products and a solid pipeline to drive excellent results.
- 08/06/2023
|
Regeneron Shares Jump After Saying It Expects an FDA Decision on Its Eye Treatment Soon
- Shares of Regeneron jumped after the drug maker indicated it expects the FDA will soon approve a higher-dose version of its blockbuster drug to treat macular degeneration.
- 08/03/2023
|
Regeneron (REGN) Q2 Earnings & Sales Top, Eylea Sales Decline
- Regeneron (REGN) beats earnings and sales estimates in second-quarter 2023 fueled by Dupixent. However, sales of the lead drug, Eylea, decline yet again.
- 08/03/2023
|
Regeneron Pharmaceuticals Inc: A Biotech Powerhouse with High Outperformance Potential
- Regeneron Pharmaceuticals Inc ( REGN , Financial), a leading player in the biotechnology industry, is currently trading at $780.98 with a market capitalization of $85.68 billion. The company's stock price has seen a gain of 6.67% today and an impressive 8.81% over the past four weeks.
- 08/03/2023
|
Drug Sales Surge Drives Regeneron Pharmaceuticals to Q2 Beat
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported second-quarter revenue of $10.24 per share on revenue of $3.16 billion today, blowing past analysts' expectations.
- 08/03/2023
|
Regeneron's stock rallies after profit, revenue rise above expectations, amid a jump in collaboration revenue
- Shares of Regeneron Pharmaceuticals Inc. REGN, -0.94% climbed 2.6% toward a 5-week high in premarket trading Thursday, after the biotechnology company reported second-quarter profit and revenue that rose above forecasts, amid strength in collaboration revenue. Net income rose to $968.4 million, or $8.50 a share, from $852.1 million, or $7.47 a share, in the year-ago period.
- 08/03/2023
|
Regeneron Pharma beats profit estimates on Dupixent demand
- Regeneron Pharmaceuticals Inc beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for eczema treatment Dupixent.
- 08/03/2023
|
Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points
- The biotechnology sector is huge and growing. Grand View Research forecasts that the industry will reach $3.88 trillion by 2030, growing at a compound annual growth rate of 14%.
- 08/01/2023
|
Regeneron (REGN) to Report Q2 Earnings: What's in Store?
- Investors' focus is likely to be on the performance of lead drugs Eylea and Dupixent when Regeneron (REGN) reports its second-quarter 2023 results.
- 07/28/2023
|
If You Can Only Buy One Biotech Stock, It Better Be One of These 3 Names
- The biotechnology industry is simply amazing, always advancing and bringing new drugs to fight complicated and serious diseases. If you are thinking about investing in this sector, it is crucial to know the best biotech stocks that can give you great returns.
- 07/26/2023
|
3 Pharma Stocks That AI is Loving in July
- When it comes to investing in pharmaceutical stocks, an intriguing area for future growth is gene editing. This is an exciting field that may provide a solution to some of our most vexing diseases, such as cancer and diabetes.
- 07/13/2023
|
3 Biotech Stocks to Buy for Long-Term Gains
- Suppose you're looking for a sector that will benefit from an end to the Federal Reserve's interest rate hiking campaign. In that case, you may look at biotech stocks, a sector filled with long-dated assets, meaning their value is sensitive to changes in interest rates.
- 07/13/2023
|
Why These 7 Stocks Are the Best Ways to Play Biotech Right Now
- Best biotech stocks represents a concept that, no matter what, the market cycle fundamentally delivers relevance. Now, let me back up by stating that no individual company offers a guarantee of success to investors.
- 07/11/2023
|
Is Regeneron Stock a Buy After a Regulatory Blow?
- Regeneron recently failed to earn approval for an important candidate. The biotech company should get over this regulatory hump eventually.
- 07/07/2023
|
Is Regeneron's Stock in Trouble After This FDA Rejection?
- The Food and Drug Administration didn't approve Regeneron's higher-dose version of Eylea. Regeneron isn't concerned, as the decision wasn't a result of any issues relating to the drug's safety or efficacy.
- 07/06/2023
|
The 3 Best Biotech Stocks to Buy In July
- Although it's been a difficult year for biotechnology stocks, there are still plenty of reasons for investors to be bullish on the sector. Many of the biggest innovations in medicine are occurring at small and midsized biotech companies in the U.S. These are the incubators for medical advancements and where important scientific breakthroughs are happening.
- 07/05/2023
|
Regeneron (REGN) Loses 13% in Three Months: What Lies Ahead?
- Regeneron (REGN) declines 13% in the last three months due to regulatory setback for 8 mg dose strength of aflibercept and competition for lead drug.
- 07/05/2023
|
Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023
- TARRYTOWN, N.Y., June 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2023 financial and operating results on Thursday, August 3, 2023, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
- 06/29/2023
|
Why Regeneron Pharmaceuticals Stock Dipped This Week
- Regeneron's high-dose version of Eylea was rejected by the FDA this week due to manufacturing issues. Wall Street thinks this setback will delay the drug's approval by no more than three months.
- 06/29/2023
|
Three-Stock Lunch: REGN, PINS & GNRC
- Lee Munson, Portfolio Wealth Advisors president and CIO, joins 'Power Lunch' to discuss three stocks: Regeneron, Pinterest and Generac Holdings.
- 06/28/2023
|
Regeneron drops as US FDA declines to approve higher-dose version of its eye disease treatment
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares plummeted by nearly 9% in after-hours trade on Tuesday after the US Food and Drug Administration (FDA) declined to approve a higher-dose version of the company's eye disease treatment. The rejected dosage was an 8-milligram injection of Eylea, intended for patients with wet age-related macular degeneration (wAMD), the primary cause of blindness among the elderly, as well as two other common eye diseases associated with diabetes.
- 06/28/2023
|
Regeneron (REGN) Gets CRL for Aflibercept 8 mg Drug, Shares Fall
- Regeneron (REGN) receives a completed response letter for the application seeking approval of aflibercept 8 mg for treating several retinopathic indications. The stock falls 9% following the news.
- 06/28/2023
|
Regeneron shares fall after FDA rejects high-dose eye disease treatment
- Regeneron said the rejection was "solely due to an ongoing review of inspection findings at a third-party filler."
- 06/27/2023
|
Regeneron Stock Slumps After FDA Decision Delays Blockbuster Release
- The Food and Drug Administration rejected its application for approval of a new, higher-dose version of eye disease treatment Eylea.
- 06/27/2023
|
Regeneron's high-dose Eylea not approved by FDA
- Regeneron Pharmaceuticals Inc. REGN, -1.34% said Tuesday that the U.S. Food and Drug Administration issued a complete response letter for the biologics license application for a higher-dose version of Eylea for treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. The complete response letter, which indicates that the FDA has decided not to approve an application in its present form, was issued solely due to an ongoing review of inspection findings at a third-party filler and did not identify any issues with the treatment's efficacy or safety, trial design, labeling or manufacturing, Regeneron said in a release Tuesday.
- 06/27/2023
|
US FDA declines to approve Regeneron high-dose Eylea
- The U.S. Food and Drug Administration on Tuesday declined to approve a higher-dose version of Regeneron Pharmaceuticals' blockbuster treatment Eylea, the company said, marking a blow in the drugmaker's plans to defend the eye drug against a fast-gaining rival.
- 06/27/2023
|
Regeneron Pharmaceuticals Inc. (REGN) Presents at Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)
- Regeneron Pharmaceuticals Inc. (NASDAQ:REGN ) Goldman Sachs 44th Annual Global Healthcare Conference June 14, 2023 11:40 AM ET Company Participants Ryan Crowe - VP, IR Bob Landry - EVP & CFO Marion McCourt - EVP & Head of Commercial Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Great. Good morning, everyone.
- 06/14/2023
|
2 Stocks to Buy No Matter What Happens in June and Beyond
- Regeneron has important regulatory milestones to hit in the next year. Microsoft's diversified business and growth opportunities bode well for its future.
- 06/14/2023
|
Regeneron: Solid Investment Based On Continued EYLEA Expansion
- Regeneron Pharmaceuticals, Inc. has potential to receive FDA approval of higher dosing of 8 mg of EYLEA, which has been set with an FDA target action date of June 27, 2023. The additional indication in preterm infants with retinopathy of prematurity makes it the fifth retinal disorder in which EYLEA has been approved for. Dupixent is another solid drug in the pipeline, where Regeneron and its collaboration partner recorded global net sales increase of 37% to $2.49 billion.
- 06/13/2023
|
Regeneron Pharmaceuticals, Inc. (REGN) Jefferies Global Healthcare Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Jefferies Global Healthcare Conference Call June 7, 2023 8:30 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Bolanle Akinlade - Senior Vice President, Clinical Development, Immunology & Inflammation Brook Jennings - Vice President, Commercial Dermatology Conference Call Participants Akash Tewari - Jefferies Akash Tewari Good morning, everyone. For those who just got back from ASCO, I feel sorry for you, I am exhausted as well.
- 06/07/2023
|
3 Biotech Stocks to Sell in June Before They Crash and Burn
- The biotechnology sector has seen better days. From the heady days of the pandemic when companies were racing to develop a vaccine against Covid-19, the industry is now enduring a hangover as both demand and sales decline.
- 06/06/2023
|
Regeneron Pharmaceuticals, Inc. (REGN) TD Cowen 4th Annual Oncology Innovation Summit (Transcript)
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) TD Cowen 4th Annual Oncology Innovation Summit May 30, 2023 12:30 PM ET Company Participants Izzy Lowy - SVP, Solid Organ Oncology Development Andres Sirulnik - SVP, Translational & Clinical Sciences, Hematology Ryan Crowe - VP, IR Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren All right. We'll give it a couple of seconds for everyone to join.
- 05/30/2023
|
Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study
- A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.
- 05/26/2023
|
Regeneron (REGN) Faces Challenges as Eylea Sales Decline
- Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the top line.
- 05/19/2023
|
Regeneron Announces Investor Conference Presentations
- TARRYTOWN, N.Y., May 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
- 05/18/2023
|
The 7 Growth Stocks You Need to Own Now for Maximum Returns
- Although recent headwinds like stubbornly high inflation and the banking sector crisis knocked the wind out of several publicly traded enterprises, a select number of hardened survivors potentially represent growth stocks to buy now. Using Gurufocus, all the companies below feature (on a per-share basis) five-year and ten-year growth rates of 20% and 15%, respectively.
- 05/17/2023
|
Regeneron Pharmaceuticals, Inc. (REGN) Bank of America Global Healthcare Conference Call Transcript
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Bank of America Global Healthcare Conference Call May 9, 2023 4:40 PM ET Company Participants Ryan Crowe - VP, IR Robert Landry - EVP, Finance & CFO Conference Call Participants Geoff Meacham - Bank of America Merrill Lynch Geoff Meacham Welcome to the afternoon of the first day of the BofA Healthcare Conference. So my name is Geoff Meacham.
- 05/13/2023
|
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
- Regeneron Pharmaceuticals Inc. NASDAQ: REGN gapped down more than 6% on May 4, despite reporting better-than-expected first-quarter earnings and revenue.
- 05/05/2023
|
Why Regeneron Pharmaceuticals Stock Is Tanking Today
- Regeneron Pharmaceuticals posted overall positive 2023 Q1 results today. Even so, investors are concerned about the competitive positioning of the drugmaker's blockbuster eye-care treatment.
- 05/04/2023
|
Regeneron (REGN) Q1 Earnings and Revenues Top Estimates
- Regeneron (REGN) came out with quarterly earnings of $10.09 per share, beating the Zacks Consensus Estimate of $9.25 per share. This compares to earnings of $11.49 per share a year ago.
- 05/04/2023
|
Regeneron Pharma Dives As Competition Undercuts Its Biggest Moneymaker
- Regeneron Pharmaceuticals beat first-quarter sales and profit calls, but Eylea revenue came up short and REGN stock tumbled. The post Regeneron Pharma Dives As Competition Undercuts Its Biggest Moneymaker appeared first on Investor's Business Daily.
- 05/04/2023
|
Regeneron tops Q1 estimates but lowers margin guidance, sending stock lower
- Regeneron Pharmaceuticals Inc. ‘s stock REGN, +0.59% slid 4% premarket Thursday, after the company topped estimates for first-quarter earnings but lowered margin guidance for 2023. The Tarrytown, N.Y.
- 05/04/2023
|
LGND vs. REGN: Which Stock Is the Better Value Option?
- Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Ligand Pharmaceuticals (LGND) and Regeneron (REGN). But which of these two stocks presents investors with the better value opportunity right now?
- 05/02/2023
|
Is a Beat on the Cards for Regeneron's (REGN) Q1 Earnings?
- Regeneron's (REGN) first-quarter earnings are likely to have gotten a boost from the solid performance of Dupixent.
- 05/01/2023
|
3 Biotech Stocks To Watch Today
- Biotech stocks for your late-April 2023 watchlist.
- 04/25/2023
|
4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates
- We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter.
- 04/24/2023
|
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
- Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
- 04/21/2023
|
The Greatest 7 Blue-Chip Stocks to Buy for Your Portfolio
- While the debate will certainly rage over which ideas legitimately rank as the greatest blue-chip stocks to buy of all time, for right now, certain enterprises stand out for a combination of their relevance and resilience. As well, a select few large-capitalization companies may be too undervalued and beaten down for their own good.
- 04/20/2023
|
Regeneron: New Highs Following Dupixent's COPD Data
- Shares of Regeneron jumped to new all-time highs following the successful phase 3 results of Dupixent in COPD. COPD could be a $3 billion or greater a year opportunity for Dupixent and should push its peak sales well above $20 billion by the end of the decade.
- 04/13/2023
|
Regeneron Announces Investor Conference Presentations
- TARRYTOWN, N.Y., April 11, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
- 04/11/2023
|
Investing $1,000 In These 2 Top Stocks Would Be a Great Move
- HCA Healthcare will recover from pandemic-related troubles given enough time. Regeneron's recent clinical and regulatory developments should improve its prospects.
- 04/09/2023
|
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
- Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 04/07/2023
|
2 Top Growth Stocks That Could Soar This Spring
- An experimental new gene therapy from Sarepta Therapeutics has an upcoming date with the Food and Drug Administration and a panel of independent experts. An approval decision coming in June could extend patent-protected exclusivity for Regeneron's biggest revenue stream.
- 04/06/2023
|
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
- The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
- 04/04/2023
|
Regeneron to Report First Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2023
- TARRYTOWN, N.Y., April 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2023 financial and operating results on Thursday, May 4, 2023, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
- 04/03/2023
|
Xeris Biopharma announces research evaluation collaboration and option agreement with Regeneron for XeriJect
- Xeris Biopharma Holdings (NASDAQ:XERS) told investors it has entered into a platform research evaluation collaboration and option agreement with Regeneron Pharmaceuticals Inc. Under the terms of the agreement, the company said it will use its proprietary drug-formulation platform, XeriJect, to develop ultra-highly concentrated, ready-to-use, small-volume subcutaneous injections of two undisclosed monoclonal antibodies (mAbs) developed by Regeneron. Xeris will receive an upfront payment and potential milestone payments for preclinical achievements.
- 03/30/2023
|
Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity?
- Dupixent's recent clinical data suggest it is a viable treatment option for adult patients with chronic obstructive pulmonary disease (COPD). The medicine could top $3 billion in annual revenue for Sanofi and Regeneron to split.
- 03/30/2023
|
Final Trades: Regeneron, Hess & Bank of America
- The "Halftime Report" traders give their top picks to watch for the second half.
- 03/27/2023
|
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
- Shares of Sanofi (NASDAQ: SNY) were up 10.20% the week ended March 24, while Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) finished with a gain of 9.68%, following promising news about the companies' jointly developed medication Dupixent.
- 03/27/2023
|
Regeneron, Sanofi Look for Billions From COPD Drug
- The companies said Dupixent showed positive results in a late-stage study of current or former smokers with the killer disease.
- 03/25/2023
|
Stock Trading Action Plan: Can The Market Bootstrap Itself To A Strong March Finish?
- The Nasdaq defended gains, plus its budding rally attempt, as stock trading heads into what could be a strong final week of March. The post Stock Trading Action Plan: Can The Market Bootstrap Itself To A Strong March Finish?
- 03/24/2023
|
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
- Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.
- 03/24/2023
|
Biotech Growth Stock Soars To New Highs On Lung Disease Breakthrough
- Regeneron is scaling new highs after a lung disease breakthrough and analyst upgrade. The post Biotech Growth Stock Soars To New Highs On Lung Disease Breakthrough appeared first on Investor's Business Daily.
- 03/24/2023
|
The Cream Of The Crop: 5 Biotech Stocks That Outrank 91% Of All Stocks
- The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
- 03/24/2023
|
Wall Street Has High Hopes for These 2 Nasdaq Stocks
- Markets were volatile early Friday. Regeneron got an analyst upgrade after releasing good news about a COPD treatment.
- 03/24/2023
|
ETFs in Focus on Sanofi and Regeneron's COPD Drug Data
- Shares of drugmakers Sanofi and Regeneron surged more than 6% on Mar 23 on COPD drug data.
- 03/24/2023
|
Regeneron (REGN) Soars 6.8%: Is Further Upside Left in the Stock?
- Regeneron (REGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 03/24/2023
|
Regeneron's Dupixent shows promise as COPD treatment
- CNBC's Meg Tirrell joins 'Closing Bell' to report that Regeneron's drug Dupixent has shown promise in treating COPD during phase 3 results.
- 03/23/2023
|
Sanofi, Regeneron shares pop more than 6% after data shows asthma drug Dupixent may also treat COPD
- Sanofi and Regeneron unveiled data on their jointly developed drug for a difficult-to-treat chronic lung disorder that analysts say "exceeded expectations."
- 03/23/2023
|
Why Shares of Regeneron Are Rising Thursday
- If Dupixent is approved to treat COPD, it will be the seventh indication for the drug. Regeneron's sales dropped 24% last year.
- 03/23/2023
|
Why Are Stocks Up Today?
- Stocks are up today as investors react to the latest news from the Federal Reverse concerning interest rate increases. The news traders are talking about is a 0.25% increase in interest rates.
- 03/23/2023
|
REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data
- Regeneron Pharmaceuticals (NASDAQ: REGN ) stock is on the rise Thursday after the company released its latest data on Dupixent. Dupixent is a drug candidate for treating adults on maximal standard-of-care inhaled therapy with uncontrolled chronic obstructive pulmonary disease and evidence of type 2 inflammation.
- 03/23/2023
|
Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung'
- Sanofi and Regeneron's asthma drug Dupixent succeeded in a study of patients with "smoker's lung," leading SNY and REGN stocks to rocket. The post Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung' appeared first on Investor's Business Daily.
- 03/23/2023
|
Coinbase' stock tumbles on SEC warning, while First Republic and Regeneron shares rally, and other stocks on the move
- Here were some of the more active stocks in premarket trading on Thursday, a day after sharp losses on Wall Street after the Federal Reserve's latest interest rate hike:
- 03/23/2023
|
Regeneron (REGN) Gets Label Extension for Cholesterol Drug
- Regeneron (REGN) gets FDA approval for Evkeeza to treat children aged 5 to 11 with homozygous familial hypercholesterolemia.
- 03/22/2023
|
7 Value Stocks Worth Buying at These 52-Week Highs
- With the market still digesting the tremors of the banking sector fallout, investors may want to consider compelling value stocks to buy, even those trading near their 52-week highs. True, investors often wax poetic about buying low and selling high.
- 03/22/2023
|
Regeneron (REGN) Gains 9.3% in a Year: Will the Uptrend Last?
- Regeneron (REGN) has had a good run in the past 12 months and the momentum should continue in 2023 on the back of growth in Dupixent, as Eylea faces challenges.
- 03/17/2023
|
Medicare Negotiation Undercuts Biotech Stocks Regeneron, Halozyme
- Confusion over new Centers for Medicare and Medicaid Services negotiating plans sent REGN and HALO stocks tumbling Thursday. The post Medicare Negotiation Undercuts Biotech Stocks Regeneron, Halozyme appeared first on Investor's Business Daily.
- 03/17/2023
|
2 Biotech Stocks To Watch In March 2022
- Check out these 2 biotech stocks in the stock market today.
- 03/16/2023
|
Medicare Negotiation Hammers Biotech Stocks Regeneron, Halozyme
- Confusion over new Centers for Medicare and Medicaid Services negotiating plans sent REGN and HALO stocks tumbling Thursday. The post Medicare Negotiation Hammers Biotech Stocks Regeneron, Halozyme appeared first on Investor's Business Daily.
- 03/16/2023
|
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Barclays Global Healthcare Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Barclays Global Healthcare Conference March 15, 2023 9:00 AM ET Company Participants Ryan Crowe - Vice President of Investor Relations Robert Landry - Chief Financial Officer Conference Call Participants Carter Gould - Barclays Carter Gould [Technical difficulty] -- Barclays Global Healthcare Conference. My name is Carter Gould, senior biopharma analyst, here at Barclays.
- 03/15/2023
|
Regeneron Borrows From Big Pharma Playbook
- Eylea, the company's top-selling blockbuster, isn't going away soon.
- 03/11/2023
|
Three-Stock Lunch: Regeneron, General Mills and DocuSign
- Eva Ados, chief investment strategist at ERShares, joins ‘Power Lunch' to discuss Regeneron, General Mills and DocuSign.
- 02/21/2023
|
Regeneron (REGN) Rare Disease Drug Gets FDA's Priority Review
- Regeneron's (REGN) application seeking approval of pozelimab for the ultra-rare hereditary immune disease CHAPLE gets Priority Review by the FDA.
- 02/21/2023
|
Competition Coming For AbbVie's Blockbuster Humira
- It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie.
- 02/16/2023
|
5 Least-Hurt Biotech ETFs of the Last Week
- Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.
- 02/15/2023
|
Regeneron Pharmaceuticals, Inc. (REGN) SVB Securities Global Biopharma Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) SVB Securities Global Biopharma Conference February 14, 2023 9:20 AM ET Company Participants Ryan Crowe - VP, IR Izzy Lowy - SVP of Clinical Development for Oncology Andres Sirulnik - SVP, Translational & Clinical Sciences, Hematology Conference Call Participants David Risinger - SVB Securities David Risinger So good morning, everybody, and thank you for joining our session with Regeneron. My name is Dave Risinger.
- 02/14/2023
|
2 Top Healthcare Stocks Defying the Bear Market
- These companies have impeccable long-term investment theses.
- 02/14/2023
|
2 Biotech Stocks That Could Help Set You Up for Life
- The two companies have seen similar share growth over the past year.
- 02/11/2023
|
Regeneron's (REGN) Eylea Gets FDA Nod for ROP in Infants
- Regeneron's (REGN) Eylea gets FDA approval for the treatment of preterm infants with retinopathy of prematurity (ROP).
- 02/09/2023
|
The 7 Best Biotech Stocks to Buy for February 2023
- While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities. Better yet, the volatility largely centers on developments of the industry itself rather than the broader economy.
- 02/07/2023
|
Is Biotech Immunocore About To Make A 25% Price Move?
- The industry is home to some large-cap heavyweights, including Amgen Inc. (NASDAQ: AMGN), Gilead Sciences Inc. (NASDAQ: GILD), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), and Moderna Inc. (NASDAQ: MRNA), among others.
- 02/07/2023
|
Drug, Chip Stocks Hit 52-Week Highs As One Breaks Out Of Bullish Chart Pattern
- Regeneron and Analog Devices hit new highs and break out. REGN had strong fourth quarter earnings.
- 02/03/2023
|
Compared to Estimates, Regeneron (REGN) Q4 Earnings: A Look at Key Metrics
- While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 02/03/2023
|
Regeneron (REGN) Q4 Earnings & Sales Beat, Eylea Sales Decline
- Regeneron (REGN) tops earnings and sales estimates for the fourth quarter. However, sales of the lead drug Eylea decline year over year.
- 02/03/2023
|
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2022 Earnings Call Transcript
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q4 2022 Earnings Conference Call February 3, 2023 8:30 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Leonard Schleifer - Co-Founder, President and Chief Executive Officer George Yancopoulos - Co-Founder, President and Chief Scientific Officer Marion McCourt - Executive Vice President and Head, Commercial Bob Landry - Executive Vice President and Chief Financial Officer Conference Call Participants Tyler Van Buren - Cowen Matthew Harrison - Morgan Stanley Carter Gould - Barclays Brian Abrams - RBC Capital Markets Evan Seigerman - BMO Capital Markets Salveen Richter - Goldman Sachs Mohit Bansal - Wells Fargo Colin Bristow - UBS Chris Raymond - Piper Sandler Chris Schott - JPMorgan Robyn Karnauskas - Truist Operator Welcome to the Regeneron Pharmaceuticals' Fourth Quarter 2022 Earnings Conference Call. My name is Shannon and I will be your operator for today's call.
- 02/03/2023
|
Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples
- Regeneron Pharma beat quarterly forecasts Friday, but its partner Sanofi posted a mixed report. Regeneron stock rose as SNY stock toppled.
- 02/03/2023
|
Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates
- Regeneron (REGN) delivered earnings and revenue surprises of 29.75% and 7.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/03/2023
|
Regeneron stock rallies after profit and revenue beat expectations by wide margins
- Shares of Regeneron Pharmaceuticals Inc. REGN, -0.90% rallied 1.9% toward a two-month high in premarket trading Friday, after the biotechnology company reported fourth-quarter profit and revenue that fell, as sales of its COVID-19 treatment dropped, but beat expectations by wide margins. Net income fell to $1.20 billion, or $10.50 a share, from $2.23 billion, or $19.69 a share, in the year-ago period.
- 02/03/2023
|
The 7 Most Undervalued Stocks to Buy in February 2023
- As Feb. gets underway, I'm finding under-appreciated, undervalued stocks to buy. When seeking value in the stock market the hope is that other investors will see what you see: The underappreciated value inherent in strong businesses that don't necessarily garner a lot of attention.
- 02/02/2023
|
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
- You don't have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edge of medical science.
- 02/02/2023
|
Why Regeneron (REGN) Might Surprise This Earnings Season
- Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/02/2023
|
Time to Buy Cigna or Regeneron Stock Before Earnings?
- Among the Finance and Medical sector, Cigna (CI) and Regeneron Pharmaceuticals (REGN) are both leaders in their respective industries and have had strong performances over the last year as the broader market and economy declined.
- 02/01/2023
|
Regeneron Announces Investor Conference Presentations
- TARRYTON, N.Y., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
- 01/31/2023
|
Regeneron: Eylea Growth Scare And Many Other Developments
- Regeneron reported preliminary Eylea U.S. net sales in early January that were below expectations. The net sales miss was not driven by increasing pressure from Vabysmo but by a temporary shutdown of a fund that helps with patient copays.
- 01/30/2023
|
Will Eylea and Dupixent Fuel Regeneron's (REGN) Q4 Earnings?
- Regeneron's (REGN) fourth-quarter earnings are likely to have gotten a boost from the solid performances of Eylea and Dupixent.
- 01/30/2023
|
Why Regeneron (REGN) is Poised to Beat Earnings Estimates Again
- Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 01/27/2023
|
Regeneron, Sanofi's Dupixent is one step closer to approval for young children in Europe
- Shares of Regeneron Pharmaceuticals Inc. REGN, +0.15% gained about 2.5% in premarket trading on Friday after the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Dupixent, the atopic dermatitis therapy developed with Sanofi SAN, -0.37% SNY, -0.16% , for children as young as six months old. European regulators are expected to make a final decision in the coming months.
- 01/27/2023
|
JPMorgan sees another 20% upside in Regeneron shares: this is why
- Shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have already gained about 25% since early September but a JPMorgan analyst is convinced the stock will continue to move up in the coming months. Regeneron shares could climb further to $850 Chris Schott recommends that investors buy Regeneron shares as they have upside to $850.
- 01/20/2023
|
REGN or TECH: Which Is the Better Value Stock Right Now?
- REGN vs. TECH: Which Stock Is the Better Value Option?
- 01/11/2023
|
Regeneron CEO on the prospects for its eye drug Eylea
- CNBC's Meg Tirrell sits down with Regeneron CEO Len Schleifer to discuss the company's future, next-gen COVID antibody drug, and more.
- 01/10/2023
|
Regeneron Pharmaceuticals, Inc. (REGN) 41st Annual J.P. Morgan Healthcare Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) 41st Annual J.P. Morgan Healthcare Conference January 9, 2023 12:00 PM ET Company Participants Leonard Schleifer - President and CEO George Yancopoulos - President and Chief Scientific Officer Marion McCourt - EVP and Head of Commercial Conference Call Participants Chris Schott - JPMorgan Chris Schott Good morning, everybody.
- 01/09/2023
|
Biotech Giant Regeneron Hit As Eylea Gives Ground To Avastin
- Regeneron Pharmaceuticals said sales of its linchpin Eylea drug have been negatively impacted by a short-term shift to rival drug Avastin. The post Biotech Giant Regeneron Hit As Eylea Gives Ground To Avastin appeared first on Investor's Business Daily.
- 01/09/2023
|
Four Undervalued Healthcare Stocks for 2023
- These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.
- 01/06/2023
|
Jim Cramer says he likes these 5 Nasdaq stocks for 2023
- Cramer offered investors a list of stocks listed in the Nasdaq Composite that he believes could be winners this year.
- 01/05/2023
|
VERA Dips Despite Positive Data From IgA Nephropathy Study
- VERA posts positive top-line data from the phase IIb ORIGIN study evaluating atacicept for the treatment of IgA nephropathy.
- 01/04/2023
|
Regeneron to Report Fourth Quarter and Full Year 2022 Financial and Operating Results and Host Conference Call and Webcast on February 3, 2023
- TARRYTOWN, N.Y., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2022 financial and operating results on Friday, February 3, 2023, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
- 01/03/2023
|
What's in Store for Regeneron Pharmaceuticals (REGN) in 2023?
- Regeneron Pharmaceuticals (REGN) had a good run in 2022 and the momentum should continue in 2023 on the back of growth in Eylea and Dupixent.
- 01/03/2023
|
100 Best Stocks Of 2022: Oil Stocks And Medicals Shine
- Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business Daily.
- 12/30/2022
|
Regeneron (REGN) Presents Positive Data on MM and FL Drugs
- Regeneron (REGN) releases positive initial data on two candidates - linvoseltamab and odronextamab at ASH.
- 12/13/2022
|
Our 7 Top Biotech Stock Picks for 2023
- If there's a silver lining regarding the coronavirus pandemic, it's that it demonstrated the importance of the top biotech stock picks for 2023. While medical innovations may seem frustratingly slow, the Covid-19 crisis proved that when humanity comes together, it can foster incredible advancements at breakneck speed.
- 12/09/2022
|
Can These 2 Stocks Crush the Market Again in 2023?
- Both are riding the wave of major clinical wins
- 12/04/2022
|
Stocks To Invest In Right Now? 3 Biotech Stocks To Watch
- Is now a good time to add these biotech stocks to your watchlsit?
- 12/02/2022
|
Regeneron's (REGN) sBLA for Evkeeza Gets FDA Priority Review
- The FDA accepts for priority review Regeneron's (REGN) sBLA for Evkeeza for treating children aged five to 11 years with homozygous familial hypercholesterolemia. A decision is due on Mar 30, 2023.
- 12/01/2022
|
Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 34th Annual Healthcare Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Piper Sandler 34th Annual Healthcare Conference Call November 30, 2022 8:00 AM ET Company Participants Ryan Crowe - Vice President of Investor Relations Robert Landry - Executive Vice President & Chief Financial Officer Conference Call Participants Chris Raymond - Piper Sandler Chris Raymond Okay. Let's go ahead and get started.
- 11/30/2022
|
2 Market-Beating Stocks That Can Continue Rising in 2023
- It's not too late to get in on the potential 2023 growth for these two stocks.
- 11/30/2022
|
7 Undervalued Biotech Stocks to Buy Before They Boom
- You'll often hear people say that bear markets are great for finding bargains, and that's true. With the exception of energy, every major sector is in the red for the year.
- 11/29/2022
|
Regeneron Pharmaceuticals, Inc. (REGN) 5th Annual Evercore ISI HealthCONx Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) 5th Annual Evercore ISI HealthCONx Conference November 29, 2022 11:45 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations John Lin - Senior Vice President, Immuno-Oncology & Head, Bi-Specifics Neil Stahl - Executive Vice President, Research & Development Conference Call Participants Josh Schimmer - Evercore ISI Josh Schimmer All right. Welcome, everyone.
- 11/29/2022
|
Regeneron (REGN) Outperforms YTD: What's in Store for 2023?
- Regeneron (REGN) has had a good run in 2022 so far and the momentum should continue in 2023 as well.
- 11/25/2022
|
Dexcom Leads 5 Stocks Near Buy Points
- Dexcom and other top stocks to watch this week combine strong technicals with generally solid fundamentals. The post Dexcom Leads 5 Stocks Near Buy Points appeared first on Investor's Business Daily.
- 11/25/2022
|
Regeneron's (REGN) Libtayo Gets EC Nod for Cervical Cancer
- Regeneron (REGN) gets EC's approval for the label expansion of PD-1 inhibitor Libtayo for the treatment of adult patients with recurrent or metastatic cervical cancer.
- 11/23/2022
|
Regeneron: Stock Priced Too High To Buy, But Keep One Eye On This Pharma
- Regeneron Pharmaceuticals, Inc. had a strong Q3 even if there are no longer sales of COVID therapy REGEN-Cov swelling the top line. The company's lead asset Eylea looks likely to face generic competition from 2023.
- 11/22/2022
|
Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference - (Transcript)
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Jefferies London Healthcare Conference November 16, 2022 10:15 AM ET Company Participants Ryan Crowe - VP, IR Robert Landry - EVP, Finance & CFO Conference Call Participants Akash Tewari - Jefferies Akash Tewari All right. Well, good afternoon.
- 11/16/2022
|
2 Top Biotech Stocks to Buy in November
- Both of these companies have potential catalysts on the way.
- 11/12/2022
|
Regeneron (REGN) Gets FDA Nod for Libtayo's Label Expansion
- Regeneron (REGN) obtains FDA approval for the second advanced NSCLC indication, which expands the patient population eligible for a Libtayo-based regimen to include combination treatment with chemotherapy, irrespective of PD-L1 expression levels.
- 11/09/2022
|
7 Cash-Rich Stocks to Buy for Peace of Mind
- Companies of all sizes appear to be hoarding cash for the much-discussed impending recession. If we do dive into a recession, cash-rich stocks will be more than prepared for whatever slowdown comes their way.
- 11/04/2022
|
Regeneron (REGN) Q3 Earnings & Sales Beat on Eylea, Dupixent
- Regeneron (REGN) tops earnings and sales estimates for the third quarter, driven by its lead drug Eylea and profits from the asthma drug, Dupixent. However, earnings decline year over year.
- 11/03/2022
|
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2022 Earnings Call Transcript
- Regeneron Pharmaceuticals, Inc. (AAPL) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Leonard Schleifer - President, Chief Executive Officer George Yancopoulos - President, Chief Scientific Officer Marion McCourt - Executive Vice President, Head of Commercial Robert Landry - Executive Vice President, Chief Financial Officer Conference Call Participants Evan Seigerman - BMO Tyler Van Buren - Cowen Salveen Richter - Goldman Sachs Matthew Harrison - Morgan Stanley Tim Anderson - Wolfe Research Mohit Bansal - Wells Fargo Christopher Raymond - Piper Sandler Colin Bristow - UBS Brian Abrahams - RBC Carter Gould - Barclays Operator Hello, and welcome to Regeneron Pharmaceuticals' Third Quarter 2022 Earnings Conference Call. My name is Towanda, and I will be your operator for today's call.
- 11/03/2022
|
Regeneron (REGN) Surpasses Q3 Earnings and Revenue Estimates
- Regeneron (REGN) delivered earnings and revenue surprises of 14.85% and 5.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/03/2022
|
Regeneron Pharmaceuticals Q3 tops earnings and revenue marks
- Regeneron Pharmaceuticals Inc. REGN, -2.56% said Thursday its third-quarter net income fell 19% to $1.32 billion or $11.66 a share, from $1.63 billion or $14.33 a share, in the year-ago period. Adjusted net income fell to $11.14 a share from $15.37 a share.
- 11/03/2022
|
Final Trades: Boeing, Amazon, Regeneron & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 10/28/2022
|
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
- Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments moving through the pipeline toward FDA approval. The post CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
- 10/20/2022
|
Regeneron (REGN) Drug Gets Positive CHMP View for Cervical Cancer
- Regeneron (REGN) gets a positive recommendation from CHMP for the label expansion of its oncology drug for treating adult patients with recurrent or metastatic cervical cancer.
- 10/17/2022
|
Biotech Stock Sitting Out Today's Rally
- While the rest of the market is making moves higher today, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is static, last seen off 0.1% at $735.31.
- 10/17/2022
|
Regeneron's (REGN) Eylea sBLA Gets FDA's Priority Review
- The FDA accepts and grants priority review to Regeneron's (REGN) sBLA for Eylea injection to treat retinopathy of prematurity in preterm infants. A decision is due on Feb 11, 2023.
- 10/13/2022
|
3 Red-Hot Stocks That Could Continue to Beat the Market
- Investors are betting on these companies' revenue growth prospects.
- 10/13/2022
|
These Are The Five Best And Worst Performing Large-Cap Stocks In September 2022
- September has been a tough month for the U.S. stock market historically, and this year was no different.
- 10/10/2022
|
These 7 Biotech Stocks Are Set to Boom in 2023
- Among biotech stocks, there are several established names that have products in markets and deep pipelines. These companies deliver predictable revenue and earnings, and maybe even a dividend for good measure.
- 10/10/2022
|
Best Stocks To Buy For October 2022? 2 Healthcare Stocks In Focus
- 2 top healthcare stocks to watch in October 2022.
- 10/06/2022
|
Final Trades: Lamar, Wynn, Eaton & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 10/05/2022
|
REGN vs. RGEN: Which Stock Is the Better Value Option?
- REGN vs. RGEN: Which Stock Is the Better Value Option?
- 10/04/2022
|
Regeneron (REGN) Recently Broke Out Above the 20-Day Moving Average
- Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
- 10/04/2022
|
Will Loss of REGEN-COV Sales Hurt Regeneron (REGN) in 2022?
- Regeneron's (REGN) top line is affected by negligible sales from REGEN-COV while lead drug Eylea faces stiff competition.
- 10/04/2022
|
Market Indexes Jump Higher As Oil Leads; Denbury, Sinclair, Regeneron In Focus | Stock Market Today
- Big gains for market indexes doesn't mean the correction is over. Stock Market Today: October 3, 2022 Hosts: Ali Coram & Ed Carson Get more IBD by subscribing to our channel: https://bit.ly/3OqppAs Visit our website: https://www.investors.com Like us on Facebook: https://www.facebook.com/investorsbusinessdaily Follow us on Twitter: https://twitter.com/IBDinvestors Follow us on Instagram: https://www.instagram.com/investorsbusinessdaily/ Follow us on StockTwits: https://stocktwits.com/InvestorsBusinessdaily Follow us on LinkedIn: https://www.linkedin.com/company/investors-business-daily Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing data, stock market research, education and the latest financial and business news to help investors make more money in the stock market.
- 10/03/2022
|
9 Stocks Turned $10,000 Into $129,224 In 9 Months
- It's a tough S&P 500 stock market to make money on. But some investors are still finding a way to do it.
- 09/30/2022
|
Piper Sandler's Kantrowitz likes stocks with Regeneron and General Mills
- Michael Kantrowitz, Piper Sandler chief investment strategist, joins 'Power Lunch' to discuss the companies he thinks investors should buy, the names to avoid and what will happen to companies with poor earnings reports next year.
- 09/23/2022
|
Regeneron (REGN)/ Alnylam Report Promising Data from NASH Study
- Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.
- 09/16/2022
|
Is A Fall Imminent For Regeneron Stock After A Stellar 25% Rise In A Week?
- Regeneron Pharmaceuticals stock (NASDAQ: REGN) is up a solid 25% in a week, while it has seen a 16% rise in a month, significantly outperforming the broader indices, with the S&P500 index rising 3.7% in a week but down 3.2% in a month.
- 09/13/2022
|
Here's who could benefit from Biden's biotech initiative, according to Oppenheimer's Jared Holz
- Oppenheimer's Jared Holz on President Biden's cancer initiative and what it means for biotech in the U.S. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Courtney Garcia, Guy Adami and Karen Finerman.
- 09/12/2022
|
Regeneron Pharmaceuticals, Inc. (REGN) CEO Leonard Schleifer Presents at Morgan Stanley 20th Annual Global Healthcare Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Morgan Stanley 20th Annual Global Healthcare Conference September 12, 2022 11:05 AM ET Company Participants Ryan Crowe - VP of IR Leonard Schleifer - Founder, President and CEO Marion McCourt - EVP of Commercial Conference Call Participants Matthew Harrison - Morgan Stanley Matthew Harrison Good morning, everybody. Thanks for joining us for the next session.
- 09/12/2022
|
Regeneron Pharmaceuticals, Inc. (REGN) ESMO 2022 Investor Event (Transcript)
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) ESMO 2022 Investor Event September 12, 2022 8:00 AM ET Company Participants Ryan Crowe - Head, IR David Weinreich - EVP, Global Clinical Development Israel Lowy - SVP, Translational Sciences & Oncology Justin Holko - VP, Global Commercial Business Unit Conference Call Participants Brian Abrahams - RBC Christopher Raymond - Piper Sandler David Risinger - SVB Securities Evan Seigerman - BMO Justin Burns - Barclays Mohit Bansal - Wells Fargo Robyn Karnauskas - Truist Salveen Richter - Goldman Sachs Tyler Van Buren - Cowen Yatin Suneja - Guggenheim Partners Operator Good day, and thank you for standing by. Welcome to the Regeneron ESMO 2022 Investor Event.
- 09/12/2022
|
The 3 Best Healthcare Stocks to Buy Now
- With the exception of energy and utilities, all sectors of the S&P 500 are in the red for the year. Of the losing sectors, healthcare stocks have held up relatively well, outperformed only by consumer staples.
- 09/09/2022
|
Three Stock Lunch: Regeneron, Match Group and Caesars Entertainment
- Tim Seymour, Seymour Asset Management CIO and CNBC contributor, joins 'Power Lunch' to discuss his investing take on three stocks; Regeneron, Match Group and Caesars Entertainment.
- 09/09/2022
|
Morgan Stanley just upgraded this large cap biotech stock
- Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is now back to near its year-to-date high but a Morgan Stanley analyst says the stock is not done pleasing its investors yet.
- 09/09/2022
|
Regeneron Gets Praised by Wall Street. High-Dose Eylea Data Look 'Strong.
- Jefferies upgrades the stock and other analysts raise their price targets on Regeneron following better-than-expected data on a new formulation of the company's signature eye medication.
- 09/09/2022
|
Regeneron Announces Investor Call and Webcast at ESMO 2022
- TARRYTOWN, N.Y. , Sept. 9, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and simultaneous webcast to share updates on the company's oncology portfolio in conjunction with the European Society for Medical Oncology (ESMO) Annual Congress on Monday, September 12, 2022.
- 09/09/2022
|
Regeneron (REGN) Up on Higher Dose Eye Drug Studies Success
- Regeneron (REGN) stock jumps as aflibercept 8 mg with 12- and 16-week dosing regimens in patients with DME and wAMD meet primary goals.
- 09/09/2022
|
Regeneron stock surges on positive results in eye disease drug trial
- Yahoo Finance Live examines Regeneron Pharmaceuticals' stock following reports of positive results in its eye treatment drug trials.
- 09/08/2022
|
Regeneron Pharmaceuticals, Inc. (REGN) 2022 Wells Fargo Healthcare Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) 2022 Wells Fargo Healthcare Conference September 8, 2022 11:00 AM ET Company Participants Ryan Crowe - Head, IR Robert Landry - CFO Conference Call Participants Mohit Bansal - Wells Fargo Mohit Bansal Great. Thank you very much for joining us today.
- 09/08/2022
|
Why Regeneron Pharmaceuticals Stock Is Crushing It Today
- The biotech's crown jewel scores a key win in the clinic.
- 09/08/2022
|
Regeneron Stock Surges on Promising Eye Disease Drug Trial
- Regeneron announces promising results from late-stage clinical trials on its signature eye drug medication, Eylea.
- 09/08/2022
|
Stocks fluctuate, Regeneron stock surges, oil above $83 a barrel
- Yahoo Finance's Ines Ferré discusses how markets are moving in early trading.
- 09/08/2022
|
Regeneron says Eylea met the primary endpoints in two trials
- Regeneron Pharmaceuticals Inc. REGN, +3.91% said Thursday that an 8-milligram dose of aflibercept successfully treated patients with diabetic macular edema and wet age-related macular degeneration in a pair of pivotal trials. Regeneron's stock was halted ahead of the announcement.
- 09/08/2022
|
Regeneron (REGN) Down 2.3% Since Last Earnings Report: Can It Rebound?
- Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?
- 09/02/2022
|
5 Top Stocks Cathie Wood Is Selling This Week
- Shares of Cathie Wood's flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEARCA: ARKK ) closed the week down about 2.5%, losing out on earlier gains during the week. However, retail investors haven't lost hope in ARKK, or Cathie Wood just yet.
- 08/26/2022
|
Regeneron Announces Investor Conference Presentations
- TARRYTOWN, N.Y. , Aug. 25, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2022 Wells Fargo Healthcare Conference at 11:00 a.m.
- 08/25/2022
|
Regeneron: There Are Challenges But Growth To Resume In 2023
- Regeneron will report a decline in revenues this year due to the lack of COVID-19 antibody sales. Growth is set to resume in 2023, driven primarily by Dupixent.
- 08/25/2022
|
7 Cathie Wood Stocks to Buy on the Dip
- Cathie Wood is well-known in the investment world as the face of ARK Invest, the firm she founded in 2014. ARK itself stands for Active Research Knowledge.
- 08/22/2022
|
Regeneron Shares Climb on Drug Sales, NASH Research
- Regeneron Pharmaceuticals Inc. ( REGN , Financial) didn't just get past hump day, the company soared over it. Shares of the Tarrytown, New York-based drug company traded as high as $623 Wednesday before closing at $608.77, a gain just short of 6%.
- 08/03/2022
|
Regeneron Pharmaceuticals, Inc.'s (REGN) CEO Leonard Schleifer on Q2 2022 Results - Earnings Call Transcript
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Leonard Schleifer - President, Chief Executive Officer George Yancopoulos - President, Chief Scientific Officer Marion McCourt - Executive Vice President, Head of Commercial Robert Landry - Executive Vice President, Chief Financial Officer Conference Call Participants Mohit Bansal - Wells Fargo Evan Seigerman - BMO Capital Markets Tyler Van Buren - Cowen Salveen Richter - Goldman Sachs Matthew Harrison - Morgan Stanley Tim Anderson - Wolfe Research Chris Raymond - Piper Sandler Carter Gould - Barclays Capital Operator Welcome to the Regeneron Pharmaceuticals Second Quarter 2022 Earnings Conference Call. My name is Bella and I will be your operator for today's call.
- 08/03/2022
|
Regeneron (REGN) Q2 Earnings & Sales Beat on Eylea, Dupixent
- Regeneron (REGN) tops earnings and sales in the second quarter, driven by its lead drug Eylea and profits from asthma drug Dupixent. However, earnings decline year over year.
- 08/03/2022
|
Regeneron Pharmaceutical Beats Second-Quarter Views But Logs No Covid Sales
- Regeneron Pharmaceutical beat second-quarter estimates on Wednesday, leaning on Eylea as its Covid drug logged no sales. REGN stock rose.
- 08/03/2022
|
Regeneron (REGN) Q2 Earnings and Revenues Beat Estimates
- Regeneron (REGN) delivered earnings and revenue surprises of 14.54% and 3.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/03/2022
|
Regeneron quarterly profit slumps as COVID antibody sales dry up
- (Reuters) -Regeneron Pharmaceuticals reported a 72.5% fall in quarterly profit on Wednesday, hurt by lacklustre sales of its COVID-19 antibody cocktail after the U.S. health regulator decided to limit its use earlier this year.
- 08/03/2022
|
How This Multibillion-Dollar Company Is Shaking Off the Competition
- The company has posted growth despite lower demand for several key products.
- 07/30/2022
|
3 High-Margin Businesses That Can Absorb Inflation
- These companies regularly post gross margins of 80% or better.
- 07/20/2022
|
These are 10 of the best-performing stocks since Jim Cramer's 'Mad Money' debuted on TV
- "Mad Money" host Jim Cramer breaks down some of the best-performing S&P 500 stocks since his show debuted on CNBC more than 17 years ago.
- 07/18/2022
|
Regeneron Post COVID Bolus
- Regeneron's COVID therapy provided a revenue bolus in 2021. Possible biosimilar competition to Eylea is a concern.
- 07/16/2022
|
3 Biotech Stocks Outperforming a Bear Market
- These biotech stocks are the most attractive from a valuation and growth perspective as they are less impacted by a slowing economy or change in monetary policy. The post 3 Biotech Stocks Outperforming a Bear Market appeared first on InvestorPlace.
- 07/15/2022
|
Regeneron (REGN) And Ultima Genomics Partnering On Development Agreement
- Ultima Genomics has signed an agreement with Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) to further advance Ultima Genomics' sequencing architecture. These are the details.
- 07/12/2022
|
Stock Split Watch: Could Regeneron Be Next?
- It's the highest-priced biotech stock.
- 07/11/2022
|
7 Moonshot Investments Upending a $10 Trillion Industry
- Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. The post 7 Moonshot Investments Upending a $10 Trillion Industry appeared first on InvestorPlace.
- 07/08/2022
|
What Stocks To Buy Today? 5 Health Care Stocks To Know
- Could health care stocks be the best stocks to jump on in the second half of 2022?
- 07/05/2022
|
3rd-Quarter Clinical Trial Data Could Shake Up Pharma Stocks
- Health care investors would be wise to keep tabs on the results of numerous drug trials scheduled to be revealed in the third quarter. Trial data can impact the stock price of a pharmaceutical company, sometimes sending it up, sometimes down.
- 07/05/2022
|
5 Top Biotech Stocks To Watch In July 2022
- Amid choppy markets, could there be potential in these top biotech stocks?
- 06/30/2022
|
Regeneron (REGN) Eylea sBLA for Extended Regimen Accepted
- FDA accepts Regeneron's (REGN) application seeking label expansion for Eylea for an extended period in patients with diabetic retinopathy.
- 06/30/2022
|
Regeneron Pharmaceuticals: Lack Of Appreciation For The Purchase Of Libtayo
- Regeneron acquired the global rights to Libtayo from Sanofi. The deal also brings acceleration of repayments to Sanofi.
- 06/21/2022
|
Regeneron (REGN) Moves 4.4% Higher: Will This Strength Last?
- Regeneron (REGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- 06/20/2022
|
4 Top Biotech Stocks To Watch Today
- As the industry continues to make new discoveries, could biotech stocks be in focus?
- 06/17/2022
|
Is Regeneron Absurdly Cheap or Has it Become a Value Trap?
- The company has made some recent moves that could change its short- and long-term prospects.
- 06/16/2022
|
Regeneron Pharmaceuticals, Inc.'s (REGN) Management Presents at Goldman Sachs 43rd Annual Global Healthcare Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Goldman Sachs 43rd Annual Global Healthcare Conference Transcript June 14, 2022 11:40 AM ET Executives Bob Landry - Chief Financial Officer Marion McCourt - Head, Commercial Ryan Crowe - Investor Relations Analysts Salveen Richter - Goldman Sachs Salveen Richter Hey. Good morning.
- 06/14/2022
|
Regeneron Looks Significantly Undervalued
- As I was browsing through Dodge & Cox's Global Stock Fund annual letter for 2021 (published in February 2022), I came across the asset management company's commentary on Regeneron Pharmaceuticals Inc. ( REGN , Financial):
- 06/09/2022
|
Regeneron Gets Wall Street-Low Price Target. The Stock May Be Done Outperforming the Market.
- Jefferies initiates coverage of Regeneron Pharmaceuticals at Underperform, sending the stock lower.
- 06/06/2022
|
Regeneron (REGN) to Buy Sanofi's Stake in Libtayo, Stock Down
- Regeneron (REGN) will obtain global rights to Libtayo from Sanofi in exchange for an upfront payment of $900 million and royalties.
- 06/03/2022
|
Regeneron to buy Sanofi's cancer drug in $1B deal
- Regeneron CEO Leonard Schleifer on the decision to spend $1.1B to buy Sanofi's cancer drug portfolio. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Karen Finerman and Dan Nathan.
- 06/02/2022
|
Why Regeneron Wasn't a Healthy Stock Today
- The company is forking over $900 million in an upfront payment to fully own a cancer drug.
- 06/02/2022
|
Regeneron to pay Sanofi up to $1.1 billion plus royalties for its stake in Libtayo collaboration
- Regeneron Pharmaceuticals Inc. REGN, -0.88% announced Thursday an agreement in which it will pay up to $1.1 billion plus royalties for Sanofi S.A.'s SNY, -0.08% stake in the Regeneron-Sanofi collaboration on cancer treatment Libtayo.
- 06/02/2022
|
FDA Accepts Regeneron, Sanofi's Filing For Review In Skin Disease
- The U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for review submitted by Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) for the lead drug candidate Dupixent (dupilumab) for the treatment of patients with prurigo.
- 05/31/2022
|
4 Profitable Companies With Solid Financial Conditions
- When screening the market for value opportunities, investors may want to consider stocks that represent companies with high profitability and robust financial conditions. The companies below meet these criteria, according to their GuruFocus profitability and financial strength ratings of at least 6 out of 10.
- 05/27/2022
|
Why Regeneron Investors Shouldn't Fear Its Patent Cliff
- New treatments will step in to replace blockbuster eye medication EYLEA.
- 05/26/2022
|
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)
- The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
- 05/25/2022
|
Regeneron's (REGN) Evkeeza Positive in Late-Stage Study
- Regeneron (REGN) announces positive data on a phase III study on cholesterol treatment Evkeeza.
- 05/23/2022
|
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication
- The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
- 05/23/2022
|
Regeneron: Bright Future Ahead
- Regeneron has a very strong pipeline consisting of treatments that can complement current cash cows (EYLEA and Dupixent) along with potential blockbusters. Even if EYLEA rapidly loses market share after its patent expirations, the growth from Dupixent and Libtayo will be more than enough to offset the loss.
- 05/23/2022
|
Regeneron's Growth Set To Slow, But Could Outperform Downbeat Consensus Forecasts
- Regeneron just posted another impressive quarter for earnings (+16% YoY) and revenues (+17% YoY). Growth is set to slow after a one-time boost from its COVID antibody cocktail last year and an upcoming patent expiry for Eylea.
- 05/20/2022
|
My 'Do Nothing Club' Returned 68% in the Past Year
- Certain predators can't see their prey if the prey holds still.
- 05/16/2022
|
Is Regeneron In Trouble After Sales Declined 40% In a Single Quarter?
- The pharmaceutical company's COVID-19 treatment wasn't the only product suffering this past quarter.
- 05/12/2022
|
How Biotech Company Regeneron Flipped The Script In Drug Development
- It's hard to imagine Regeneron Pharmaceuticals as anything but a powerhouse in drug development, but Chief Financial Officer Robert Landry recalls a different time for his company and the rest of the industry. Get more IBD by subscribing to our channel: https://bit.ly/3OqppAs Visit our website: investors.com Like us on Facebook: https://www.facebook.com/investorsbusinessdaily Follow us on Twitter: https://twitter.com/IBDinvestors Follow us on Instagram: https://www.instagram.com/investorsbusinessdaily/ Follow us on StockTwits: https://stocktwits.com/InvestorsBusinessdaily Follow us on LinkedIn: https://www.linkedin.com/company/investors-business-daily Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing data, stock market research, education and the latest financial and business news to help investors make more money in the stock market.
- 05/09/2022
|
Regeneron (REGN) Q1 Earnings Beat, COVID Antibody Sales Affected
- Regeneron (REGN) beats on Q1 earnings and sales record year-over-year growth on the solid performance of Dupixent and Eylea.
- 05/04/2022
|
Regeneron Pharmaceuticals (REGN) CEO, Leonard Schleifer on Q1 2022 Results - Earnings Call Transcript
- Regeneron Pharmaceuticals Inc. (NASDAQ:REGN ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Leonard Schleifer - President, Chief Executive Officer George Yancopoulos - President, Chief Scientific Officer Marion McCourt - Executive Vice President, Head of Commercial Robert Landry - Executive Vice President, Chief Financial Officer Ryan Crowe - Vice President, Investor Relations Conference Call Participants Chris Raymond - Piper Sandler Cory Kasimov - JP Morgan Evan Siegerman - BMO Capital Markets Salveen Richter - Goldman Sachs Brian Abrahams - RBC Capital Markets Carter Gould - Barclays Capital Luke Hermann - Baird Brittany Woods - Cowen & Co. Dane Leone - Raymond James Charlie Yang - Morgan Stanley Mohit Bansal - Wells Fargo Operator Welcome to the Regeneron Pharmaceuticals first quarter 2022 earnings conference call. My name is Gigi and I'll be your operator for today's call.
- 05/04/2022
|
Regeneron Posts Drop In Q1 Profit As COVID Antibody Sales Hit, Shares Fall
- Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned $11.49 per share for Q1 FY22, up 16% Y/Y, beating the $10.04 estimate. Sales increased 17% to $2.96 billion, surpassing the analysts' consensus of $2.73 billion, fueled by sales of COVID-19 treatment, REGEN-COV.
- 05/04/2022
|
Regeneron (REGN) Q1 Earnings and Revenues Beat Estimates
- Regeneron (REGN) delivered earnings and revenue surprises of 22.63% and 9.47%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/04/2022
|
Regeneron Stock Rises as First-Quarter Earnings Top Forecasts
- The pharmaceutical company posts first-quarter revenue of $2.97 billion, up 17% from a year earlier.
- 05/04/2022
|
Regeneron quarterly profit drops as COVID antibody sales hit
- (Reuters) -Regeneron Pharmaceuticals reported a 13% fall in quarterly profit on Wednesday, as sales of its COVID-19 antibody cocktail were hit by the U.S. health regulator's decision to limit its use.
- 05/04/2022
|
Regeneron shares up 1.4% premarket after earnings top estimates
- Regeneron Pharmaceuticals Inc. shares REGN, +1.30% rose 1.4% in premarket trade Wednesday, after the company beat consensus estimates for the first quarter. The company posted net income of $974 million, or $8.61 a share, for the quarter, down from $1.115 billion, or $10.09 a share, in the year-earlier period.
- 05/04/2022
|
5 Graham's Lost Formula Biotech Stocks to Consider for May
- After a brutal month in April, U.S. market indexes were lower on Tuesday as investors await the Federal Open Market Committee's decision on interest rates.
- 05/03/2022
|
Regeneron Announces Investor Conference Presentations
- TARRYTOWN, N.Y. , May 2, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: BofA Securities Healthcare Conference at 1:20 p.m.
- 05/02/2022
|
5 Big Pharma, Biotech Stocks Set to Beat Q1 Earnings Estimates
- Let us take a look at some pharma/biotech stocks, REGN, BIIB, NVO, VRTX and MRNA that are poised to beat on first-quarter earnings.
- 04/29/2022
|
Many Big Pharma Stocks Have Outperformed. It Isn't Too Late to Buy.
- The companies' earnings don't depend on the strength of the economy. Drug demand doesn't waver when consumers tighten their budgets.
- 04/28/2022
|
Regeneron (REGN) to Buy Checkmate Pharmaceuticals for $250M
- Regeneron (REGN) is set to acquire Checkmate Pharmaceuticals for $250 million to broaden its portfolio of diverse immuno-oncology candidates.
- 04/20/2022
|
3 Top Biotech Stocks Ready for a Bull Run
- The hype has died down. Now it's time for science to take over.
- 04/20/2022
|
Checkmate Pharma Shares Skyrocket Over 300% On Regeneron $250M Acquisition Deal
- Regeneron Pharmaceuticals Inc (NASDAQ: REGN) will acquire Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) for $10.50 per share, equivalent to a total equity value of approximately $250 million. Checkmate is a clinical-stage biopharmaceutical company focused on proprietary.
- 04/19/2022
|
Regeneron (REGN) REGEN-COV BLA Review Extended by 3 Months
- Regeneron (REGN) biologics license application for antibody cocktail REGEN-COV (casirivimab and imdevimab) gets a three-month FDA extension.
- 04/18/2022
|
3 Fantastic Biotech Stocks to Buy in April
- These stocks are bright spots in an overall dismal market for biotech stocks.
- 04/18/2022
|
Regeneron says FDA is still evaluating whether to fully approve its COVID-19 treatment
- Regeneron Pharmaceuticals Inc. REGN, +2.25% said Thursday that the Food and Drug Administration extended the review time by three months on whether to fully approve Regen-Cov as a treatment for non-hospitalized COVID-19 patients and as a prophylactic. Regeneron said the extension has to do with using Regen-Cov to prevent COVID-19 infections.
- 04/14/2022
|
Antibody Treatments for COVD-19 Face Challenges in the U.S.
- With the emergence of the highly transmissible Omicron variant, the authorized antibody treatments of companies like Vir Biotechnology (VIR), Glaxo (GSK) and Regeneron (REGN) suffer setbacks due to a lack of efficacy against the same.
- 04/08/2022
|
Regeneron (REGN), Sanofi's Dupixent Gets EU Nod for Asthma in Kids
- Regeneron (REGN) and Sanofi's (SNY) Dupixent receives label expansion in the European Union for severe asthma with type 2 inflammation in children aged between 6 years and 11 years.
- 04/07/2022
|
BioPharma Giants Print Fresh All-Time Highs
- The trend is our friend in this market, and these two biopharmaceutical stocks are trending exceptionally well.
- 04/07/2022
|
Can Regeneron (REGN) Keep the Earnings Surprise Streak Alive?
- Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 04/06/2022
|
Regeneron Builds On Retinal Disease Expertise Via Gene Therapy Pact With ViGeneron
- Regeneron Pharmaceuticals Inc (NASDAQ: REGN) beefed up its gene therapy capabilities after signing a new deal with the German biotech ViGeneron. The companies did not specify their target but noted it would be some inherited retinal disease.
- 04/06/2022
|
7 Safe Stocks to Buy to Guard Against a Recession
- It's not too late to buy safe stocks. These seven stocks, all A-rated, are perfect plays for riding out continued volatility in the markets.
- 04/05/2022
|
Regeneron to Report First Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2022
- TARRYTOWN, N.Y , April 5, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2022 financial and operating results on Wednesday, May 4, 2022, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
- 04/05/2022
|
Ari Wald on Regeneron: it's one of my favourite charts in biotech
- Regeneron Pharmaceuticals Inc (NASDAQ: REGN) hit an all-time high on Tuesday but an Oppenheimer analyst says it might just be the beginning of what's yet to come. Ari Wald sees another 15% upside in Regeneron stock Ari Wald dubs “REGN” his favourite chart in the biotech space and sees another 15% upside in the stock […] The post Ari Wald on Regeneron: it's one of my favourite charts in biotech appeared first on Invezz.
- 04/05/2022
|
Three Buys & a Bail: REGN, WMT, AMZN & FDX
- Oppenheimer's Ari Wald joins 'The Exchange' to discuss three stocks he likes and one he doesn't.
- 04/05/2022
|
Regeneron (REGN), Sanofi Get Priority Review for Dupixent sBLA
- The FDA accepts and grants priority review to Regeneron (REGN) and Sanofi's sBLA for Dupixent to treat eosinophilic esophagitis in patients aged 12 years and older. A decision is due on Aug 3, 2022.
- 04/04/2022
|
Regeneron, IGM Biosciences Shares Up Big on Sanofi Deals
- A week filled with promising announcements failed to jump-start Sanofi SA's ( SNY , Financial) shares, but it did for the two companies it's working with.
- 03/31/2022
|
Tekla Healthcare Investors: A Dividend Paymaster That Can Compensate For Poor Price Performance
- Tekla Healthcare Investors: A Dividend Paymaster That Can Compensate For Poor Price Performance
- 03/29/2022
|
Market Rally Pauses But Still Healthy; Marriott Worldwide, Regeneron, Carlisle Near Buy Points
- Market rally pauses but still healthy; Marriott Worldwide, Regeneron, Carlisle near buy points. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing data, stock market research, education and the latest financial and business news to help investors make more money in the stock market.
- 03/25/2022
|
3 Top Stock-Split Candidates After Amazon and Alphabet
- These companies haven't said they'll split their stocks, but the topic should be on their minds.
- 03/25/2022
|
Regeneron Searching For A New High
- 88% technical buy signals. 8 new highs and up 15.01% in the last month.
- 03/22/2022
|
3 Top Biotech Stocks To Watch This Week
- Should you be paying attention to these biotech stocks right now?
- 03/22/2022
|
Regeneron (REGN) Gains But Lags Market: What You Should Know
- Regeneron (REGN) closed the most recent trading day at $665.93, moving +1.45% from the previous trading session.
- 03/15/2022
|
Stocks Cap Another Losing Week: Regeneron Flashes Buy Signals; Harmony, Builders FirstSource Set Up
- Stocks Cap Another Losing Week: Regeneron Flashes Buy Signals; Harmony, Builders FirstSource Set Up Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing data, stock market research, education and the latest financial and business news to help investors make more money in the stock market. Learn more.
- 03/11/2022
|
Is Regeneron Stock a Buy Now?
- It's not all smooth sailing for this drugmaker.
- 03/11/2022
|
BioNTech (BNTX), Regeneron Expand Agreement for Lung Cancer Study
- BioNTech (BNTX) expands its strategic collaboration deal with Regeneron to evaluate the combo of BNT116 plus Libtayo for treating advanced non-small cell lung cancer.
- 03/09/2022
|
Regeneron, BioNTech to test experimental combination therapy for lung cancer
- BioNTech SE BNTX, -1.36% and Regeneron Pharmaceuticals Inc. REGN, -0.58% said they plan to test an experimental BioNTech cancer vaccine in combination with Regeneron's Libtayo in patients with advanced non-small cell lung cancer, starting with a Phase 1/2 clinical trial. Libtayo is approved in the U.S. to treat advanced basal cell carcinoma.
- 03/08/2022
|
WHO Backs Merck's Antiviral Pill For High-Risk Covid Patients But Finds Regeneron's Antibody Cocktail ‘Ineffective' Against Omicron
- The WHO panel is also evaluating data for Pfizer's antiviral pill, paxlovid, and a widely available antidepressant, fluvoxamine, to treat Covid-19.
- 03/03/2022
|
7 Low Volatility Stocks to Buy Right Now for Steady Returns
- A great way to find low volatility stocks is to look for a beta that's less than 1.0. Here are seven to buy as market turbulence increases.
- 02/24/2022
|
Best Stocks To Invest In Right Now? 5 Health Care Stocks In Focus
- Can these top health care stocks be the way to go amidst all the uncertainty in the stock market now?
- 02/23/2022
|
Palo Alto Is Leading the Nasdaq Higher, but 1 Biotech Is Getting Crushed Wednesday
- Investors are trying to take a longer-term view on the geopolitical situation.
- 02/23/2022
|
Regeneron: Large Upside Even After Recent Growth
- Regeneron has grown at a rapid pace over the past few years, but still has room to grow due to its great management team and strong pipeline.
- 02/22/2022
|
Is Regeneron Pharmaceuticals (REGN) Stock a Suitable Value Pick?
- Let's see if Regeneron Pharmaceuticals, Inc. (REGN) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
- 02/18/2022
|
Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial
- Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab) in chronic spontaneous urticaria (CSU). The trial included CSU patients who don't respond to biologic treatment, Novartis AG (NYSE: NVS) / Roche Holdings AG's (OTC: RHHBY) Xolair (omalizumab).
- 02/18/2022
|
Which ETFs Should Investors Be Watching Now? Our Favorite Is The IBB
- Which ETFs Should Investors Be Watching Now? Our Favorite Is The IBB
- 02/15/2022
|
The Vanguard Health Care Fund's Top 5 Trades
- The Vanguard Health Care Fund (Trades, Portfolio) released its fourth-quarter 2021 portfolio earlier this week.
- 02/10/2022
|
Regeneron (REGN), Sanofi Get Priority Review for Dupixent sBLA
- Regeneron (REGN) and Sanofi get Priority Review for their sBLA in the United States seeking label expansion of Dupixent.
- 02/10/2022
|
Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis
- The FDA has accepted for Priority Review the supplemental marketing application for Dupixent (dupilumab) for children aged six months to 5 years with moderate-to-severe atopic dermatitis. Get the Inside Access Traders Are Using to Profit More and Win Bigger.
- 02/10/2022
|
4 Pharmaceutical Stocks To Watch In February 2022
- Should investors be putting these pharmaceutical stocks on their watchlists?
- 02/08/2022
|
Regeneron beats fourth-quarter estimates
- Regeneron (NASDAQ: REGN) recorded $23.72 EPS in the fourth quarter, which topped the $18.37 analyst estimates by $5.35. In addition, the company reported $4.95 billion in revenue in the same quarter, which also beat the $4.42 billion analyst estimates.
- 02/04/2022
|
Regeneron Pharmaceuticals, Inc. (REGN) CEO Dr. Len Schleifer on Q4 2021 Results - Earnings Call Transcript
- Regeneron Pharmaceuticals, Inc. (REGN) CEO Dr. Len Schleifer on Q4 2021 Results - Earnings Call Transcript
- 02/04/2022
|
This Will Put a Big Dent in Eli Lilly's and Regeneron's Sales This Year
- The FDA recently revoked Emergency Use Authorization of their COVID-19 treatments.
- 02/04/2022
|
Top- and Bottom-Line Beat Gives Regeneron Stock a Boost
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is up 1.9% to trade at $632.42 at last check, after the drug maker posted a top- and bottom-line beat for its fourth quarter, which included revenues nearly doubling on sales of its Covid-19 antibody treatment, as well as higher demand for its Dupixent and Eylea drugs.
- 02/04/2022
|
Regeneron (REGN) Q4 Earnings and Revenues Top Estimates
- Regeneron (REGN) delivered earnings and revenue surprises of 28.29% and 7.74%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/04/2022
|
Regeneron's Q4 Sales, Profits More Than Double With Boost From COVID-19 Treatment Sales
- Regeneron Pharmaceuticals Inc REGN earned $23.72 per share for Q4 FY21, more than double from $9.53 a year ago, beating the $18.11 estimate. Get the Inside Access Traders Are Using to Profit More and Win Bigger.
- 02/04/2022
|
Regeneron shares up premarket after Q4 revenue doubles and blows past estimates
- Regeneron Pharmaceuticals Inc. shares REGN, -0.35% rose 1.8% in premarket trade Friday, after the company doubled its fourth-quarter revenue as sales of its COVID-19 antibody treatment came to $2.3 billion. The company posted net income of $2.229 billion, or $19.69 a share, for the quarter, up 94% from $1.149 billion, or $10.24 a share, in the year-earlier period.
- 02/04/2022
|
Regeneron quarterly profit nearly doubles on robust sales of COVID-19 therapy
- Regeneron Pharmaceuticals quarterly profit nearly doubled on Thursday, on strong sales of its COVID-19 antibody cocktail.
- 02/04/2022
|
Why Regeneron (REGN) Might Surprise This Earnings Season
- Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/03/2022
|
A Trio of Stocks That Look Like Bargains
- As of Jan. 31, the following stocks look underestimated by the market, as their price-earnings ratios without non-recurring items trade below 20 while their price-earnings to growth (PEG) ratios trade near or below 1.
- 02/01/2022
|
4 Top Biotech Stocks to Gain Amid Industry Challenges
- New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position VRTX, REGN, DVAX and RGEN well amid the volatility.
- 02/01/2022
|
3 Biotech Stocks That Could Boom or Bust in Q1
- The biotech industry is exploding. Biotech stocks provide lots of opportunities for investors who are taking a risk on the medicine's future.
- 02/01/2022
|
Regeneron (REGN) Withdraws sBLA for Libtayo in Cervical Cancer
- Regeneron (REGN) and partner Sanofi voluntarily withdraw the supplemental biologics license application for Libtayo in second-line treatment of advanced cervical cancer.
- 01/31/2022
|
CHMP Backs Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6 - 11 Years With Type 2 Inflammation
- The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending expanding the use of Dupixent (dupilumab). [ALERT] Nic Chahine shares his Bear Market Beating options trading strategy.
- 01/31/2022
|
Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 01/28/2022
|
Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use
- Regeneron Pharmaceuticals Inc REGN and its partner Sanofi SA SNY have voluntarily withdrawn their application with the FDA for the expanded use of Libtayo in patients with advanced cervical cancer. [ALERT[ Matt Maley just released his latest pick with an upside of over 100% in 2 years.
- 01/28/2022
|
Regeneron, Sanofi withdraw application for Libtaya as a cervical cancer treatment in the U.S.
- Shares of Regeneron Pharmaceuticals Inc. REGN, +0.57% were down 0.1% in premarket trading on Friday after the company and Sanofi SNY, +3.00% said they will no longer seek Food and Drug Administration approval for Libtaya as a second-line treatment for cervical cancer. The therapy is currently approved to treat two forms of skin cancer and a type of lung cancer.
- 01/28/2022
|
LABU - A Compelling Biotech Trade
- LABU - A Compelling Biotech Trade
- 01/26/2022
|
FDA Limits Use of Regeneron & Lilly's COVID Antibody Cocktails
- The FDA modifies EUA for COVID-19 antibody cocktail drugs of Regeneron (REGN) and Lilly (LLY), limiting their use to treat individuals with COVID-19 infection from non-Omicron variants.
- 01/25/2022
|
Large Cap Pharma, Biotech Stocks Down on Regulatory Updates
- Pharma giants like Pfizer (PFE), Merck (MRK) and Eli Lilly (LLY), along with biotech bigwig Regeneron (REGN), are down on regulatory updates.
- 01/25/2022
|
FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why
- Antibody treatments made by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Eli Lilly And Co (NYSE: LLY) are not likely to work against the Omicron variant of COVID-19 and their emergency use authorization has been rescinded by the U.S. Food And Drug Administration. What Happened: The regulator said in a statement, “data show these treatments are highly unlikely to be active against the omicron variant, which is circulating at a very high frequency throughout the United States, these treatments are not authorized for use in any U.S. states, territories, and jurisdictions at this time.
- 01/24/2022
|
FDA Rescinds Authorization For Covid Antibody Treatments By Regeneron, Eli Lilly
- Monoclonal antibody treatments by Regeneron and Eli Lilly proved ineffective against the omicron variant, the FDA said.
- 01/24/2022
|
Regeneron (REGN) Rides on Solid Product Portfolio: Should You Buy?
- Regeneron (REGN) is expected to maintain momentum on the back of a solid and diverse portfolio. The promising pipeline also sets the stage for further growth.
- 01/21/2022
|
Regeneron (REGN)/Sanofi's Libtayo sBLA Accepted by the FDA
- Regeneron (REGN) sBLA seeking label expansion of Libtayo in combination with chemotherapy as first-line treatment in advanced lung cancer accepted by the FDA.
- 01/20/2022
|
Will 2022 Be a Better Year for Biotech Than 2021? 3 Big Picks
- Regeneron (REGN), Vertex Pharmaceuticals (VRTX) and BioNTech (BNTX) are three large biotech stocks that are worth betting on in the current scenario.
- 01/19/2022
|
Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease
- Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have announced data from the second Phase 3 trial of Dupixent (dupilumab) in adults with uncontrolled prurigo nodularis, a chronic type 2 inflammatory skin disease. The trial met its primary and key secondary endpoints, showing it significantly reduced itch and skin lesions compared to placebo at 24 weeks.
- 01/19/2022
|
Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLC
- Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLC © 2022 Benzinga.com. Benzinga does not provide investment advice.
- 01/19/2022
|
5 ROE Stocks to Buy as Q4 Earnings Witness Shaky Start
- CommScope (COMM), Microchip (MCHP), Regeneron (REGN), Bunge (BG) and Hologic (HOLX) are some of the stocks with high ROE to profit as Q4 earnings witness shaky start to the season.
- 01/18/2022
|
2 Top Biotech Stocks to Buy and Hold for 10 Years
- Both companies are involved in the fight against COVID-19.
- 01/17/2022
|
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
- Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 01/14/2022
|
1 Key Ratio All Investors Should Be Looking at When Buying Growth Stocks in 2022
- It can help investors spot a risky stock.
- 01/13/2022
|
Regeneron Pharmaceuticals, Inc. (REGN) CEO Len Schleifer Presents at 40th Annual JPMorgan Virtual Healthcare Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (REGN) CEO Len Schleifer Presents at 40th Annual JPMorgan Virtual Healthcare Conference (Transcript)
- 01/10/2022
|
Rob Sechan's top 2022 stocks picks: REGN, JPM, EOG & XOP
- Rob Sechan, NewEdge Wealth managing partner co-founder, joins the 'Halftime Report' to discuss his top stock picks for 2022.
- 01/10/2022
|
Will Regeneron Stock Rebound After Its Recent 6% Fall?
- The stock price of Regeneron has seen a 6% fall over the last twenty-one trading days, while it is down 7% over the last week. The volatility in REGN stock is being driven by the developments for REGEN-COV, its Covid-19 antibody cocktail.
- 01/10/2022
|
This biotech stock is a buy despite bearish view from BofA Securities
- Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was a notable beneficiary of the global pandemic that resulted in a 30% increase in its stock price last year. But BofA Securities warns 2022 will be a very different story.
- 01/05/2022
|
Why This Pfizer, Regeneron Analyst Has Contrasting Recommendations For The COVID Stock Plays
- An analyst at BofA Securities on Wednesday shared a pair trade idea in the large-cap pharma space. The Biopharma Analyst: Geoff Meacham upgraded Pfizer, Inc. (NYSE:PFE) shares from Neutral to Buy and increased the price target from $59 to $70.
- 01/05/2022
|
Jim Cramer says Regeneron a buy despite Covid headwinds
- Mad Money host Jim Cramer and the 'Squawk on the Street' team discuss shares of Regeneron and GlaxoSmithKline ahead of the market open.
- 01/05/2022
|
Follow The Leader: 3 Biopharma Stocks Displaying Relative Strength
- 3 Biopharma Stocks Displaying Relative Strength Heading Into 2022
- 12/29/2021
|
Best covid stocks to buy now
- The latest variant of the coronavirus pandemic, Omicron, is wreaking havoc in the global stock markets. However, as some companies struggle with the adverse economic effects of the pandemic, a few could gain significantly from the products they have created to mitigate the pandemic.
- 12/29/2021
|
U.S. Halts Distribution of Regeneron and Eli Lilly Covid Antibody Drugs
- Regulators say it is "unlikely" the drugs will have an effect against the new variant, pending new data.
- 12/24/2021
|
Regeneron: Still Room To Grow
- Regeneron easily beat the revenue and EPS expectation for 3Q 2021. Rapid revenue growth will continue into the foreseeable future, thanks to strong EYLEA, Dupixent, and Covid-treatment performance.
- 12/24/2021
|
This is an attractive entry point for health care, says Medley's Ben Emons
- Ben Emons, Medley Global Advisors, joins Closing Bell to discuss the health care sector and whether now's the time to buy.
- 12/23/2021
|
Regeneron (REGN) Gains But Lags Market: What You Should Know
- Regeneron (REGN) closed the most recent trading day at $606.81, moving +0.61% from the previous trading session.
- 12/21/2021
|
Omicron Variant Puts COVID-19 Antibody Treatments in Focus
- We take a look at the data reported so far on antibody treatments by Regeneron (REGN), AstraZeneca (AZN) and Vir (VIR) amid the Omicron variant scare. The results have been mixed mostly.
- 12/20/2021
|
Pfizer, Merck, Regeneron: Covid Treatment Stocks Back In Focus As Infections Soar
- Our indicative theme on Covid-19 Treatment Stocks – which includes biotech and pharma companies selling or developing treatments for the Covid-19 virus – is up by 25% year-to-date, compared to the S&P 500 which is up about 26% over the same period. Although we were somewhat circumspect about the.
- 12/20/2021
|
3 Stocks With a Record of Operating Income Margin Growth
- When the operating income margin continues to grow, it means a company is becoming more efficient in generating profits from its operating activities.
- 12/16/2021
|
Regeneron Pharmaceuticals is ready for its next strike against Omicron
- Regeneron Pharmaceuticals Inc (NASDAQ: REGN) lost 2.0% in the stock market this morning after the biotech company said its COVID-19 antibody cocktail loses potency against the latest Omicron variant of the Coronavirus. Regeneron has not yet lost against Omicron Interestingly, however, CEO Leonard Schleifer confirmed on CNBC's “Squawk Box” that new cocktails, which seem to […] The post Regeneron Pharmaceuticals is ready for its next strike against Omicron appeared first on Invezz.
- 12/16/2021
|
Regeneron Developing New Antibody Covid Cocktail—Current Treatment Less Effective Against Omicron
- The company announced their current antibody treatment authorized for use has “diminished potency” against the omicron variant.
- 12/16/2021
|
Regeneron CEO: We'll need Covid antibodies to work against omicron if it surges
- Regeneron CEO Len Schleifer sits down with CNBC's Meg Tirrell and the 'Squawk Box' team to break down the company's latest data on its Covid-19 antibody's defense against the omicron variant.
- 12/16/2021
|
Regeneron developing antibodies to target omicron as current cocktail loses potency against variant
- CEO Leonard Schleifer told CNBC Regeneron plans to conduct trials on the new antibodies in the first quarter of 2022.
- 12/16/2021
|
Regeneron says Covid antibody loses potency against omicron
- CNBC's Meg Tirrell joins 'Squawk Box' to report on the latest news from Regeneron, which found that its Covid-19 antibody has diminished potency against the worrisome omicron variant.
- 12/16/2021
|
Are These Stocks Cheaper Than Starbucks?
- We believe that there are other stocks that are currently better valued than Starbucks' stock. SBUX's current price-to-operating income ratio (P/EBIT) of 33.5x is higher than levels of 22.4x for Pioneer Natural Resources, 9.8x for FedEx, 9.5x for Regeneron Pharmaceuticals, 9.4x for Northrop Grumman.
- 12/16/2021
|
Nasdaq Pares Losses After Early Dive; Nucor, Regeneron Strong; Cadence Makes Key Test
- Nasdaq Pares Losses After Early Dive; Nucor, Regeneron Strong; Cadence Makes Key Test Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing data, stock market research, education and the latest financial and business news to help investors make more money in the stock market. Learn more.
- 12/14/2021
|
Regeneron (REGN) Dips More Than Broader Markets: What You Should Know
- Regeneron (REGN) closed at $660.15 in the latest trading session, marking a -1.4% move from the prior day.
- 12/13/2021
|
Regeneron Pharmaceuticals Stock (REGN): Why The Price Increased Today
- The stock price of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) increased by over 1.4% pre-market today. This is why it happened.
- 12/13/2021
|
Regeneron Stock (REGN): $824 Price Target From Goldman Sachs
- The shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have received an $824 price target from Goldman Sachs. These are the details.
- 12/12/2021
|
Regeneron Pharmaceuticals Stock (REGN): Why The Price Increased Today
- The stock price of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) increased by 1.79% today. This is why it happened.
- 12/09/2021
|
New studies show Covid boosters drive down mortality risks
- CNBC's Jim Cramer and the 'Squawk on the Street' team discuss new studies out of Israel looking at how well Pfizer and BioNTech's Covid-19 booster works in people over age 50.
- 12/09/2021
|
5 Biotech Stocks To Watch In The Stock Market Today
- Should investors be watching these biotech stocks with all the current focus on the Omicron Covid variant?
- 12/06/2021
|
Regeneron Pharmaceuticals Stock (REGN): $824 Price Target From Goldman Sachs
- The shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have received an $824 price target from Goldman Sachs. These are the details.
- 12/06/2021
|
COVID-19 Vaccine & Drug Makers Gear Up to Fight Omicron
- The Omicron variant ignites fears that currently available COVID-19 vaccines and treatments could be less effective against it. MRNA, PFE, BNTX, REGN and JNJ are some of the industry players gearing up to fight against this new variant.
- 12/03/2021
|
Regeneron: Surfing on Covid, With More Under the Surface
- Regeneron has made billions from its Covid-19 drug, and it has new drugs like Dupixent that could make many billions more. The post Regeneron: Surfing on Covid, With More Under the Surface appeared first on InvestorPlace.
- 12/02/2021
|
People should get vaccinated and boosted, Dr. Fauci says
- Dr. Anthony Fauci, National Institute of Allergy and Infectious Diseases, speaks from the White House on the omicron variant, which was discovered in a patient in California.
- 12/01/2021
|
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Piper Sandler 33rd Annual Healthcare Conference Call (Transcript)
- Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Piper Sandler 33rd Annual Healthcare Conference Call (Transcript)
- 12/01/2021
|
Which companies see growth opportunities during rising Covid concerns
- Michael Yee, Jefferies biotech analyst and managing director, joins 'Power Lunch' to discuss how company stocks are reacting to rising omicron concerns and which are the best to play with Covid concerns.
- 12/01/2021
|
Biotech Stock Starts Rocky Month with Covid-19 Headwinds
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has been in the spotlight this week, after the company's CEO Leonard Schleifer noted its Covid-19 antibody cocktail may be less effective against the omicron variant.
- 12/01/2021
|
Why Are Stocks Down Today? 4 Things to Know.
- Why are stocks down today? It seems that fears over tapering, inflation and the omicron variant are worrying investors on Tuesday.
- 11/30/2021
|
HC Wainwright Sees 'Buying Opportunity' For This COVID-19 Antibody Stock After Sell-Off
- H.C. Wainwright recommends using the selloff today for Regeneron Pharmaceuticals Inc (NASDAQ:REGN) as a buying opportunity. The analyst keeps a Buy rating on Regeneron with an $844 price target.
- 11/30/2021
|
Regeneron Pharmaceuticals' (REGN) Management on 4th Annual Evercore ISI HealthCONx Conference - Transcript
- Regeneron Pharmaceuticals' (REGN) Management on 4th Annual Evercore ISI HealthCONx Conference - Transcript
- 11/30/2021
|
Regeneron warns its antibody cocktail may be less effective against Omicron variant
- Regeneron -- which markets REGEN-COV, the most widely used monoclonal antibody therapy to treat COVID-19 in the US -- cautioned that further studies are needed to determine whether the Omicron variant can evade its therapies.
- 11/30/2021
|
Regeneron CEO says Covid antibody cocktail may be less effective against omicron variant
- Regeneron Pharmaceuticals' Covid-19 antibody cocktail, and similar drugs, could be less effective against the omicron coronavirus variant, the company said.
- 11/30/2021
|
Regeneron: Antibody cocktail is less effective against omicron
- The "Squawk Box" team discusses a report from Regeneron that its antibody treatment is less effective against the omicron variant.
- 11/30/2021
|
Regeneron Says Covid-19 Treatment Might Not Work as Well Against Omicron
- The biotech company's monoclonal antibody is likely to be less effective against the new strain.
- 11/30/2021
|
Tests suggest Regeneron antibody treatment for COVID loses effectiveness against omicron variant: WSJ
- Early tests suggest that the COVID-19 antibody treatment developed by Regeneron Pharmaceuticals Inc. REGN, +1.72% loses effectiveness against the omicron variant of the coronavirus that causes COVID, but the full impact will only be known in the coming weeks after further testing, the company's president and chief scientific officer George Yancopoulos told the Wall Street Journal on Tuesday. Evercore analysts had raised that issue in a note to clients on Friday.
- 11/30/2021
|
ADGI Stock Soars as Analysts Lock On to Its Omicron-Fighting Potential
- Shares of ADGI stock are soaring higher by 80% after the company stated that its ADG-20 antibody is effective against the omicron variant. The post ADGI Stock Soars as Analysts Lock On to Its Omicron-Fighting Potential appeared first on InvestorPlace.
- 11/29/2021
|
Regeneron Extends Hearing Loss Gene Therapy pact With Decibel
- Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has extended the research term of its collaboration with Decibel Therapeutics Inc (NASDAQ: DBTX) to discover and develop gene therapies for hearing loss. The research term is extended to November 15, 2023, and Regeneron will pay Decibel an extension fee of $10 million in Q4 of 2022.
- 11/22/2021
|
Why Regeneron's Results for Its COVID Antibody Therapy Won't Boost Sales Much
- The therapy will likely face stiff competition from more convenient COVID-19 pills.
- 11/20/2021
|
Regeneron Announces Investor Conference Presentations
- TARRYTOWN, N.Y., Nov. 16, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Evercore ISI 4th Annual HealthCONx Conference at 9:15 a.m.
- 11/16/2021
|
Regeneron (REGN), Roche Get EC Nod for COVID-19 Cocktail
- Regeneron (REGN) and partner Roche win the European Commission's approval for antibody cocktail to treat and prevent COVID-19.
- 11/15/2021
|
Regeneron's board OKs $3 billion share buyback program
- Regeneron Pharmaceuticals Inc. REGN, +0.73% said late Friday its board has authorized a share buyback program of up to $3 billion, saying it's an opportunity to continue to invest in the business given the "strength" of its balance sheet and business. Repurchases will be made from time to time at management's discretion, the company said.
- 11/12/2021
|
Europe Approves Regeneron - Roche's COVID-19 Antibody Cocktail
- The European Commission (EC) has approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 antibody cocktail, known as REGEN-COV in the U.S. and Ronapreve in the European Union (EU) and other countries. The authorization comes for people aged 12 years and older to treat non-hospitalized patients (outpatients) with confirmed COVID-19 who do not require oxygen supplementation and who are at increased risk of progressing to severe COVID-19 and to prevent COVID-19.
- 11/12/2021
|
Regeneron (REGN)-Roche COVID-19 Cocktail Gets Positive CHMP Opinion
- Regeneron (REGN) and partner Roche obtain a positive opinion from CHMP for their antibody cocktail for the treatment of non-hospitalized patients with confirmed COVID-19 and to prevent the disease.
- 11/12/2021
|
EU Regulator Backs Regeneron-Roche's COVID-19 Drug
- The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) REGEN-COV. The casirivimab and imdevimab antibody cocktail (Ronapreve) was backed by the CHMP for treating adults and children over 12 with COVID-19 who do not require oxygen support and are at high risk of severe disease.
- 11/11/2021
|
10 Stocks Post-Pandemic: What to Consider, Keep and Run From
- More than a year and a half into the Covid-19 pandemic, the world is changing. More people are returning to the office after months of working at home and restaurants have reopened.
- 11/09/2021
|
4 Top Biotech Stocks To Watch This Week
- Check out these biotech stocks that could prove to be valuable additions to your portfolio.
- 11/08/2021
|
REGN vs. TECH: Which Stock Is the Better Value Option?
- REGN vs. TECH: Which Stock Is the Better Value Option?
- 11/08/2021
|
More Good Covid Treatment News; Markets Up Again
- The Dow is +140 points, the S&P 500 +10 and the Nasdaq +2 points in the pre-market.
- 11/08/2021
|
Markets Up on COVID Pill News
- Markets Up on COVID Pill News
- 11/08/2021
|
Regeneron Says Antibody Cocktail Protects Against Covid For Up To Eight Months
- One dose of the antibody cocktail, given via four injections, cut the risk of contracting Covid-19 by over 80%.
- 11/08/2021
|
Regeneron CEO on how antibody cocktail may protect against Covid-19
- Regeneron CEO Leonard Schleifer joins CNBC's 'Squawk Box' to discuss the latest data around its Covid-19 antibody cocktail, which the company says provides long-term protection against the disease.
- 11/08/2021
|
Regeneron Pharmaceuticals now offers long-term immunity against COVID-19
- Regeneron Pharmaceuticals Inc (NASDAQ: REGN) on Monday said a single dose of REGEN-COV triggers long-term immunity against COVID-19. Shares of the biotech company were up more than 1.0% in premarket trading.
- 11/08/2021
|
Regeneron CEO says its monoclonal antibodies protect people from Covid for months
|
Cramer's First Take: Regeneron's not been treated with respect
- CNBC's Jim Cramer joins 'Squawk Box' to discuss Regeneron's latest news and how the company has been treated as a whole.
- 11/08/2021
|
Regeneron-Roche's COVID-19 Treatment Shows Long Term Benefit After Single Dose
- Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has announced additional results from a Phase 3 trial, which assessed a single dose of REGEN-COV (1,200 mg administered via 4 subcutaneous injections) to prevent COVID-19 in uninfected individuals. The new analyses show REGEN-COV reduced the risk of contracting COVID-19 by 81.6% during the pre-specified follow-up period (months 2-8), maintaining the 81.4% risk reduction during the first month after administration.
- 11/08/2021
|
Regeneron says single dose of Covid antibody cocktail provides long-term protection
- Regeneron says a single dose of its antibody cocktail reduced the risk of contracting Covid-19 by 81.6%. CNBC's 'Squawk Box' reports.
- 11/08/2021
|
Regeneron says its COVID-19 antibody cocktail can prevent COVID-19 infections for months
- Shares of Regeneron Pharmaceuticals Inc. REGN, -5.57% gained 3.7% in premarket trading on Monday after the company said four subcutaneous injections of its monoclonal antibody treatment protected unvaccinated people from contracting COVID-19 by 81.6% for up to eight months. Four infusions of the treatment are considered one dose.
- 11/08/2021
|
Billions Wiped From Covid Pharma Heavyweights—Including Moderna, Regeneron, Merck—As Pfizer's Antiviral Pill Triggers Selloff
- Pfizer jumped 8% Friday morning, while Moderna dropped 17.8%, Regeneron 6.2% and Merck 9%.
- 11/05/2021
|
3 Reasons Why Investors Should Love Regeneron's Q3 Update
- The big biotech delivered an exceptionally strong performance in Q3.
- 11/05/2021
|
Regeneron Pharmaceuticals, Inc. (REGN) CEO Leonard Schleifer on Q3 2021 Results - Earnings Call Transcript
- Regeneron Pharmaceuticals, Inc. (REGN) CEO Leonard Schleifer on Q3 2021 Results - Earnings Call Transcript
- 11/04/2021
|
Regeneron (REGN) Q3 Earnings Beat, REGEN-COV Boosts Growth
- Regeneron (REGN) beats on Q3 earnings while sales record strong year-over-year growth on the solid performance of Dupixent and Eylea, and incremental contribution from REGEN-COV.
- 11/04/2021
|
4 Health Care Stocks For Your November 2021 Watchlist
- Could these health care stocks be buys on President Biden's latest vaccine mandate?
- 11/04/2021
|
Regeneron Stock Slips Despite Earnings, Revenue Beat
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN) threw its hat into the earnings ring this morning, reporting third-quarter earnings and revenue that trounced Wall Street's estimates.
- 11/04/2021
|
Why Regeneron Shares Are Rising Today
- Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is trading higher Thursday after the company announced better-than-expected third-quarter financial results. Regeneron reported quarterly adjusted earnings of $15.37 per share, which beat the estimate of $9.49 per share.
- 11/04/2021
|
Regeneron quarterly profit nearly doubles on strong demand for eczema drug
- Regeneron Pharmaceuticals Inc's third-quarter profit nearly doubled on Thursday, helped by robust demand for its blockbuster drugs Dupixent to treat eczema and eye treatment Eylea.
- 11/04/2021
|
Is Regeneron Pharmaceuticals (REGN) Outperforming Other Medical Stocks This Year?
- Is (REGN) Outperforming Other Medical Stocks This Year?
- 11/03/2021
|
Will Eylea, Dupixent, REGEN COV Aid Regeneron (REGN) Q3 Earnings?
- Regeneron's third-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent and incremental contribution from its antibody cocktail.
- 11/01/2021
|
4 Big Drug, Biotech Stocks Set to Beat Q3 Earnings Estimates
- Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.
- 10/29/2021
|
Top 5 High ROE Stocks to Buy as Fed Tapering Looms Large
- Seagate Technology (STX), Best Buy (BBY), Celanese Corporation (CE), CBRE Group (CBRE), and Regeneron Pharmaceuticals (REGN) are some stocks with high ROE to buy as the Fed tapering decision is expected soon.
- 10/28/2021
|
Regeneron Looks Oversold, Ready To Jump Up On Catalysts
- The stock price has corrected sharply in recent months against the backdrop of which a multiple contraction has occurred. I think the dip was driven by a) Cathie Wood's transactions and b) declining new COVID-19 cases.
- 10/25/2021
|
Major Stock Indexes Hit Record-High Level: 5 Top-Ranked Picks
- We have narrowed down our search to five stocks that are members of any of the three major stock indexes. These are: GS, XOM, CVX, COP and REGN.
- 10/22/2021
|
Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know
- In the latest trading session, Regeneron (REGN) closed at $562.71, marking a +1.92% move from the previous day.
- 10/20/2021
|
4 Top-Ranked Stocks to Invest in for Solid Earnings Growth
- Regeneron Pharmaceuticals (REGN), Evercore (EVR), Houlihan Lokey (HLI) & DICK'S Sporting Goods (DKS) currently have striking earnings growth and positive estimate revisions, which make them must-buys.
- 10/18/2021
|
3 No-Brainer Biotech Stocks to Buy Right Now
- Regeneron Pharmaceuticals, Vertex Pharmaceuticals, and Viatris should have plenty of room to run.
- 10/16/2021
|
2 Cheap Growth Stocks That Could Be Even Better Buys in November
- Both of these companies are reporting earnings within the next month, and there could be a dip in price that follows.
- 10/15/2021
|
Why Regeneron Shares Are Rising Today
- Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is trading higher Thursday after the company announced the FDA accepted for priority review a Biologics License Application for REGEN-COV to treat COVID-19 in non-hospitalized patients and as prophylaxis in certain individuals. The FDA assigned a target action date of April 13, 2022 and plans to hold an advisory committee meeting to discuss the application beforehand.
- 10/14/2021
|
Regeneron is seeking full FDA approval for its monoclonal antibody for two types of COVID-19 patients
- Shares of Regeneron Pharmaceuticals Inc. REGN, +0.49% gained 2.7% in premarket trading on Thursday after the company said the Food and Drug Administration accepted its application for approval of its monoclonal antibody treatment for non-hospitalized COVID-19 patients and as a prophylaxis for some people who have been exposed to the virus. The FDA said it will decide whether to approve the therapy by April 13 based on the priority review designation it granted to the application.
- 10/14/2021
|
FDA Accepts REGEN-COV® (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19
- TARRYTOWN, N.Y., Oct. 14, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) for REGEN-COV® (casirivimab and imdevimab) to treat COVID-19 in non-hospitalized patients and as prophylaxis in certain individuals.
- 10/14/2021
|
Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know
- In the latest trading session, Regeneron (REGN) closed at $547.12, marking a +0.49% move from the previous day.
- 10/13/2021
|
Top 3 undervalued US biotech stocks to buy
- With the US Q3 earnings season just getting started, there are a few biotech stocks that present an exciting opportunity for value investors. Some of these stocks look significantly undervalued after a decline in their stock prices.
- 10/12/2021
|
Regeneron to Report Third Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2021
- TARRYTOWN, N.Y., Oct. 11, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2021 financial and operating results on Thursday, November 4, 2021, before the U.S. financial markets open.
- 10/11/2021
|
Regeneron Could Have a Big Catalyst Coming in 2022
- Cancer drug Libtayo could receive FDA approval for its fourth indication in January.
- 10/09/2021
|
3 Reasons Why Growth Investors Shouldn't Overlook Regeneron (REGN)
- Regeneron (REGN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 10/08/2021
|
REGN or TECH: Which Is the Better Value Stock Right Now?
- REGN vs. TECH: Which Stock Is the Better Value Option?
- 10/08/2021
|
Should Value Investors Buy Regeneron (REGN) Stock?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 10/08/2021
|
Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know
- Regeneron (REGN) closed at $546.57 in the latest trading session, marking a -0.79% move from the prior day.
- 10/06/2021
|
Will Regeneron Stock See Lower Levels After Merck's Positive Data?
- The stock price of Regeneron has seen a 16% fall over the last twenty-one trading days, while it is down 6% over the last year. The volatility in REGN stock is being driven by the developments for REGEN-COV, its Covid-19 antibody cocktail.
- 10/05/2021
|
Regeneron Pharmaceuticals: Undervalued Cash Generating Machine
- Regeneron Pharmaceuticals: Undervalued Cash Generating Machine
- 10/04/2021
|
Here's Why Regeneron (REGN) is Poised for a Turnaround After Losing 16% in 4 Weeks
- Regeneron (REGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 10/04/2021
|
REGN Stock Price: Why It Fell Over 5%
- The stock price of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) fell by over 5% in the previous trading session. This is why it happened.
- 10/02/2021
|
Is Regeneron Pharmaceuticals (REGN) Outperforming Other Medical Stocks This Year?
- Is (REGN) Outperforming Other Medical Stocks This Year?
- 10/01/2021
|
Core PCE Inflation Stays at Record-High in August
- Core PCE Inflation Stays at Record-High in August.
- 10/01/2021
|
Regeneron (REGN) Reports Positive Data on Antibody Cocktail
- Regeneron's (REGN) phase III study assessing REGEN-COV in patients hospitalized with COVID-19 meets its primary goal.
- 10/01/2021
|
Regeneron-Roche Post Encouraging New Data For COVID-19 Antibody Cocktail
- Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Roche Holdings AG (OTC: RHHBY) announced positive data from Phase 2/3 2066 study of Ronapreve (casirivimab and imdevimab) or REGN-COV in hospitalized COVID-19 patients. Related: WHO Backs Regeneron COVID-19 Antibody Cocktail As It Calls For Equal Access.
- 09/30/2021
|
New REGEN-COV™ (casirivimab and imdevimab) Data Show Supportive Results in Patients Hospitalized with COVID-19
- TARRYTOWN, N.Y., Sept. 30, 2021 /PRNewswire/ -- Trial met primary endpoint, showing REGEN-COV significantly reduced viral load within 7 days of treatment; trial conducted in patients hospitalized with COVID-19 who did not require high-flow oxygen or mechanical ventilation at baseline Numeric improvements with REGEN-COV observed for all clinical endpoints, including a 36% reduced risk of death by day 29 in the overall population, increasing to 56% reduced risk in patients who were seronegative at baseline Similar efficacy observed with both doses (2,400 mg and 8,000 mg); U.S. FDA is currently reviewing request to add treatment in hospital settings to REGEN-COV authorization Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that a trial assessing investigational REGEN-COV™ (casirivimab and imdevimab) in patients hospitalized with COVID-19 met its primary endpoint.
- 09/30/2021
|
New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19
- TARRYTOWN, N.Y., Sept. 29, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the New England Journal of Medicine (NEJM) published positive detailed results from a Phase 3 trial that assessed the ability of REGEN-COV™ (casirivimab and imdevimab) to treat COVID-19 in infected high-risk non-hospitalized patients (outpatients).
- 09/29/2021
|
7 Biotech Stocks Entering the Golden Boom Phase
- These biotech stocks offer a more mature take on an otherwise risky sector. These companies already have successes under their belt.
- 09/28/2021
|
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Cantor Fitzgerald Virtual Global Healthcare 2021 Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Cantor Fitzgerald Virtual Global Healthcare 2021 Conference (Transcript)
- 09/27/2021
|
Regeneron (REGN) Antibody Cocktail REGEN-COV Gets WHO Recommendation
- Regeneron (REGN) monoclonal antibody cocktail is being conditionally recommended by WHO for the treatment of certain patients with COVID-19. However, the high cost is a deterrent.
- 09/27/2021
|
WHO Backs Regeneron COVID-19 Antibody Cocktail As It Calls For Equal Access
- The World Health Organization (WHO) has supported another COVID-19 therapeutic but urged the related companies and governments to address the high price and limited production of Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) antibody combination. Related Content: WHO Recommends IL-6 Drugs From Sanofi, Roche For Critically-Ill COVID-19 Patients.
- 09/24/2021
|
U.S. Household Net Worth Hits Record High in Q2: 5 Picks
- We have narrowed down our search to five large-cap stocks that have given double-digit returns in the past three months. These are: CLR, DAR, REGN, ORLY and MOS.
- 09/24/2021
|
WHO recommends Regeneron's monoclonal antibody treatment for COVID-19
- Shares of Regeneron Pharmaceuticals Inc. REGN, -0.08% were down 0.1% in premarket trading on Friday after the World Health Organization recommended its monoclonal antibody as a treatment for COVID-19. The global body says the combination treatment can be used in COVID-19 patients who are at high risk of severe disease as well as in severe and critically ill COVID-19 patients who have not yet developed antibodies.
- 09/24/2021
|
WHO Recommends Regeneron Antibody Cocktail For High-Risk Covid Patients
- The health agency also joined calls for Regeneron to boost access to its drug, ramp up production and lower its prices to ensure it is distributed fairly.
- 09/24/2021
|
Can Regeneron (REGN) Stock Continue to Grow Earnings?
- If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Regeneron (REGN).
- 09/23/2021
|
4 Top Biotech Stocks to Watch as Economic Recovery Picks Up Pace
- New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position REGN, MRNA, VRTX, and HZNP well amid the economic recovery.
- 09/23/2021
|
5 Stocks With High ROE as Markets Await Fed Tapering Outlook
- OneMain Holdings (OMF), KLA Corporation (KLAC), Bunge Limited (BG), CBRE Group, (CBRE) and Regeneron Pharmaceuticals (REGN) are some of the stocks with high ROE to buy as markets await Fed tapering clarity.
- 09/22/2021
|
2 Outperforming Biotech Stocks to Examine on Covid-19 Vaccine Updates
- With recent updates from Pfizer Inc. ( PFE , Financial) and BioNTech SE ( BNTX , Financial) regarding the effectiveness of their Covid-19 vaccine among children ages 5 to 11 and Johnson & Johnson's ( JNJ , Financial) booster shot announcement, consumers and investors alike are continuing to carefully watch the health care space.
- 09/21/2021
|
New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV
- New Dupixent ® (dupilumab) data in patients as young as 6 years old with moderate -to-severe a topic dermatitis to be presented at WCPD and EADV
- 09/21/2021
|
New Dupixent® (dupilumab) Data in Patients as Young as Six Years Old With Moderate-to-Severe Atopic Dermatitis to Be Presented at WCPD and EADV
- TARRYTOWN, N.Y. and PARIS, Sept.
- 09/21/2021
|
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Regeneron Oncology Investor Event, ESMO 2021 Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Regeneron Oncology Investor Event, ESMO 2021 Conference (Transcript)
- 09/20/2021
|
Sanofi, Regeneron, Share Competitive Libtayo Survival Data in 1L NSCLC
- Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) hope to expand Libtayo into a broader population with a chemo combo regimen. According to data released at the European Society for Medical Oncology 2021 ( ESMO21 ), Libtayo, used on top of platinum doublet chemotherapy, reduced the risk of death by 29% over chemo alone in patients with previously untreated, advanced non-small cell lung cancer (NSCLC).
- 09/20/2021
|
ESMO Late-breaking Data Show Libtayo® (cemiplimab) and Chemotherapy First-line Treatment Combination Significantly Improved Overall Survival in Patients with Advanced NSCLC
- TARRYTOWN, N.Y. and PARIS, Sept.
- 09/19/2021
|
AbbVie's Pain Is Sanofi's and Regeneron's Gain
- There are both winners and losers with the new Food and Drug Administration restrictions on JAK inhibitors.
- 09/18/2021
|
Has Regeneron Pharmaceuticals (REGN) Outpaced Other Medical Stocks This Year?
- Is (REGN) Outperforming Other Medical Stocks This Year?
- 09/15/2021
|
7 Gene Editing Stocks Promising to Change our DNA
- Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market. The post 7 Gene Editing Stocks Promising to Change our DNA appeared first on InvestorPlace.
- 09/15/2021
|
U.S. to pay $2.9 billion for an additional 1.4 million doses of Regeneron's COVID-19 therapy
- Shares of Regeneron Pharmaceuticals Inc. REGN, +0.88% gained 2.1% in premarket trading on Wednesday, the day after the company said the U.S. government had purchased an additional 1.4 million doses of its monoclonal antibody treatment for COVID-19 for $2.9 billion. The treatment, which costs $2,100 per dose, is free to Americans at high risk of hospitalization and death who have tested positive or have been exposed to the virus.
- 09/15/2021
|
Regeneron Announces New U.S. Government Agreement to Purchase Additional Doses of REGEN-COV™ (casirivimab and imdevimab) Antibody Cocktail
- TARRYTOWN, N.Y., Sept. 14, 2021 /PRNewswire/ -- New agreement for 1.4 million doses of REGEN-COV, brings total purchased by the U.S. government to nearly 3 million doses REGEN-COV currently authorized to treat certain infected patients to reduce risk of hospitalization or death from COVID-19, and for post-exposure prophylaxis for close contacts of infected individuals Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DOD) will purchase 1.4 million additional doses of REGEN-COV (casirivimab and imdevimab).
- 09/14/2021
|
Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know
- In the latest trading session, Regeneron (REGN) closed at $639.52, marking a -1.69% move from the previous day.
- 09/13/2021
|
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)
- 09/13/2021
|
Regeneron Announces Investor Conference Presentations
- TARRYTOWN, N.Y., Sept. 8, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Morgan Stanley 19th Annual Global Healthcare Conference at 8:45 a.m.
- 09/08/2021
|
Bet on These 5 Low-Beta Stocks to Combat Market Volatility
- It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. REGN, CAJ, COG, EXC & WMT are well poised to gain.
- 09/07/2021
|
My Fat-Margin Stocks Returned 78% Last Year
- It's been a great year for stocks with fat profit margins.
- 09/07/2021
|
3 Large Biotech Stocks Worth Adding to Your Portfolio
- REGN, MRNA & VRTX are the three biotech companies that are likely to outperform the sector on the back of strong fundamentals.
- 09/02/2021
|
Now May Be the Big Moment for These 2 COVID Stocks
- Their products are seeing a surge in demand.
- 09/02/2021
|
Antibody drugs take off in new Covid surge
- Meg Tirrell joins The Exchange with more information about Covid antibody treatments and the increasing demand for these drugs in places where the delta variant is surging. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic Turn to CNBC TV for the latest stock market news and analysis.
- 08/31/2021
|
Is Regeneron Pharmaceuticals (REGN) Outperforming Other Medical Stocks This Year?
- Is (REGN) Outperforming Other Medical Stocks This Year?
- 08/30/2021
|
Sanofi (SNY)/Regeneron's Dupixent Meets Eczema Study Goal
- Sanofi (SNY) and Regeneron (REGN)'s Dupixent meet all primary and secondary endpoints in phase III study to treat children aged six months to five years with moderate-to-severe atopic dermatitis.
- 08/30/2021
|
Coronavirus antibody drugs take off
- CNBC's Meg Tirrell reports on the surge in Covid antibody drug orders.
- 08/30/2021
|
Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months
- Dupixent ® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months
- 08/30/2021
|
Dupixent® (dupilumab) Pivotal Trial Meets All Primary and Secondary Endpoints Becoming First Biologic Medicine to Significantly Reduce Signs and Symptoms of Moderate-to-severe Atopic Dermatitis in Children as Young as 6 Months
- TARRYTOWN, N.Y. and PARIS, Aug. 30, 2021 /PRNewswire/ -- Dupixent rapidly improved symptoms after first dose, improving itch in one week and skin clearance in two weeks More than seven times as many patients treated with Dupixent plus topical corticosteroids (TCS) achieved clear or almost clear skin compared to TCS alone at week 16 Dupixent plus TCS reduced overall disease severity by 70% and itch by 49% Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced positive pivotal Phase 3 results from a trial evaluating Dupixent® (dupilumab) to treat moderate-to-severe atopic dermatitis in children aged 6 months to 5 years.
- 08/30/2021
|
5 Bigwigs to Buy on Double-Digit Returns in the Past Month
- We have narrowed down our search to five U.S. corporate bigwigs that have provided more than 10% returns in the past month. These are: MRNA, REGN, AIG, CARR and NVDA.
- 08/27/2021
|
3 Growth Stocks Near Record Highs That Are Still Worth Buying
- Look for the current all-time highs to be broken.
- 08/27/2021
|
Regeneron's (REGN) Wet AMD Study on High Dose Eylea Meets Goal
- Regeneron's (REGN) phase II study evaluating a higher 8-mg dose of Eylea injection in patients with wet age-related macular degeneration has met the primary safety endpoint.
- 08/25/2021
|
Nvidia, Intuit, Regeneron: Cash-Rich Companies Are Outperforming Big This Year
- Our theme of Cash-Rich Stocks filters for consistently profitable and growing companies within the S&P 500 that have a net cash position (total cash and investments less debt) that stands at 25% or more of their total assets. The theme has outperformed the broader markets considerably, with ytd.
- 08/25/2021
|
6 Must-Buy Corporate Giants As Major Indexes Hit Record High
- We have narrowed down our search to six stocks that are members of any of the three major indexes. These are: MRNA, NVDA, TJX, AAPL, DE and REGN.
- 08/25/2021
|
CARA Drug Wins FDA Nod for Pruritus Associated With CKD
- CARA gets a significant boost with FDA approval for Korsuva injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.
- 08/24/2021
|
5 Stocks At the Forefront of the Latest S&P 500 Rally
- The S&P 500 showed strength to start the new week and hit a new peak on a vaccine boost. This benefited the KR, REGN, TJX, ISRG, MSFT stocks.
- 08/24/2021
|
Regeneron Announces Encouraging Topline Phase 2 Data of High-dose aflibercept in Wet Age-related Macular Degeneration
- TARRYTOWN, N.Y., Aug. 24, 2021 /PRNewswire/ -- Phase 3 trials in wet AMD and diabetic macular edema fully recruited, with results expected in the second half of 2022 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that an ongoing Phase 2 proof-of-concept trial evaluating an investigational 8 mg dose of aflibercept met its primary safety endpoint, with no new safety signals observed compared to the currently-approved 2 mg dose of EYLEA® (aflibercept) Injection in patients with wet age-related macular degeneration (wet AMD).
- 08/24/2021
|
Regeneron Pharmaceuticals Shares: $727 Target From Benchmark
- The shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) received a price target of $727 by Benchmark. These are the details.
- 08/23/2021
|
Regeneron (REGN) COVID-19 Antibody Cocktail Gets CMA in the UK
- Regeneron (REGN) gets Conditional Marketing Authorization for its antibody cocktail, casirivimab and imdevimab for COVID-19 infection in the United Kingdom.
- 08/23/2021
|
Combat the Choppy Market With These 5 Low-Beta Stocks
- It is imperative to build a portfolio of low-beta stocks to sail through choppy market conditions. CHWY, REGN, VSTO, RGR & CICHY are the frontrunners.
- 08/20/2021
|
5 Stocks With High ROE to Buy Amid Fresh COVID-19 Fears
- T. Rowe Price Group (TROW), KLA Corporation (KLAC), Whirlpool (WHR), CBRE Group (CBRE) and Regeneron Pharmaceuticals (REGN) are some of the stocks with high ROE to buy as coronavirus resurgence fear soars.
- 08/20/2021
|
UK Approves Regeneron - Roche's COVID-19 Antibody Cocktail
- The U.K. drug regulator has approved an antibody cocktail developed by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Roche Holding AG (OTC: RHHBY) to prevent and treat COVID-19. The U.K. chief medical officers confirmed the antibody would be rolled out on the National Health Service in the coming weeks.
- 08/20/2021
|
UK Authorizes Regeneron Antibody Cocktail to Prevent and Treat Acute COVID-19 Infection
- TARRYTOWN, N.Y., Aug. 20, 2021 /PRNewswire/ -- UK chief medical officers to confirm how antibody cocktail will be rolled-out on the National Health Service (NHS) in the coming weeks In the U.S., Regeneron has completed the first FDA BLA submission for the antibody cocktail; more than 130,000 doses were distributed in the past week to address COVID-19 outbreaks Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the United Kingdom's (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted Conditional Marketing Authorization (CMA) for the casirivimab and imdevimab antibody cocktail, known as REGEN-COV™ in the U.S. and Ronapreve® in the UK and other countries, to prevent and treat acute COVID-19 infection.
- 08/20/2021
|
Why Regeneron Pharmaceuticals (REGN) Isn't Done Growing Earnings Yet
- If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Regeneron Pharmaceuticals (REGN).
- 08/19/2021
|
Regeneron: All-Time High Share Price Hasn't Yet Reached Full Potential
- Regeneron: All-Time High Share Price Hasn't Yet Reached Full Potential
- 08/19/2021
|
PreMarket Prep Stock Of The Day: Regeneron
- Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session.
- 08/18/2021
|
3 Growth Stocks Cathie Wood Is Selling That Are Still Worth Buying
- Wood might regret trimming her positions in these great growth stocks.
- 08/17/2021
|
Regeneron's Antibody Cocktail Authorized for Preventing COVID: Why It's Not a Big Deal for the Stock
- The biotech's EUA expansion for REGEN-COV will probably provide only an incremental sales boost.
- 08/14/2021
|
Is Regeneron Pharmaceuticals (REGN) Stock Outpacing Its Medical Peers This Year?
- Is (REGN) Outperforming Other Medical Stocks This Year?
- 08/12/2021
|
Instead of Panicking About a Market Crash, Do This
- The stock market may be at all-time highs, but that doesn't mean investing is too dangerous.
- 08/11/2021
|
REGN Stock Price: $825 Target From Oppenheimer
- The shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have received a price target increase from $725 to $825 by Oppenheimer. These are the details.
- 08/07/2021
|
Ocular Therapeutix, Regeneron Cull Aflibercept Agreement For Retinal Diseases
- Ocular Therapeutix Inc (NASDAQ: OCUL) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have terminated the option and license agreement collaboration. The termination is effective immediately.
- 08/06/2021
|
Regeneron Pharmaceuticals Inc. (REGN) CEO Leonard Schleifer on Q2 2021 Results - Earnings Call Transcript
- Regeneron Pharmaceuticals Inc. (REGN) CEO Leonard Schleifer on Q2 2021 Results - Earnings Call Transcript
- 08/05/2021
|
Weekly Jobless Claims Decline
- Weekly Jobless Claims Decline
- 08/05/2021
|
Sanofi - Regeneron's Libtayo/Chemo Treatment Improves Overall Survival First-Line Lung Cancer
- The Phase 3 trial of Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Libtayo in combination with platinum-doublet chemotherapy was stopped early after meeting its overall survival (OS) primary endpoint in patients with advanced non-small-cell lung cancer (NSCLC). These data are planned to form the basis of regulatory submissions in the U.S. and European Union.
- 08/05/2021
|
Regeneron Beats Street Estimates Big In Q2 As COVID-19 Antibody Boosts Topline, Cuts FY21 R&D Spend Outlook
- Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned $25.80 per share for the second quarter, beating the $17.69 estimate. It clocked revenue of $5.1 billion, surpassing the analysts' consensus of $3.89 billion and higher than $1.95 billion a year ago, primarily attributable to sales from COVID-19 treatment, REGEN-COV.
- 08/05/2021
|
Regeneron (REGN) Q2 Earnings and Revenues Top Estimates
- Regeneron (REGN) delivered earnings and revenue surprises of 31.97% and 31.92%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/05/2021
|
Regeneron Earnings Top Estimates. Its Stock May Be Breaking Out.
- The company credited record sales of asthma medication Dupixent and age-related macular degeneration drug Eylea, among other factors, for the beat.
- 08/05/2021
|
Regeneron quarterly profit surges on COVID-19 antibody cocktail demand
- Regeneron Pharmaceuticals Inc reported a more than tripling of its quarterly profit on Thursday, buoyed by robust demand for its COVID-19 antibody cocktail.
- 08/05/2021
|
Regeneron Reports Second Quarter 2021 Financial and Operating Results
- TARRYTOWN, N.Y., Aug. 5, 2021 /PRNewswire/ -- Second quarter 2021 revenues increased 163% to $5.14 billion versus second quarter 2020 including $2.76 billion attributable to REGEN-COV TM(2) ; revenues excluding REGEN-COV (1)(2) increased 22% Second quarter 2021 EYLEA® U.S. net sales increased 28% versus second quarter 2020 to a record $1.42 billion Second quarter 2021 Dupixent® global net sales (3) , which are recorded by Sanofi, increased 59% to $1.50 billion versus second quarter 2020 Second quarter 2021 GAAP diluted EPS was $27.97 and non-GAAP diluted EPS (1) was $25.80 FDA updated REGEN-COV Emergency Use Authorization (EUA) with lower dose, subcutaneous administration, and post-exposure prophylaxis REGEN-COV Phase 3 RECOVERY trial in hospitalized patients with severe COVID-19 met primary outcome Reported that Dupixent significantly improved itch and hives in patients with chronic spontaneous urticaria, marking the fifth disease to show positive pivotal results Phase 3 trial of Libtayo® combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2021 and provided a business update.
- 08/05/2021
|
3 Biotech Stocks That Could Make You Richer in August (and Beyond)
- All three have blockbuster products already on the market.
- 08/05/2021
|
Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer
- Phase 3 t rial of Libtayo ® ( cemiplimab ) c ombined with c hemotherapy s topped e arly d ue to s ignificant i mprovement in o verall s urvival in p atients with f irst-line a dvanced n on-small c ell l ung c ancer
- 08/05/2021
|
New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Prevent SARS-CoV-2 Infection
- TARRYTOWN, N.Y., Aug. 4, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the New England Journal of Medicine (NEJM) published positive detailed results from a Phase 3 trial that assessed the ability of REGEN-COV™ (casirivimab and imdevimab) to prevent COVID-19 infection among household contacts of SARS-CoV-2 infected individuals.
- 08/04/2021
|
Drug/Biotech Stocks Q2 Earnings Due on Aug 5: REGN, MRNA, ZTS, ILMN
- Let us take a look at what is in store for some of the drug/biotech stocks, which are scheduled to report on Aug 5.
- 08/04/2021
|
Regeneron: Rapid Growth Seems To Be On A Pause
- Regeneron has developed some truly life changing treatment options and has exposure to some undertreated spaces. The stock has run up quite a bit on their stellar performances in the past.
- 08/02/2021
|
FDA Approves Regeneron - Roche's COVID-19 Antibody Cocktail For Post-Exposure Prophylaxis
- Following the June update that allowed for a lower dose of REGEN-COV, the FDA has again expanded emergency use authorization for the investigational COVID-19 antibody cocktail. REGEN-COV (casirivimab and imdevimab) has been developed by Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Roche Holdings AG (OTC:RHHBY).
- 08/02/2021
|
FDA Expands Authorized Use of REGEN-COV™ (casirivimab and imdevimab)
- TARRYTOWN, N.Y., July 30, 2021 /PRNewswire/ -- Expanded authorization enables use of REGEN-COV for post-exposure prophylaxis in certain people exposed to a SARS-CoV-2 infected individual, or who are at high risk of exposure to an infected individual in an institutional setting Supported by pivotal Phase 3 data showing 81% reduced risk of symptomatic infections in close contacts of SARS-CoV-2 infected individuals Only COVID-19 antibody therapy currently available across the U.S. for both treatment and post-exposure prophylaxis; REGEN-COV retains potency against variants of concern Use of REGEN-COV across the U.S. is rapidly increasing to address ongoing outbreaks Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) updated the Emergency Use Authorization (EUA) for the investigational COVID-19 antibody cocktail REGEN-COV™ (casirivimab and imdevimab).
- 07/30/2021
|
4 Pharma/Biotech Stocks Poised to Beat on Earnings in Q2
- We take a look at a few pharma/biotech companies, which are poised to beat on earnings in the second quarter.
- 07/29/2021
|
Regeneron - Sanofi's Dupixent Improves Itch, Hives In Inflammatory Skin Disease Patients
- Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) have announced topline results from Phase 3 trial evaluating Dupixent (dupilumab) in patients with moderate-to-severe chronic spontaneous urticaria (CSU), an inflammatory skin disease. The 138-subject study met its primary endpoints and all key secondary endpoints at 24 weeks.
- 07/29/2021
|
Dupixent® (dupilumab) significantly improved itch and hives in patients with chronic spontaneous urticaria, a step forward in demonstrating the role of type 2 inflammation in these patients
- Dupixent ® (dupilumab) s ignificantly i mproved i tch and h ives in p atients with c hronic s pontaneous u rticaria, a s tep f orward in d emonstrating the r ole of t ype 2 i nflammation in t hese p atients
- 07/29/2021
|
Dupixent® (dupilumab) Significantly Improved Itch and Hives in Patients with Chronic Spontaneous Urticaria, a Step Forward in Demonstrating the Role of Type 2 Inflammation in These Patients
- TARRYTOWN, N.Y. and PARIS, July 29, 2021 /PRNewswire/ -- Fifth disease in which Dupixent has demonstrated positive pivotal results Phase 3 trial met primary and all key secondary endpoints at 24 weeks, showing Dupixent nearly doubled reduction in itch and urticaria activity scores CSU results further demonstrate the potential of targeting IL-4 and IL-13 via IL-4Ra blockade to improve diseases with components of type 2 inflammation Approximately 300,000 people in the U.S. have moderate-to-severe CSU that does not respond adequately to antihistamines alone Data continue to support well-established safety profile of Dupixent Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced a pivotal Phase 3 trial evaluating Dupixent® (dupilumab) in patients with moderate-to-severe chronic spontaneous urticaria (CSU) met its primary and all key secondary endpoints at 24 weeks.
- 07/29/2021
|
Regeneron, AstraZeneca to develop obesity treatment
- Shares of Regeneron Pharmaceuticals Inc. were down 0.1% in premarket trading on Tuesday after the company announced a deal with AstraZeneca to develop and commercialize obesity treatments that target a specific gene, GPR75. The companies will split development costs and profits if the drug is successful.
- 07/27/2021
|
Regeneron and AstraZeneca to Research, Develop and Commercialize New Small Molecule Medicines for Obesity
- TARRYTOWN, N.Y., July 27, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and AstraZeneca today announced that the companies have entered into a collaboration to research, develop and commercialize small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities.
- 07/27/2021
|
Sanofi-Regeneron's COPD Drug Fails In Mid-Stage Trial, But Shows Potential Benefit In Subgroup of Former Smokers
- Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) started their collaboration in chronic obstructive pulmonary disorder (COPD) to target all patients, and the data is pointing them towards former smokers. What Happened: A phase 2a study, published in The Lancet, showed that the companies' itepekimab, a monoclonal antibody lowered acute COPD exacerbations in former smokers.
- 07/22/2021
|
REGN or INCY: Which Is the Better Value Stock Right Now?
- REGN vs. INCY: Which Stock Is the Better Value Option?
- 07/22/2021
|
Will Regeneron Stock See Higher Levels After A 9% Rise In A Month?
- The stock price of Regeneron has seen a 9% rise over the last twenty-one trading days, while it is down 8% over the last year. The volatility in REGN stock is being driven by the developments for REGEN-COV, its Covid-19 antibody cocktail.
- 07/22/2021
|
Has Regeneron Pharmaceuticals (REGN) Outpaced Other Medical Stocks This Year?
- Is (REGN) Outperforming Other Medical Stocks This Year?
- 07/21/2021
|
Buy These 5 Low-Beta Stocks to Beat Market Volatility
- It is imperative to build a portfolio of low-beta stocks to sail through choppy market conditions. DG, CAJ, TYL, REGN & FANH are the frontrunners.
- 07/21/2021
|
Regeneron's (REGN) Antibody Cocktail for COVID-19 Approved in Japan
- Regeneron's(REGN) cocktail for the treatment of COVID-19 gets approval in Japan as Ronapreve.
- 07/20/2021
|
Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19
- TARRYTOWN, N.Y., July 20, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Regeneron's casirivimab and imdevimab antibody cocktail to treat patients with mild to moderate COVID-19.
- 07/20/2021
|
This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar
- The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
- 07/15/2021
|
Is This Coronavirus Stock Undervalued?
- This biotech giant might be down, but it isn't out just yet.
- 07/14/2021
|
Can Regeneron (REGN) Keep the Earnings Surprise Streak Alive?
- Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 07/12/2021
|
Regeneron: Only 1 Year Of High Growth Left
- Collaborating with leading pharmaceutical companies has helped Regeneron establish itself as a biotechnology company globally. The company is diversifying its product portfolio along with the development of its proprietary technology to speed up drug development.
- 07/12/2021
|
3 Top Biotech Stocks to Buy in July
- Now's the time to get into these companies while their valuation is still favorable.
- 07/11/2021
|
IDNA: Genetics Now Have A Lot Of Influence On Healthcare
- IDNA: Genetics Now Have A Lot Of Influence On Healthcare
- 07/10/2021
|
Regeneron Stock: $636 Target From Benchmark
- The shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have received a price target increase from $590 to $636. These are the details.
- 07/09/2021
|
WHO Guidelines Put Spotlight on Arthritis Drugs Actemra & Kevzara
- The latest guideline update by the WHO includes the use of arthritis drugs like Roche's (RHHBY) Actemra and Sanofi's (SNY) Kevzara for the treatment of severe COVID-19.
- 07/08/2021
|
Here's Why Regeneron Gained 11% Last Month
- The biopharma outfit dropped news that may mean more for the medicine industry than anybody fully understands.
- 07/07/2021
|
Regeneron to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2021
- TARRYTOWN, N.Y., July 7, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2021 financial and operating results on Thursday, August 5, 2021, before the U.S. financial markets open.
- 07/07/2021
|
WHO recommends Roche, Sanofi/Regeneron drugs as COVID-19 treatments, calls for lower prices
- The World Health Organization began recommending the use of medicines called interleukin-6 receptor blockers as COVID-19 treatments for the severely ill, based on the findings of a large clinical study published Tuesday in JAMA. Roche Holding AG's Actemra and Sanofi and Regeneron Pharmaceuticals Inc.'s Kevzara are both approved in the U.S. as treatments for rheumatoid arthritis.
- 07/07/2021
|
3 Biotech Stocks Poised to Gain in the Second Half of 2021
- Here we present three biotech companies, which outperformed the sector in the year so far and are likely to witness a winning run in the near term.
- 07/06/2021
|
These COVID Therapies Appear to Be the Best and Worst at Treating New Variants
- Here's how several leading COVID-19 antibody therapies compare based on pre-clinical testing.
- 07/03/2021
|
3 Reasons to Invest in Regeneron Pharmaceuticals (REGN) Now
- Regeneron's (REGN) efforts to expand the label of its approved drugs and concurrently develop the pipeline are impressive and makes it a good bet for investors, for now.
- 07/02/2021
|
Regeneron Genetics Center Discovers GPR75 Gene Mutations that Protect Against Obesity
- TARRYTOWN, N.Y., July 1, 2021 /PRNewswire/ -- Publication in Science reports that people with these protective mutations have 54% reduced risk of obesity Regeneron used its VelociGene® technology to create mice with similar protective mutation that are resistant to obesity Regeneron already creating potential therapeutics to fight obesity using its VelocImmune® technology and collaborator Alnylam's siRNA technology Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that scientists from the Regeneron Genetics Center® (RGC) have discovered rare genetic mutations in the GPR75 gene associated with protection against obesity.
- 07/01/2021
|
Genomics ETFs Surge on a Major Breakthrough in CRISPR Study
- The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.
- 06/30/2021
|
Why Regeneron Pharmaceuticals Analyst Says Competitive Concerns Are Overblown, Pipeline Opportunity Underappreciated
- Regeneron Pharmaceuticals Inc.'s (NASDAQ:REGN) robust pipeline and attractive valuation has prompted an analyst at HC Wainwright to join the bullish camp. The Regeneron Analyst: Analyst Michael King initiated coverage of Regeneron shares with a Buy rating and a $703 price target.
- 06/29/2021
|
Ignoring Monday's 2 Big Nasdaq Winners Could Cost You Serious Money
- Find out why these stocks are climbing higher.
- 06/28/2021
|
REGN vs. INCY: Which Stock Is the Better Value Option?
- REGN vs. INCY: Which Stock Is the Better Value Option?
- 06/28/2021
|
Has Regeneron Pharmaceuticals (REGN) Outpaced Other Medical Stocks This Year?
- Is (REGN) Outperforming Other Medical Stocks This Year?
- 06/28/2021
|
Dupixent® (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis
- Dupixent ® (dupilumab) SmPC update d with long-term data reinforc ing well -established safety profile in adults with moderate-to-severe atopic dermatitis
- 06/28/2021
|
Dupixent® (dupilumab) SmPC Updated with Long-term Data Reinforcing Well-established Safety Profile in Adults with Moderate-to-severe Atopic Dermatitis
- TARRYTOWN, N.Y. and PARIS, June 28, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency will update the Dupixent® (dupilumab) summary of product characteristics (SmPC) adding long-term safety results for adults with moderate-to-severe atopic dermatitis based on a positive opinion by the Committee for Medicinal Products for Human Use (CHMP).
- 06/28/2021
|
Sanofi - Regeneron's Immunotherapy Scores European Approval For Skin And Lung Cancer Settings
- The European Commission (EC) has approved Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Libtayo (cemiplimab) for two additional indications - basal cell carcinoma (BCC) and non-small cell lung cancer with over 50% PD-L1 expression. BCC (skin cancer) approval covers adults with locally advanced or metastatic disease who have progressed on or are intolerant to a hedgehog pathway inhibitor.
- 06/25/2021
|
Sanofi: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma
- Libtayo ® ( cemiplimab ) a pproved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma
- 06/25/2021
|
Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression
- Libtayo ® ( cemiplimab ) approve d by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD - L 1 expressio n
- 06/25/2021
|
3 Companies With Low Debt to Buy in Case Interest Rates Rise
- These companies are generating tons of free cash and don't need to rely on debt to grow.
- 06/23/2021
|
Regeneron to Participate in Guggenheim Biopharma Strategy Series
- TARRYTOWN, N.Y., June 22, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is scheduled to participate in a virtual fireside chat at the Guggenheim Biopharma Strategy Series – Biopharma's Next Decade: Views from the Top on Global Strategy and Innovation – at 10:00 a.m.
- 06/22/2021
|
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at BMO Biopharma Day Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at BMO Biopharma Day Conference (Transcript)
- 06/22/2021
|
3 Bargain Stocks You Can Buy Today
- The market is mispricing these names, ignoring the long-term growth prospects ahead for each of them.
- 06/21/2021
|
How This Pharma Company Can Benefit From Its Competitors
- Delays in FDA approval for Incyte could spell good news for Sanofi.
- 06/20/2021
|
Jim Cramer Thinks Powell Got It Right and Offers a Few Top Picks
- All the major indexes pulled back on again Wednesday, and again the Nasdaq led the charge lower.
- 06/17/2021
|
Regeneron's antibody drug reduces risk of death in some Covid patients
- CNBC's Meg Tirrell joins ‘The News with Shepard Smith' to discuss the Regeneron antibody drug, which reduces the risk of death by 20% in some Covid patients. The drug is a combination of two antibodies which combat the virus,
- 06/16/2021
|
Regeneron's life-saving antibody drug , FTC chair's serious antitrust tone
- Yahoo Finance's Julie Hyman breaks down today's business headlines, including: An antibody treatment created by Regeneron being able to cut the risk of death from COVID-19, rent for single-families going up 5.3% as record demand for rental homes soars, a federal judge blocks Biden's ban on leases for drilling on public land which means drilling could resume in Alaska and the Gulf of Mexico, and Biden's pick for FTC chair signaling the administration's serious tone on antitrust enforcement. Watch the 2021 Berkshire Hathaway Annual Shareholders Meeting on YouTube: https://youtu.be/gx-OzwHpM9k
- 06/16/2021
|
RAPT Reports Positive Data From Atopic Dermatitis Study
- RAPT up on positive data from an early-stage study in patients with moderate-to-severe atopic dermatitis.
- 06/16/2021
|
REGN Stock Price Increases Over 1%: Why It Happened
- The stock price of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) increased by over 1% during intraday trading. This is why it happened.
- 06/16/2021
|
Regeneron antibody cocktail cuts risk of death for patients in hospital, study finds
- Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) antibody cocktail cuts the risk of death when given to patients hospitalised with severe COVID-19 that haven't built an immune response to the virus. The treatment uses a combination of two monoclonal antibodies, casirivimab and imdevimab, that bind to two different sites on the coronavirus spike protein, neutralising the ability of the virus to infect cells.
- 06/16/2021
|
Regeneron Antibody Therapy Saves Lives Of Hospitalized Covid-19 Patients, Large U.K. Study Finds
- The company, whose treatment was used on former President Trump after he was diagnosed with the virus, said it will ask the FDA to expand its emergency use authorization in the U.S. to reach more patients.
- 06/16/2021
|
Regeneron antibody 'cocktail' can save lives in hospitalized Covid patients, study finds
- Another potentially life-saving treatment for hospitalized Covid-19 patients has been discovered by researchers at the University of Oxford University.
- 06/16/2021
|
Regeneron Antibody Treatment Cuts Risk Of Death In Some Critical COVID-19 Patients, Large-Scale Study Finds
- Regeneron Pharmaceutical Inc.'s (NASDAQ: REGN) COVID-19 monoclonal antibody cocktail reduced the risk of death by 20% in hospitalized COVID-19 patients who have not mounted their own antibody response, a large-scale study in the U.K. published on Wednesday found. What Happened: Regeneron said that the Phase 3 RECOVERY trial met the primary outcome, improving survival in hospitalized COVID-19 patients lacking an immune response to the coronavirus.
- 06/16/2021
|
REGEN-COV™ (casirivimab and imdevimab) Phase 3 RECOVERY Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-CoV-2
- TARRYTOWN, N.Y., June 16, 2021 /PRNewswire/ -- UK RECOVERY investigators found REGEN-COV reduced risk of death by 20% in patients hospitalized with COVID-19 who had not mounted their own immune response (primary outcome for the primary analysis population) First trial to demonstrate that any antibody treatment improved survival in patients hospitalized with COVID-19 Regeneron will share new data with regulatory authorities immediately and request that the U.S. EUA be expanded to include appropriate hospitalized patients Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today welcomed positive results from the largest trial assessing any monoclonal antibody treatment in patients hospitalized with severe COVID-19.
- 06/16/2021
|
REGN vs. INCY: Which Stock Should Value Investors Buy Now?
- REGN vs. INCY: Which Stock Is the Better Value Option?
- 06/11/2021
|
Has Regeneron Pharmaceuticals (REGN) Outpaced Other Medical Stocks This Year?
- Is (REGN) Outperforming Other Medical Stocks This Year?
- 06/11/2021
|
Twitter And Regeneron Lead The SPY In Another Mixed Day Of Trading
- U.S. indices at a mixed day of trading Wednesday as investors and traders weighed the U.S. 30-Year Treasury note falling to 2.1483%, the lowest level since March 1. The SPDR S&P 500 ETF Trust (NASDAQ:SPY) finished slightly higher by 0.02% to $422.28
- 06/09/2021
|
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript)
- 06/08/2021
|
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (Transcript)
- Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (Transcript)
- 06/07/2021
|
Chewy, Regeneron, UPS, Merck, and Other Stocks to Watch This Week
- Companies reporting earnings or speaking with investors this week include Chewy, Campbell Soup, Merck, UPS, and Regeneron. Plus, inflation data and sentiment surveys.
- 06/06/2021
|
Regeneron's COVID-19 antibody drug can now be administered subcutaneously
- Shares of Regeneron Pharmaceuticals Inc. were up 1.0% in premarket trading on Friday after the company said U.S. regulators had authorized a lower-dose and subcutaneous version of its COVID-19 antibody treatment. The updated emergency-use authorization now says that patients will receive a dose that is half the size of the original dose of the monoclonal antibody.
- 06/04/2021
|
FDA Authorizes Lower 1,200 mg Intravenous and Subcutaneous Dose of REGEN-COV™ (casirivimab and imdevimab) Antibody Cocktail to Treat Patients with COVID-19
- TARRYTOWN, N.Y., June 4, 2021 /PRNewswire/ -- EUA supported by pivotal Phase 3 data showing 1,200 mg dose reduced risk of hospitalization or death by 70% Only antibody therapy currently available in all 50 states, including eight states with high rates of two variants of concern Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) updated the Emergency Use Authorization (EUA) for REGEN-COV™, lowering the dose to 1,200 mg (600 mg casirivimab and 600 mg imdevimab), which is half the dose originally authorized.
- 06/04/2021
|
2 Top Value Stocks to Hedge Against Inflation Woes
- Here are two stocks that can simultaneously add wealth to and protect your portfolio.
- 06/03/2021
|
This Biotech's Thrifty CEO Is Serious About Investing for the Future
- That spending might help him win the war on cancer.
- 06/03/2021
|
Regeneron Pharmaceuticals, Inc. (REGN) CEO Leonard Schleifer Presents at Annual Bernstein Strategic Decisions Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (REGN) CEO Leonard Schleifer Presents at Annual Bernstein Strategic Decisions Conference (Transcript)
- 06/02/2021
|
Regeneron (REGN) Stock Up 3.5% YTD: What's in Store for 2H21?
- Regeneron's performance so far in the year has been good on the back of a solid product portfolio and an incremental contribution from the antibody cocktail.
- 06/01/2021
|
Regeneron Just Got a COVID-19 Boost
- It may be short lived.
- 05/29/2021
|
Bill Nygren's Top 6 Trades in the 1st Quarter
- Bill Nygren (Trades, Portfolio), manager of the Oakmark Fund, disclosed this week that his firm's top six trades for the first quarter of 2021 included the closure of its positions in Aptiv PLC ( APTV , Financial) and Parker Hannifin Corp. ( PH , Financial), new stakes in Altria Group Inc. ( MO , Financial) and ConocoPhillips ( COP , Financial) and boosts to its holdings in Regeneron Pharmaceuticals Inc. ( REGN , Financial) and Fiserv Inc. ( FISV , Financial).
- 05/28/2021
|
U.S. stops distributing Lilly's COVID-19 antibody therapy in six states, instead recommends Regeneron's treatment
- The U.S. government said this week it is halting distribution of Eli Lilly & Co.'s COVID-19 antibody treatment in six states due to the growing prevalence of the P.1 and B.1.351 variants there. Lilly's combination therapy of bamlanivimab and etesevimab "are not active against either the P.1 or B.1.351 variants," which were first identified in Brazil and South Africa, respectively, the Assistant Secretary for Preparedness and Response said Wednesday.
- 05/28/2021
|
Novartis (NVS) & Molecular Partners Initiate Study for COVID-19
- Novartis (NVS) initiates study for investigating its novel DARPin therapeutic candidate, ensovibep (MP0420), for the treatment of COVID-19, in collaboration with Molecular Partners.
- 05/27/2021
|
Regeneron, Novavax CEOs Top List of Highest Paid in 2020
- Shareholders would probably agree that a majority of the 15 highest-paid pharma CEOs earned their money in 2020. The stocks of all but four advanced last year and those in negative territory suffered relatively minor declines.
- 05/25/2021
|
Regeneron Announces Investor Conference Presentations
- TARRYTOWN, N.Y., May 25, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Bernstein's 37th Annual Strategic Decisions Conference at 8:00 a.m.
- 05/25/2021
|
Regeneron-Sanofi's Libtayo Scores CHMP's Positive Opinion For Two Advanced Cancer Settings
- The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Libtayo (cemiplimab) as monotherapy in two advanced cancers. The CHMP recommended the approval of Libtayo for the first-line treatment of adults with non-small cell lung cancer (NSCLC) expressing PD-L1 in ≥50% of tumor cells with no EGFR, ALK, or ROS1 aberrations.
- 05/24/2021
|
Libtayo® (cemiplimab) Receives Positive CHMP Opinion for the Treatment in Europe of Two Advanced Cancers
- TARRYTOWN, N.Y. and PARIS, May 24, 2021 /PRNewswire/ -- Libtayo recommended for approval in the first-line treatment of certain patients with advanced non-small cell lung cancer whose tumors have ≥50% PD-L1 expression Libtayo also recommended for approval in patients with advanced basal cell carcinoma who have progressed on or are intolerant to a hedgehog pathway inhibitor CHMP has now issued three positive opinions for Libtayo in advanced cancers Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for Libtayo® (cemiplimab) as monotherapy in two advanced cancers.
- 05/24/2021
|
Teen Scientists and Engineers Win $5 Million at Largest Global High School STEM Competition
- TARRYTOWN, N.Y. and WASHINGTON, May 21, 2021 /PRNewswire/ -- $75,000 Top Award Goes to 16-year-old Michelle Hua for Novel Human Action Recognition Algorithm in Regeneron International Science and Engineering Fair 2021 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Michelle Hua, 16, of Troy, Michigan, won the $75,000 top award in the 2021 Regeneron International Science and Engineering Fair (Regeneron ISEF), the world's largest global high school competition.
- 05/21/2021
|
3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem
- 3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem
- 05/20/2021
|
Regeneron: Priced For Value, Poised For Growth
- Regeneron achieved three FDA approvals in February 2021 and continued to announce positive clinical results in the following months, but the shares have since traded roughly sideways. Regeneron is conducting one of the largest genetic sequencing efforts in the world, positioning the company as a leader in the field now and in the future.
- 05/19/2021
|
Libtayo® (cemiplimab-rwlc) Presentations at ASCO Highlight Expanding Clinical Data in Diverse Cancers
- TARRYTOWN, N.Y., May 19, 2021 /PRNewswire/ -- Presentations include first positive clinical data for the fianlimab (LAG-3 inhibitor) and Libtayo combination in advanced melanoma Regeneron will host an investor webcast on Monday, June 7 to provide further updates across its oncology portfolio Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the company will share a range of presentations for its PD-1 inhibitor Libtayo® (cemiplimab-rwlc) and broader oncology portfolio at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8, taking place virtually.
- 05/19/2021
|
Facebook And Regeneron Lead The Nasdaq Lower Tuesday
- U.S. indices were trading lower Tuesday after U.S. Treasury Secretary Janet Yellen called for business leaders across the country to pay higher taxes to compensate for President Biden's proposed infrastructure plan. The SPDR Dow Jones Industrial Average ETF Trust (NASDAQ:DIA) fell by 0.74% to $341.11.
- 05/18/2021
|
Regeneron (REGN) Resumes Enrollment in Lymphoma Cohorts
- Regeneron (REGN) resumes enrollment in two patient cohorts of pipeline candidate, odronextamab, a CD20xCD3 bispecific antibody, after the FDA lifts partial clinical hold.
- 05/18/2021
|
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at RBC Capital Markets Virtual Global Healthcare Conference Call - (Transcript)
- Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at RBC Capital Markets Virtual Global Healthcare Conference Call - (Transcript)
- 05/18/2021
|
Regeneron and Weis Markets Head Up the Do Nothing Club
- Stocks that soar or plunge get all the attention.
- 05/17/2021
|
Phase 3 Data Presented at ATS 2021 Show REGEN-COV™ (casirivimab with imdevimab) Reduced Risk of Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients
- TARRYTOWN, N.Y., May 17, 2021 /PRNewswire/ -- Patients treated with REGEN-COV had 4-day shorter duration of symptoms and significantly reduced viral load compared to placebo Similar efficacy observed with both doses (1,200 mg and 2,400 mg); U.S. FDA is currently reviewing request to add lower 1,200 mg dose to EUA Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of detailed results from the Phase 3 pivotal trial showing REGEN–COV™ (casirivimab with imdevimab) significantly reduced the risk of hospitalization or death, shortened symptom duration and reduced viral load in non-hospitalized patients (outpatients) with COVID-19.
- 05/17/2021
|
Pivotal data at ATS 2021 show Dupixent® (dupilumab) significantly reduced asthma attacks and improved lung function in children
- Pivotal d ata at ATS 2021 s how Dupixent ® (dupilumab) s ignificantly r educed a sthma a ttacks and i mproved l ung f unction in c hildren
- 05/17/2021
|
Pivotal Data at ATS 2021 Show Dupixent® (dupilumab) Significantly Reduced Asthma Attacks and Improved Lung Function in Children
- TARRYTOWN, N.Y. and PARIS, May 17, 2021 /PRNewswire/ -- Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma in a randomized Phase 3 trial, with potential to be best-in-class treatment for these patients FDA decision for children with moderate-to-severe asthma expected by October 21, 2021 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that detailed results from a Phase 3 trial showed Dupixent® (dupilumab) significantly reduced severe asthma attacks, and within two weeks rapidly improved lung function in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma, with evidence of type 2 inflammation.
- 05/17/2021
|
Positive Phase 3 Libtayo® (cemiplimab) Results in Advanced Cervical Cancer Presented at ESMO Virtual Plenary
- TARRYTOWN, N.Y. and PARIS, May 12, 2021 /PRNewswire/ -- Libtayo is the first immunotherapy to demonstrate an improvement in overall survival in advanced cervical cancer, as well as progression-free survival and objective response rate, compared to chemotherapy Improvements in overall survival were seen in the overall population and both squamous cell carcinoma and adenocarcinoma subgroups Additionally, the Phase 3 trial found significant differences in patient-reported outcomes favoring Libtayo over chemotherapy Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the presentation of positive results from the Phase 3 trial investigating the PD-1 inhibitor Libtayo® (cemiplimab) in patients with recurrent or metastatic cervical cancer who had previously progressed on chemotherapy.
- 05/12/2021
|
3 Stock Picks for the Value Investor
- In my opinion, picking U.S.-listed equities that have the following characteristics represents a solid starting point when looking for potential value opportunities:
- 05/09/2021
|
Buying This Beaten-Down ETF Could Make You a Fortune Over the Next 10 Years
- It definitely made investors a lot of money over the last decade. And its future could be brighter than the past.
- 05/07/2021
|
Regeneron (REGN) Q1 Earnings Beat on Strong Eylea & Dupixent
- Regeneron (REGN) beats on Q1 earnings while sales record strong year-over-year growth on solid performance of Dupixent and Eylea, and incremental contribution from REGEN-COV.
- 05/06/2021
|
Why Regeneron's Q1 Results Looked Great Despite Its Revenue Miss
- The big biotech delivered impressive revenue and earnings growth.
- 05/06/2021
|
REGN Finds Redemption After Impressive Earnings Report
- The shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) are rising on the company's upbeat first-quarter earnings report, which boasted a rise in profits to $9.89 per share -- toppling analysts' estimates.
- 05/06/2021
|
Regeneron Reports Mixed Bag On Q1 Earnings; Eylea Franchise Boosts Revenue
- Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned $9.89 per share for the first quarter, beating the $9.03 estimate. Revenue of $2.53 billion narrowly missed analyst consensus of $2.56 billion.
- 05/06/2021
|
Regeneron quarterly profit rises 78% on Eylea strength
- Regeneron Pharmaceuticals Inc reported a 78% rise in first-quarter profit on Thursday, helped by a robust recovery in demand for its eye drug Eylea.
- 05/06/2021
|
Regeneron Reports First Quarter 2021 Financial and Operating Results
- TARRYTOWN, N.Y., May 6, 2021 /PRNewswire/ -- First quarter 2021 revenues increased 38% to $2.53 billion versus first quarter 2020; revenues excluding REGEN-COV TM(1) increased 20% First quarter 2021 EYLEA® U.S. net sales increased 15% to $1.35 billion versus first quarter 2020 First quarter 2021 Dupixent® global net sales (2) , which are recorded by Sanofi, increased 48% to $1.26 billion versus first quarter 2020 First quarter 2021 GAAP diluted EPS was $10.09 and non-GAAP diluted EPS (1) was $9.89 Three FDA approvals received: Libtayo® for first-line advanced non-small cell lung cancer (NSCLC) and advanced basal cell carcinoma (BCC), and Evkeeza TM for homozygous familial hypercholesterolemia (HoFH) Positive data reported from Phase 3 trials with REGEN-COV used to treat and prevent COVID-19 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2021 and provided a business update.
- 05/06/2021
|
Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical
- The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
- 05/05/2021
|
Top 5 Trades of Tom Gayner's Markel in 1st Quarter
- Tom Gayner (Trades, Portfolio), chief investment officer of Markel Corp. ( MKL , Financial), disclosed this week that his firm's top five trades during the first quarter included a new buy in Regeneron Pharmaceuticals Inc. ( REGN , Financial), position boosts in Equifax Inc. ( EFX , Financial) and International Flavors & Fragrances Inc. ( IFF , Financial) and reductions in the Microchip Technology Inc. ( MCHP , Financial) and O-I Glass Inc. ( OI , Financial) holdings.
- 05/04/2021
|
Will Eylea & Dupixent Drive Regeneron's (REGN) Q1 Earnings?
- Investors are likely to focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports first-quarter 2021 results.
- 05/03/2021
|
Regeneron: The Solid Growth At A Reasonable Price
- Risks of increased competition for Eyley are greatly overestimated. Dupixent's prospects are far from being revealed, and its approval in new indications is on the horizon.
- 05/03/2021
|
ARK Genomic Revolution ETF: Value Realization Will Take Time
- ARK Genomic Revolution ETF: Value Realization Will Take Time
- 05/03/2021
|
Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know
- In the latest trading session, Regeneron (REGN) closed at $485, marking a -0.57% move from the previous day.
- 04/29/2021
|
7 Healthcare Stocks for a Reopening World
- The stock market is at all-time highs, and the world is starting to reopen. But these healthcare stocks have more growth opportunities ahead.
- 04/26/2021
|
Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know
- In the latest trading session, Regeneron (REGN) closed at $488.64, marking a -0.36% move from the previous day.
- 04/23/2021
|
Regeneron Announces Investor Conference Presentations
- TARRYTOWN, N.Y., April 23, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Bank of America Securities Virtual Health Care Conference at 1:15 p.m.
- 04/23/2021
|
New Dupixent® (dupilumab) Analyses at Two Upcoming Dermatology Congresses Reinforce Long-term Safety and Efficacy Profile in Patients with Atopic Dermatitis as Young as 6 Years
- TARRYTOWN, N.Y., April 23, 2021 /PRNewswire/ -- Nearly 30 data presentations at AAD and ESPD highlight the impact of Dupixent on disease measures including rapid itch relief and sustained improvement in disease severity, as well as quality of life in clinical and real-world settings Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new analyses of Dupixent® (dupilumab) in patients as young as 6 years with moderate-to-severe atopic dermatitis will be presented at the American Academy of Dermatology Annual Meeting (AAD VMX 2021) from April 23-25, and at the 20th European Society for Pediatric Dermatology Annual Meeting (ESPD 2021) from May 12-14.
- 04/23/2021
|
Regeneron Pharmaceuticals: Close To Regenerated Again
- Regeneron Pharmaceuticals: Close To Regenerated Again
- 04/22/2021
|
Analysts See Plenty of Upside for Replimune
- Boston-area biotech Replimune Group Inc. (NASDAQ:REPL) just boosted its executive lineup with a heavy hitter, and the market seems to like the addition.
- 04/22/2021
|
3 Cheap Cathie Wood Stocks to Buy Right Now
- You don't need to pay a big premium for these buy-and-hold investments.
- 04/21/2021
|
Will Regeneron's COVID Cocktail Win Be Short-Lived?
- The biotech's antibody therapy continues to show promise. But there's considerable uncertainty about its long-term prospects.
- 04/21/2021
|
Health-care stocks are making a comeback, Jim Cramer says
- "I think that the left-behind health care stocks are now coming back to life at the expense of the cyclical growth plays," the "Mad Money" host said.
- 04/15/2021
|
Top Net Payout Yields - April 2021
- The top net payout yield stocks far outperformed the total return of the S&P 500 during Q1.
- 04/15/2021
|
3 More A+ Stocks To Buy And Hold Forever
- 3 More A+ Stocks To Buy And Hold Forever
- 04/13/2021
|
Regeneron's antibody drug offers strong protection against Covid-19
- A new study shows Regeneron's antibody cocktail can offer strong protection against Covid-19, but Regeneron's antibody cocktail still needs FDA approval for the drug to be used for preventative use. Meg Tirrell joins 'The News with Shepard Smith' to discuss.
- 04/12/2021
|
Vaccine Passport Potential Could Boost These 7 Pharmaceutical Stocks
- Nearly everyone will get the Covid-19 vaccination, suggesting strong revenue for a handful of pharmaceutical companies. The post Vaccine Passport Potential Could Boost These 7 Pharmaceutical Stocks appeared first on InvestorPlace.
- 04/12/2021
|
Regeneron (REGN) Posts Positive Data on COVID-19 Antibody Cocktail
- Regeneron (REGN) announces encouraging data on antibody cocktail, REGEN-COV, from two phase III studies.
- 04/12/2021
|
Regeneron CEO on FDA request for expanded EUA of Covid antibody drug
- Regeneron Pharmaceuticals said Monday it will ask the Food and Drug Administration to allow its Covid-19 antibody therapy to be used as a preventative treatment. Regeneron CEO Leonard Schleifer joined "Squawk Box" on Monday to discuss.
- 04/12/2021
|
On Sale: Glitter From The Healthcare Wreckage, Biotech Edition
- On Sale: Glitter From The Healthcare Wreckage, Biotech Edition
- 04/12/2021
|
Regeneron says its COVID-19 antibody therapy cut risk of infection progression
- Shares of Regeneron Pharmaceuticals Inc. gained 1.6% in premarket trading on Monday after the company shared additional positive clinical data from two studies about its COVID-19 monoclonal antibody cocktail. One late-stage trial found that subcutaneous administration of REGEN-COV in recently infected asymptomatic patients lessened the overall risk to progressing to symptomatic infection by 31%.
- 04/12/2021
|
Phase 3 Treatment Trial in Recently Infected Asymptomatic Patients Showed REGEN-COV™ (casirivimab with imdevimab) Significantly Reduced Progression to Symptomatic COVID-19
- TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/ -- Second Phase 3 trial undertaken in collaboration with NIAID to announce results today, both using subcutaneous administration of REGEN-COV in asymptomatic individuals without prior COVID-19 infection Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive data from a Phase 3 trial (2069B) of recently infected asymptomatic COVID-19 patients, evaluating REGEN-COV™ (casirivimab with imdevimab) 1,200 mg administered via subcutaneous (SC) administration.
- 04/12/2021
|
Regeneron to request FDA clearance to use Covid antibody drug as a preventative treatment
- Regeneron said a phase three clinical trial of the drug reduced the risk of symptomatic infections in individuals by 81%.
- 04/12/2021
|
Phase 3 Prevention Trial Showed 81% Reduced Risk of Symptomatic SARS-CoV-2 Infections with Subcutaneous Administration of REGEN-COV™ (casirivimab with imdevimab)
- TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/ -- REGEN-COV rapidly protected household contacts from exposure to SARS-CoV-2 at home, with 72% protection against symptomatic infections in the first week, and 93% in subsequent weeks Among individuals who developed symptomatic infections, REGEN-COV recipients cleared the virus faster and had much shorter symptom duration Regeneron will share data with U.S. FDA and request EUA expansion to include COVID prevention for appropriate populations, using a 1,200 mg subcutaneous dose Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from a Phase 3 trial (2069A) assessing the ability of REGEN-COV™ (casirivimab with imdevimab) to reduce the risk and burden of COVID-19 infection among household contacts of SARS-CoV-2 infected individuals.
- 04/12/2021
|
NIH recommends Lilly and Regeneron's combination antibody treatments to people with mild and moderate COVID-19
- The National Institutes of Health on Thursday recommended that patients with mild to moderate COVID-19 who are at high risk of worsening disease should be treated with monoclonal antibody cocktails. The recommendation was issued by the NIH's COVID-19 Treatment Guidelines Panel for Regeneron Pharmaceuticals Inc.'s casirivimab-imdevimab combination therapy and Eli Lilly & Co.'s bamlanivimab-etesevimab.
- 04/09/2021
|
NIH COVID-19 Treatment Guidelines Strongly Recommend Use of REGEN-COV™ (casirivimab with imdevimab) in Outpatients at High Risk of Clinical Progression
- TARRYTOWN, N.Y., April 9, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that newly updated National Institutes of Health (NIH) COVID-19 Treatment Guidelines strongly recommend that REGEN-COV™ (casirivimab with imdevimab) be used in non-hospitalized COVID-19 patients ("outpatients") at high risk of clinical progression.
- 04/09/2021
|
3 Top Biotech Stocks to Buy in April
- These big biotechs check off all the boxes.
- 04/07/2021
|
7 Best Stocks on the Nasdaq
- Investors need to hold the best companies that money can buy on the Nasdaq, amid a growing weakness in the technology stock index. The post 7 Best Stocks on the Nasdaq appeared first on InvestorPlace.
- 04/06/2021
|
3 Stocks Cathie Wood Is Selling That Long-Term Investors Should Be Buying
- Their growth prospects are too good to ignore.
- 04/06/2021
|
ARK Genomic Revolution Multi-Sector ETF: Poised For Continued Underperformance
- ARK Genomic Revolution Multi-Sector ETF: Poised For Continued Underperformance
- 04/02/2021
|
NIH-sponsored Trial Finds EYLEA® (aflibercept) Injection Reduced Vision-threatening Complications by 68% after Two Years in Diabetic Retinopathy Patients
- TARRYTOWN, N.Y., March 30, 2021 /PRNewswire/ -- Protocol W trial data confirm results from PANORAMA trial showing EYLEA significantly reduced vision-threatening complications and improved anatomic measures of diabetic retinopathy Although patients' overall vision was similar in the EYLEA and sham groups at two years in Protocol W, a new analysis from PANORAMA shows that delaying EYLEA treatment (sham group) was associated with prolonged periods of vision loss Two diabetic retinopathy trials (Protocol W and PANORAMA) have now shown the benefit of EYLEA every 16 weeks following an initial dosing period; Regeneron to discuss 16-week dosing interval with U.S. FDA Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced JAMA Ophthalmology has published initial results from the National Institutes of Health-sponsored Protocol W trial assessing EYLEA® (aflibercept) Injection in patients with moderate to severe non-proliferative diabetic retinopathy (NPDR), without center-involved diabetic macular edema (CI-DME).
- 03/30/2021
|
3 Top Biotech Stocks to Buy Right Now
- All three should have solid long-term growth prospects.
- 03/28/2021
|
Cuomo Reportedly Gave Billionaire Regeneron Founder Special Access To Covid-19 Tests
- At the height of the pandemic in New York early last year, Cuomo approved state-run tests for George Yancopoulos and a family member.
- 03/25/2021
|
Regeneron (REGN) Announces Positive Data on COVID-19 Cocktail
- Regeneron (REGN) announces positive data from a phase III study on its antibody cocktail for COVID-19.
- 03/24/2021
|
Regeneron's Covid-19 Antibody Could See Substantially Higher Sales This Year. Here's Why.
- Positive results from Regeneron Pharmaceuticals' Phase 3 trial of its Covid-19 antibody could mean far higher sales of the therapy this year than analysts had previously expected.
- 03/24/2021
|
Regeneron's President On COVID-19 Antibody Cocktail: 'Good News That Could Be Really Big News'
- Regeneron Pharmaceuticals Inc (NASDAQ: REGN) said Tuesday that a lower dose of its treatment for COVID-19 reduced hospitalization and death rates. This is "good news that could be really big news," Regeneron President George Yancopoulos said on CNBC's "Squawk Box.
- 03/23/2021
|
